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The thesis addresses two rapidly advancing fields:  improvement of drug efficacy 
using smart targeting and nanotechnology approaches; and testing drug efficacy in 
clinically relevant in vitro models. The specific aim was to create organic 
nanoformulations of novel chemotherapeutic agents and test their efficacy in a 3D 
colorectal cancer in vitro model.  
The first phase consisted in determining the best candidate for nanoformulations, in 
cell monolayers, using routine cell and molecular investigations. Different 
combinations of therapeutic agents were tested on colorectal cancer cells, including 
inhibitors of the mitogen activated protein kinase (MAPK) pathway, antagonists of 
the endothelin receptor A (ETAR) and short interfering RNA (siRNA) targeted against 
key molecules. AZD6244, an inhibitor of the MAPK pathway, produced significant 
inhibition of proliferation (p<0.05) and was chosen for nanoformulations.  
AZD6244 was encapsulated in cationic GCPQ micelles and DOPE/DC-Cholesterol 
liposomes using ultrasonication and extrusion methods, and tested in colorectal 
cancer cell monolayers. Both nanoparticles exhibited superior inhibitory effects 
compared to the free drug, shown by proliferation and metabolic activity assays 
(p<0.05). Additionally, experiments with control nanoparticles and western blot 
analysis of target proteins suggested that the superior efficacy of the 
nanoformulations was mainly due to a more efficient delivery of the drug, as opposed 
to additional toxicity from the nanoparticles.  
When the nanoformulations were tested in a collagen-based 3D model of colorectal 
cancer, the superior efficacy of the nanoformulations was reduced, while the efficacy 
of the free drug increased. Studies performed with fluorescent dye-carrying 
nanoparticles in these models revealed that nanoparticle efficacy was hindered by 
poor penetration into the tissue.  
These results highlight both the potential of organic nanoformulations as therapeutic 
delivery systems for cancer and the need to include three-dimensional in vitro 
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1 Introduction and Aims 
 
The work described in this body of research consists of three well defined sections. 
First, the search for a therapeutic combination involving the endothelin A receptor 
(ETAR) and the mitogen activated protein kinase (MAPK) pathway. Second, the 
nanoformulation of this therapeutic combination to improve its delivery/action to the 
cell. And third, the evaluation of these nanoformulations in a novel, collagen-based 
3D model of colorectal cancer, termed tumouroid, which mimics human tumour 
masses. This chapter introduces colorectal cancer, novel therapeutics against the 
target pathways, organic nanoformulations as therapeutic delivery systems and the 
use of 3D models in drug discovery. 
 
1.1 Colorectal cancer and therapeutics 
 
Colorectal cancer (CRC) ranks as the third most common cancer worldwide and 
fourth for cancer-related deaths in the world (Jemal et al. 2011). Most countries in 
developed regions are more vulnerable to colorectal cancer due to a high-fat and 
low-fibre diet and sedentary life styles (Center et al. 2010). While healthy colonic 
tissue is in a constant balance between apoptosis and proliferation, the initial stage 
of colorectal cancer pathogenesis is almost exclusively linked to the inability of 
epithelial cells to undergo apoptotic signalling (Deschner et al. 1988). 
There are certain inheritable conditions such as Familial Adenomatous Polyposis 
(FAP) or Hereditary Non-Polyposis Colon Cancer (HNPCC), which predispose 
patients to mutations that could eventually develop into colorectal cancer.  However, 
more than 80% of the cases are sporadic, with a variety of abnormalities in 
oncogenes and tumour suppressor genes, particularly in chromosomal regions such 
as 5q, 8p,17p and 18q (Muleris et al. 1987). Most of the key mechanisms involved in 
colorectal carcinogenesis involve genes such as APC, SMAD4, p53 or KRAS 




While early detection and surgery for therapeutic excision of the tumour are key 
factors in overcoming the disease, more than half of the patients develop metastases 
that represent the main cause of colorectal cancer mortality (O’Connell et al. 2004), 
and therefore require a systemic treatment. To address this problem, chemotherapy 
(normally constituting of 5-fluorouracil (5-FU) combined with other chemicals) is used 
as an adjuvant treatment after patients undergo surgery. While promising, 
chemotherapy is linked to significant side effects, such as immunosuppression, 
fatigue and severe organ damage, mostly due to its lack of specificity. For that 
reason, a number of novel new generation therapeutics that aim at specific signalling 
such as small molecule inhibitors are in constant discovery. Some of these novel 
therapeutics are targeted against key intracellular proteins such as the protein 
kinases MEK1, MEK2 or RAF or against surface receptors such as epidermal growth 
factor receptor (EGFR) or endothelin A receptor (ETAR). The ultimate goal is to 
target specific mechanisms, such as cell proliferation, apoptotic signalling or invasive 
potential, which are regarded as hallmarks of cancer  (Hanahan & Weinberg 2011). 
While the use of target-specific novel therapeutics are an improvement  to some of 
the limitations linked to traditional chemotherapy, one of their main drawbacks is that 
often, only patients with a specific mutation profile derive benefit from the treatment. 
Such is the case of cetuximab, a humanized antibody targeted against EGFR which 
has no effect on tumours with certain mutations in the downstream KRAS protein 
(Van Cutsem et al. 2009; King & Robins 2006), due to its constitutive activation. For 
that reason treatment combinations must be explored to achieve an effective 
treatment. 
 
1.1.1 MAPK pathway and its inhibitors 
 
One of the most promising targets for new generation chemotherapeutic agents is 
the MAPK pathway, which is intrinsically activated in a number of cancers, leading to 
the aforementioned cancerous behaviour (Adjei & Hidalgo 2005; Dhillon et al. 2007; 
Hoshino et al. 1999). This pathway is not only key to cancer development and 
progression, but is closely involved in chemotherapy resistance in a number of 
cancers, including colorectal (Mueller et al. 2000). 
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Inhibitors against various key proteins in this pathway are constantly being 
developed. Its signalling consists of a phosphorylation cascade that starts with a 
receptor tyrosine kinase (RTK) binding to a growth factor in the surface of the cell 
and substituting the GDP in RAS for GTP (Bolsover et al. 2004). This signal starts a 
process in which a kinase is activated by phosphorylation and phosphorylates 
another kinase, namely RAS, RAF, MEK and ERK (Peyssonnaux & Eychène 2001; 
Meloche & Pouysségur 2007; Mebratu & Tesfaigzi 2009; Crews et al. 1992; 
Roskoski 2010), with the latter triggering proliferative, angiogenic and anti-apoptotic 
signals through the activation of transcription factors (Figure 1.1). The MAPK 
pathway is essential for tumourogenesis in a great number of cancers (Dhillon et al. 
2007; Sebolt-Leopold 2004). 
 
 




Since most mutations related to the constitutive activation of the MAPK pathway 
occur in proteins upstream of MEK1/2, these two enzymes are an excellent target for 
anti-cancer therapeutics. Furthermore, ERK1/2 are the only known substrates of 
MEK1/2 (Roskoski 2012). The specificity of these enzymes and the importance of 
this pathway in tumourogenesis leads to a phenomenon called “oncogenic 
dependency” or “oncogenic addiction” in which the survival of cancer cells relies 
fundamentally on this pathway (Weinstein & Joe 2008; Weinstein 2002), supporting 
the choice of this pathway as a therapeutic target. A number of novel 
chemotherapeutic agents targeted against these proteins have been developed over 
the last years, including small molecules such as PD98059, U0126 or AZD6244, and 
even interfering RNA, with promising results in vitro, in vivo and in the clinic 
(Santarpia et al. 2012; Balmanno et al. 2009; Gailhouste et al. 2010). 
 
1.1.2 KRAS and BRAF mutations in colorectal cancer 
 
The MAPK pathway is often overactive in human cancers, and in many cases the 
points of constitutive activation are RAS or RAF (Davies et al. 2002; Imamura et al. 
2012). The fact that activating mutations in these two proteins are mutually exclusive 
suggests that they affect the same downstream proteins. 
In CRC, KRAS is the most commonly mutated protein in the RAS family (Phipps et 
al. 2013), occurring in 35-45% of CRCs (Imamura et al. 2012; Normanno et al. 
2009). Among these mutations, over 90% are either in codon 12 or codon 13 (Wood 
et al. 2007). These mutations translate into a constituent activation of the MAPK 
pathway regardless of the signalling upstream of KRAS (Conlin et al. 2005). While 
this is extremely interesting for drug discovery and sets the basis for the 
development of new therapeutics, there are mixed thoughts on whether mutations in 
KRAS have an influence on patient’s outcome (Imamura et al. 2012; Phipps et al. 
2013; Ren et al. 2012; Richman et al. 2009; Roth et al. 2010). 
On the other hand, BRAF mutations are found in only 5-10% of colorectal cancers 
(Davies et al. 2002; Yuen et al. 2002) and their presence often indicates poor patient 
outcome. Among all BRAF mutations, V600E represents 90% of cases (Davies et al. 
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2002). While mutations in KRAS are especially frequent in CRC, mutations in BRAF 
are more frequent in cancers such as ovarian, thyroid, and specially melanomas 
(Wellbrock et al. 2004; Davies et al. 2002). It is worth noting that the percentages 
shown here for BRAF and KRAS mutation frequencies do vary slightly among 
publications. 
 
1.1.3 The endothelin axis and cancer  
 
In the last fifteen years, the endothelins, and their cell surface receptors have gained 
attention as potential cancer promoters. The endothelin axis comprises two G-
protein coupled receptors (ETA and ETB), which bind to ligands ET1, ET2 and ET3 
with different affinities (Sakamoto et al. 1991). The binding of ET1 to these G-protein 
coupled receptors, triggers the activation of several proteins such as phospholipases 
A2, C and D or the adenylate and guanylate cyclases (Shome et al. 2000) (Figure 
1.2). These result in further activations; for example phospholipases C and D 
activate both PI3K (which then activates RAS) and protein kinase C (PKC) (which 
then activates Raf1 (Blaukat et al. 2000) and increases intracellular Ca2+ 
concentration). All these mechanisms ultimately result in the activation of MAPK 
pathway signalling and subsequent transcription factors, which lead to cell 
proliferation, among other processes. 
An imbalance between the signalling through these two receptors has implications in 
cancer cell mitogenesis, apoptosis, angiogenesis and metastatic potential. While all 
three endothelins bind to ETBR with similar affinity (Rubanyi & Polokoff 1994), ETAR 
has significantly higher affinity for ET1 compared to ETBR, which in the event of 
raised levels of ETAR and ET1, acts as an oncogene (Kennedy et al. 1993; 
Sakamoto et al. 1991), particularly through its mitogenic function (Bagnato et al. 
1997; Grant et al. 2007). The expression levels of both ET1 and ETAR have been 
found increased in several types of cancer including colorectal, breast, prostate, 
stomach and glioblastoma (Kusuhara et al. 1990; Bagnato et al. 1999; Ali et al. 2000; 
Nelson et al. 1995; Hoosein et al. 2007; Bagnato et al. 1997). Around 80% of primary 
CRCs have increased levels of ET-1, not only in cancer epithelial cells themselves 
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but also surrounding stromal cells (Asham et al. 2001; Shankar et al. 1998), which 
play a central role in cancer progression. 
ET1 also has implications in apoptosis, as it has been shown to counteract FasL-
induced apoptotic mechanisms in rat colon carcinoma cells and ovarian cancers and 
has been suggested to interfere with the β-catenin pathway (Kim et al. 2005; Peduto 
Eberl et al. 2003). Furthermore, the binding of ET1 to ETAR has been shown to 
increase the production of hypoxia inducible factor 1 (HIF1), COX1, COX2, the 
prostaglandin PGE2 and p38 in ovarian cancer cells, which subsequently stimulate 
VEGF production and matrix metalloproteinase (MMP) activation, resulting in 
angiogenesis and invasion, respectively (Spinella et al. 2004; Spinella et al. 2002). 
The increased expression of angiogenic and pro-invasive proteins through ET1 
stimulation was also later detected in colonic fibroblasts (Knowles et al. 2012). 
 
 
Figure 1.2 Schematic representation of the proteins activated by ETAR. 
 
 
1.1.4 Endothelin A receptor antagonism 
 
For the above reasons, the use of therapeutics targeting to impair the binding of 
ETAR to ET1 is a very promising approach. One of the most studied mechanisms is 
competitive antagonism, in which a small molecule such as ZD4054 competes with 
ET1 to bind to ETAR without triggering the signalling pathway, therefore acting as an 
antagonist. This approach has been tested in several cancers such as ovarian, in 
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which ETAR antagonists reduced proliferation of ovarian (Rosanò et al. 2007a) or 
colorectal cancer cells in which they reduced proliferation in both cancer cells and 
colonic fibroblasts (Ali et al. 2000; Knowles et al. 2012). This efficacy also translates 
to in vivo, where ETAR inhibition successfully inhibited liver metastasis growth 
(Asham et al. 2001). 
ETAR is involved in several cancerous mechanisms; its inhibition has also been 
proven to restore apoptosis. A good example of this is the inhibition of ETAR by 
ETAR-specific antagonist ZD4054 (Rosanò et al. 2007a), but also dual ETAR/ETBR 
antagonism with bosentan (Peduto Eberl et al. 2003), both reported to promote 
apoptotic mechanisms. A reduction in the metastatic potential of cancers can also be 
achieved with ETAR antagonism. The treatment of colonic fibroblasts with ZD4054 
achieved inhibition of proliferation, migration, contraction and production of MMPs, 
all mechanisms involved in cancer invasion and metastasis (Haque et al. 2013). 
This success has driven ETAR antagonists such as ZD4054 to clinical trials, showing 
acceptable tolerability in a Phase II trial with prostate cancer patients (James et al. 
2009) while failing, however, a number of subsequent studies. Currently ZD4054 is 
undergoing clinical trials in combination with the widely used FOLFIRI regime for 
advanced colorectal cancer patients. 
 
1.1.5 Crosstalk between ETAR and the MAPK pathway and possible treatment 
combinations 
 
Probably the most significant discovery regarding the endothelin axis, particularly 
with prospect of treating colorectal cancer, is the crosstalk of ETAR activation and 
the MAPK pathway. Being the MAPK pathway central to tumour development and 
progression, a combination of therapies targeted against its mainstream proteins and 
a closely related alternative pathway such as ETAR signalling has the potential for a 
synergistic cancer treatment. 
As mentioned earlier, ETAR has been proven to activate the MAPK pathway through 
the direct activation of a number of proteins such as phospholipases and cyclases 
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and indirect activation of many other proteins (Shome et al. 2000; Blaukat et al. 
2000; Spinella et al. 2002; Spinella et al. 2004). Furthermore, it has been reported 
that ETAR signalling trans-activates the epidermal growth factor receptor (EGFR), 
which triggers mainstream signalling of the MAPK pathway (Bagnato & Rosanò 
2008; Grant et al. 2007). Similarly, ETAR activation was shown to trigger the 
production of platelet-derived growth factor (PDGF) on human smooth muscle cells, 
which interacts with other RTKs (Yang et al. 1999). The transactivation of EGFR 
specifically has been exploited as a combination therapy. The co-administration of 
gefitinib, an EGFR inhibitor, and ZD4054, an ETAR competitive antagonist, achieved 
tumour regression in vivo, as well as, a reduction in key proteins involved in 
angiogenesis and metastases (Rosanò et al. 2007b). 
These results shed light on the possibility of a treatment combination that involves 
the inhibition of an intracellular MAPK pathway protein such as MEK, and the 
antagonism of the ETAR. 
 
1.1.6 RNA interference and cancer treatment 
 
Another therapeutic approach that has raised interest in the last years in cancer 
therapy is RNA interference (RNAi). It is a natural process occurring within the cell 
through the use of non-coding RNAs such as microRNA (miRNA), with functions 
such as gene expression regulation and defence against foreign genetic material 
(Hamilton & Baulcombe 1999; Wilkins et al. 2005; Huang & Zhang 2013). However, 
this natural process can be exploited to silence target genes through the use of short 
interfering RNA (siRNA) (Fire et al. 1998). These are small double stranded RNA 
molecules, of approximately 20 base pairs in length that have the ability to destroy 
target complementary mRNAs. The process involves the siRNA being processed by 
an enzyme called Dicer and incorporated into an RNA-induced silencing complex 
(RISC). The RISC containing processed siRNA then interacts with its complementary 
mRNA sequence to allow Argonaute, the active enzyme of the RISC to degrade the 
target (Hammond et al. 2000; Bernstein et al. 2001). The degradation of target 
mRNAs subsequently prevents the expression of the target protein. While there are 
not any reports on the use of siRNA as a therapeutic molecule in colorectal cancer, 
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some studies have shown promise such as proliferation inhibition observed in head 
and neck carcinoma (Ishimoto et al. 2012). 
Due to its specificity and effectiveness in the reduction of target protein expression, 
the use of siRNA as a potential treatment in combination with small molecules such 
as AZD6244 or ZD4054 could potentially exploit the connection between the MAPK 
and ETAR pathways. 
 
1.2 Organic nanocarriers for anticancer therapeutic delivery 
 
Traditional chemotherapy presents a number of limitations, such as side effects and 
toxicity. While the development of new generation therapeutics addresses these 
limitations and allows the targeting of key molecules with increasing specificity, their 
efficacy is also hindered by their physicochemical properties. Most of these new 
therapeutics, while promising, are prone to degradation or have very poor solubility 
in an aqueous environment. 
Nanotechnology is defined as the manipulation of matter in a scale ranging from 1 to 
100 nm in size, at least in one of its dimensions. The emergence of nanotechnology 
has applications in a number of fields, from novel resistant materials and 
extraordinary physical properties to medical and pharmaceutical applications. A 
subcategory within nanotechnology is nanomedicine, which can be roughly defined 
as the application of nanotechnology for medical purposes. Although there are a 
number of correct definitions of nanomedicine, it is generally considered that it 
involves applications in biosensing, therapeutics, theranostics and medical devices.  
While the concept of “nanoparticle” traditionally refers to structures smaller than 
100nm in size, in the field of nanomedicine is stretched to several hundreds of 
nanometres. Nanoparticles can be divided in inorganic (such as gold nanoparticles, 
iron oxide magnetic nanoparticles or quantum dots) and organic nanoparticles (such 
as peptides, dendrimers, micelles or liposomes). While inorganic nanoparticles are 
significantly smaller (often a few nanometres) and generally used for their unique 
physical properties (such as fluorescence, magnetic properties or energy 
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transmission) organic nanoparticles tend to be in the range between tens of 
nanometres and hundreds of nanometres. 
Organic nanoparticles are fundamentally made of carbon (although carbon 
nanotubes and fullerenes, also made of carbon, are considered inorganic 
nanoparticles), and are generally used as nanocarriers for therapeutic molecules 
such as drugs or nucleic acids, due to their larger size, biocompatibility and often 
ability to entrap smaller molecules. 
Among the different organic nanocarriers, liposomes and micelles (Figure 1.3) offer 
better properties in terms of encapsulation and protection from the environment, but 
their most interesting quality is their larger size compared to dendrimers and easily 
degradable peptide-based nanoparticles. This larger size is desirable to take 
advantage of the enhanced permeability and retention (EPR) effect, which consists 
in the selective accumulation of nanocarriers of a certain size in the tumour masses 
as opposed to other organs, minimizing the side effects that the therapeutic molecule 
would elicit systemically. The rationale behind this phenomenon is that, due to the 
fast angiogenesis in tumours, the formation of the vasculature is aberrant and 
disorganized, leaving larger fenestrations in the vessel walls. This larger 
fenestrations tend to allow the passage of macromolecules and nanocarriers of 
several tens or several hundreds of nanometres in diameter, that are two big to 
translocate through the vessel wall in other tissues. The EPR effect also comprises 
the inefficient lymphatic clearance characteristic of tumour tissue, which favours the 
accumulation of compounds and nanoparticles in the tumour mass over time. 
As opposed to active targeting, in which the surface of nanoparticles is functionalized 
to recognize specific molecules in the tumour cells, passive targeting only depends 
on the diffusion and accumulation of nanoparticles in the tumour through the EPR 
effect. However it must be noted that both active and passive targeting face similar 
limitations in terms of penetrating further into the tumour mass due to several 





Figure 1.3 Schematic representations of a liposome (left) and a micelle (right), including 




Liposomes were described for the first time by Bangham and colleagues (Bangham 
et al. 1965), and have been the most succesful nanocarrier (Mozafari 2010; Malam 
et al. 2009). Liposomes are formed from the interaction of the hydrophobic tails of 
lipid molecules forming a bilayer and exposing their polar heads to the surrounding 
aqueous environment (Figure 1.3). While some of the molecules shown in the image 
are encapsulated, others such as cholesterol or PEG have stabilization or 
accelerated blood clearance (ABC) avoidance purposes. The main advantage of 
liposomes over micelles is that, due to their hydrophobic membrane and aqueous 
core, they can encapsulate both hydrophilic and hydrophobic molecules. This has 
led to the use of liposomes to encapsulate nucleic acids such as siRNA, with 
23 
 
successful results knocking down targeted gene expression in vivo (Gao et al. 2012; 
Gao et al. 2011). The dual different affinity of the liposome membrane and core for 
hydrophobic and hydrophilic molecules has also been exploited for combination 
therapies. For example, the combination of of Mcl1-targeted siRNA and the MEK 
inhibitor PD0325901 in a cationic liposome achieved proliferation inhibition and 
increased apoptosis in vivo (Kang et al. 2011).  However, the stability of liposomes is 
often compromised by the encapsulation of a hydrophobic drug such as rhodamine 
compared to a hydrophilic molecule such as fluorescein (Khan et al. 2008), although 
certain hydrophobic compounds may elicit the opposite effect (Moribe et al. 1998). 
Often, cholesterol is used to increase the stability of the liposomal membrane, 
regardless of the nature of the biological compounds. 
 
Name Nanoformulation Drug Cancer 
Doxil Liposomal Doxorubicin 
Breast and ovarian cancer,  
Kaposi's sarcoma 
Myocet Liposomal* Doxorubicin Breast 
DaunoXome Liposomal Daunorubicin Kaposi's sarcoma 
Depocyt Liposomal Citarabine Lymphomatus meningitis** 
Genexol-PM Micellar Paclitaxel Breast, lung and ovarian*** 
 
Table 1.1 Clinically approved vesicular nanoformulations: * Non-PEGylated, ** In phase II clinical 
trials for leukemia and phase I-II for glioblastoma ***Only approved in Korea. 
 
Liposomes are far more advanced in clinical use than any other nanoparticle (Table 
1.1) (Lammers et al. 2012). The most known example is Doxil, also known as 
Caelyx, a liposomal formulation of doxorubicin, which surface has been 
functionalized with polyethylene glycol (PEG) to avoid recognition by the immune 
system and ABC. Doxil is widely used in the treatment of breast cancer and has 
been proven to reduce neutropenia and cardiotoxicity among other side effects, 
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compared to free doxorubicin, as well as, vinorelbine or mitomycin C combined with 
vinblastine (Keller et al. 2004; O’Brien et al. 2004). Apart from those already 
approved liposomes, a number of them are currently in clinical trials, such as the 
liposomal formulation of floxuridine and irinotecan under the name of CPX-1, which 




Most micelles are especially effective in solubilizing hydrophobic molecules, due to 
the spacious core created by the hydrophobic tails of amphiphiles (Figure 1.3). They 
tend to be around tens of nanometres in diameter, and this makes them generally 
smaller than the liposomes. This has implications in the ABC, as they less often 
need to undergo surface functionalization with molecules such as PEG to avoid it 
(Koide et al. 2008). However, the greatest advantage of micelles over liposomes is 
their ability to solubilize hydrophobic drugs, preventing them from aggregating in 
aqueous solution and creating emboli in vivo (Torchilin et al. 2003). 
Only one micellar formulation of paclitaxel (Genexol-PM) has reached clinical 
approval in Korea for breast, lung and ovarian cancers (Table 1.1), although it is 
undergoing clinical trials in other countries (Lammers et al. 2012). Many other 
micellar formulations are currently undergoing clinical trials, such as a formulation of 
cisplatin (NC-6004), which significantly reduced the renal toxicity commonly linked to 
other cisplatin formulations (Plummer et al. 2011). 
 
1.2.3 DOPE/DC-cholesterol liposomes and GCPQ micelles 
 
Two of the most promising organic nanocarriers are cationic liposomes made from 
3beta-[N-(N',N'-dimethylaminoethane) carbamoyl] cholesterol (DC-chol) and 
dioleoylphosphatidylethanolamine (DOPE), which have been shown to have 
potential as nucleic acid and drug nanocarriers (Zhang et al. 2010; Yang et al. 2012; 
Ciani et al. 2004), and micelles made from N-palmitoyl-N-monomethyl-N,N-dimethyl-
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N,N,N-trimethyl-6-O-glycolchitosan (GCPQ) , also cationic in nature, which have 
been used to solubilize and  orally deliver hydrophobic molecules with high efficiency 
(Qu et al. 2006; Siew et al. 2012; Lalatsa et al. 2012). Cationic nanoparticles have 
the advantage of improving internalization by interacting with the anionic cell surface 
(Pelaz et al. 2013; Hino et al. 2012; Dokka et al. 2000). Due to these positive results 
and promise, these two nanocarriers have been chosen for the present research. 
 
1.3 Three-dimensional cancer models 
 
Most investigations on anti-cancer therapeutic agents follow the same two steps, 
starting with their evaluation in a two-dimensional in vitro model, and then testing 
their efficacy in immunosuppressed animal models. Although, this workflow has 
yielded very valuable information over the years, the development of better cancer 
models is becoming increasingly urgent. On the one hand, the reductionist two-
dimensional in vitro models overlook key mechanisms such as cell-matrix 
interactions and cell three-dimensional orientation, which are extremely important for 
cellular behaviour and response to therapy (Trédan et al. 2007; Cukierman et al. 
2001). Similarly, in vivo studies are not only expensive but a crude approximation to 
real tumours, and do not consider mechanisms, which also play a key role in disease 
development, such as the immune system (Crompton et al. 2014). 
Three-dimensional in vitro models are a compromise between conventional in vitro 
models and in vivo, (Fischbach et al. 2007) and are particularly valuable for cancer 
research. They provide a cellular environment closer to the real tumour mass, whilst 
simultaneously allowing control over a number of parameters (Talukdar et al. 2011; 
Lee et al. 2007). The use of 3D in vitro cancer models has revolutionised cancer 
research, allowing a more controlled environment for cancer to be studied in the 
laboratory. Culturing cells in 3D elicits changes in proliferation, behaviour and protein 
expression compared to monolayers (Magdeldin et al. 2014; Trédan et al. 2007; 
Mikhail et al. 2013), which have an influence on cell fate. In addition, 3D cancer 
models allow for drug penetration factors to be investigated (Hickman et al. 2014; 
Huang et al. 2012).  
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One of the keys to this improvement is the presence of an extracellular matrix 
(ECM), composed of proteins, polysaccharides and proteoglycans (Cukierman et al. 
2001). The interaction of these components with both cell membrane and 
intracellular proteins creates focal adhesion points that trigger mechanotransduction 
pathways and regulate the expression of a number of genes. Three-dimensional in 





The use of spheroids in cancer research has revolutionized the field. They are large 
aggregates of cells that form without a scaffold, through methods such as gyratory 
rotation. Spheroids successfully mimic cellular behaviour in vivo and have been 
widely used for this reason (Pickl & Ries 2009). They also allow the development of 
more complex approaches, such as co-cultures of various cell types which have 
been successfully used to study a wide range of therapeutic approaches, such as 
chemotherapy, radiotherapy and immunotherapy (Santini et al. 1999). In this model, 
while cells in the periphery are highly proliferative, the core of the spheroid tends to 
contain quiescent cells due to the limited access of oxygen and nutrients (Kunz-
Schughart et al. 1998). The dense structure of spheroids also has implications in the 
penetration of therapeutic agents, providing an accurate representation of tumour 
mass density in vivo, in which density remains a physical barrier. The downside is 
that the absence of an extracellular matrix limits cell motility and arguably limits the 




While spheroids are invaluable systems for drug testing and the study of cell 
behaviour to a certain extent, more sophisticated approaches involve the use of 
scaffolds, which allow the study of cell-matrix interactions and mechanisms such as 
cell migration and invasion. These scaffolds can be natural or synthetic. 
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Natural scaffolds are composed of ECM proteins such as collagen, laminin or 
hyaluronic acid (Holliday et al. 2009; Suri & Schmidt 2010; Gurski et al. 2009). The 
presence of ECM proteins not only facilitates cell-matrix interactions, but makes the 
environment susceptible to degradation and remodelling by cells through the 
secretion of metalloproteinases (MMPs) and migration. A good example of a natural 
scaffold that has been widely used for this properties is Matrigel (Shekhar et al. 
2001), which consists of a mixture of ECM proteins. 
On the other hand, synthetic scaffolds are made of polymers such as polyglycolic 
acid (PGA) or polylactide (PL). These scaffolds are stiffer and more representative of 
the ECM mechanical properties (Mooney et al. 2006; Place et al. 2009), but require 
modifications such as the addition of RGD to allow for cell adhesion (Villanueva et al. 
2009). Due to the interest of our group in cell behaviour as opposed to matrix 
mechanical properties, our research involves the use of natural scaffolds, 
fundamentally collagen type I hydrogels. 
 
1.3.3 Tumouroid, a collagen-based in vitro model of cancer 
 
While the use of collagen type I hydrogels  mimic the ECM and is a promising 
approach, their main limitation is their high water content (Szot et al. 2011). In this 
research, we use a plastic compression technique to create tumouroids, 3D in vitro 
models of colorectal cancer, by removing the excess water from collagen type I 
hydrogels. This model mimics the mechanical properties of real tissue better than 
uncompressed collagen hydrogels (Ricketts et al. 2014; Nyga et al. 2013; Magdeldin 






The overall aim of this thesis was to create organic nanoformulations, of a suitable 
anticancer therapy and test their efficacy on a collagen-based 3D model of colorectal 
cancer. This is based on the great promise of both approaches, as described in this 
chapter. The purpose behind that aim is to merge three of the most significant 
advances in cancer research: novel targeted therapeutic molecules (e.g. AZD6244), 
the use of nanotechnology as a drug delivery platform (e.g. liposomes and micelles), 
and the inclusion of complex in vitro approaches to study both cancer behaviour and 
anti-cancer drug development (e.g. 3D models of cancer). 
By combining therapy, nanotechnology and tissue engineering this work intends to 
shed light on the need to integrate these technologies as they must evolve together 
with the process of drug discovery. The specific objectives include: 
- I) Find suitable candidates for a combination of treatments involving the ETAR 
and MAPK pathways that achieve an additive or synergistic inhibitory effect 
on cancer proliferation, including small molecules and siRNAs as therapeutic 
agents. 
- II) Create nanoformulations of the chosen treatments using DOPE/DC-
cholesterol liposomes and GCPQ micelles. 
- III) Test the efficacy of said nanoformulations in both conventional monolayer 

























2 General Materials and Methods 
 
This chapter describes general techniques that are routinely used throughout this 
research. Further details are included in the Materials and Methods sections of 
specific chapters as needed. 
 
2.1 Cell maintenance 
 
Cell lines HT29 (human colorectal adenocarcinoma) and HCT116 (human colorectal 
carcinoma) were obtained from the European Collection of Animal Cell Cultures 
(ECACC, Sigma Aldrich, Gillingham, Dorset, UK). All experiments were performed 
using cells between the 9th and the 40th passage. 
Cells were cultured routinely under aseptic conditions in 75 cm2 tissue culture 
polystyrene flasks at 37ºC and in a 5% CO2 / 95% humidified air atmosphere, using 
McCoy’s 5A (Lonza, Castleford, UK)  supplemented with 10% foetal bovine serum 
(FBS) and 1% penicillin/streptomycin (P/S) as culture medium, unless stated 
otherwise. When 80-90% confluence was reached, cells were washed with 
phosphate buffered saline (PBS), detached from the flask with 1mg/mL trypsin in 
PBS and passaged to a new flask at 1:5 to 1:10 fold dilution after neutralizing the 
enzyme activity, using medium supplemented with FBS (approximately every 72 h). 
When cells did not undergo passage, they were fed with fresh medium 
supplemented with FBS every 48 hours. 
 
2.2 Proliferation and metabolic activity assays 
 
Two types of techniques were used to determine basal or changing proliferation 
levels in these cell lines. One of the techniques is more directly related with the 
amount of cells present (e.g. cell counting, total DNA assay), and the other indirectly 
measures the relative amount of cells present by measuring their metabolic activity 
(e.g. alamar blue assay, MTT assay) or aggregate size. 
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Specific cell culture protocols from cell seeding to the proliferation and metabolic 
activity assays are described in the corresponding chapters, while the protocol for 
the assay itself is described in the following sections. 
 
2.2.1 Cell counting 
 
This technique directly measures the number of cells in a population, and hence is 
an indicator of proliferation. As the gold standard for measuring cell proliferation, cell 
counting was used to validate MTT as an indirect indicator of cell proliferation, and to 
seed known concentrations of cells in every experiment that required so.  
Cells were trypsinized and neutralized, counted in a haemocytometer, and 
calculations were made to determine the required cell dilutions. To use the 
haemocytometer, 10 µL of cell suspension were added on each side of the 
haemocytometer and the cells entrapped in 8 squares out of the total 18 were 
counted. The total value was divided by 8 and multiplied by 104 to obtain the total 
number of cells in 1 mL. The total number of cells in the suspension were 
determined, multiplying this value by the total volume of the suspension. 
 
2.2.2 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
 
Metabolic activity in conventional 2D in vitro cultures was determined through MTT 
assay. The NAD(P)H-dependent oxidoreductases present in cells are capable of 
reducing this tetrazolium compound into formazan, which forms insoluble blue 
crystals. Therefore, the amount of formazan crystals formed is proportional to the 
metabolic activity of cells. MTT solution (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was prepared dissolving 200mg of powder (Sigma 
Aldrich M2128) in a mixture of 5 mL of 100% v/v molecular grade ethanol (Sigma 
Aldrich E7023) and 5 mL of milli-Q water, making it 40 times more concentrated than 
the active concentration for cellular assays. Then 12.5 µL (24-well plate) or 25 µL 
(12-well plate) of this solution were added to the pre-existing 500 µL (24-well plate) 
or 1 mL (12-well plate), hence diluting it to its active concentration. 20 mins later, 
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when blue crystals formed (and a colour change from yellow to blue was observed), 
medium was aspirated, wells washed with PBS, and crystals dissolved in 400 µL of 
dimethyl sulfoxide (DMSO) (Sigma Aldrich D5879). 100 µL of the resulting blue liquid 
were transferred to a 96-well plate and absorbance was read at 570 nm in a 
colorimetric plate reader (Anthos 2010 Standard, Biochrom) (n=12). 
 
2.2.3 Total DNA assay 
 
Proliferation in conventional 2D in vitro cultures was determined by total DNA assay, 
using the Hoechst stain total DNA kit (Sigma Aldrich, DNAQF). Hoechst 33298 is a 
water-soluble bis-benzimide that binds to double stranded DNA. This binding shifts 
its fluorescence emission from a 510-540 nm range to a maximum 461 nm . A 
1:1000 dilution Hoechst 33298 dye solution and a 10µg/mL DNA standard solution 
were prepared following the conventional protocol. A DNA concentration standard 
curve of dilutions from 0 to 10µg/mL was prepared to extrapolate the concentration 
of DNA (µg of DNA per mL) from the fluorescence emitted from known 
concentrations of calf thymus DNA reacting with the dye. 100µL of sample or 
standard were added to 100µL of dye previously loaded in a black 96-well plate. 
Fluorescence was read immediately after (excitation=350 nm, emission=460 nm) in 
a Fluoroskan Ascent FL (Thermo Labsystems) (n=12). 
 
2.2.4 Alamar blue® assay 
 
Metabolic activity in 3D in vitro models was determined using Alamar Blue® assay 
(Invitrogen, Paisley, UK). The blue compound 7-hydroxy-3h-phenoxazin-3-one-10-
oxide, also known as resazurin shows a weak fluorescence, but when reduced by 
cell metabolism to resorufin, it changes to a pink colour with a strong red 
fluorescence. Concentrated Alamar Blue was diluted 1:10 in Phenol Red-free 
medium and protected from photodegradation using tin foil. Then wells were 
washed, medium was substituted by an equal volume of the diluted Alamar Blue, 
covered in tin foil, and incubated for four h in a 370C, 5%CO2/air humidified 
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atmosphere, rocking occasionally. After observing a colour change from blue to pink, 
100µL of the resulting solution were transferred to a black 96-well plate and 
fluorescence was read (excitation=530 nm, emission=620 nm) in a Fluoroskan 
Ascent FL (Thermo Labsystems) (n=12) 
 
2.2.5 Aggregate area measurement 
 
Another technique to measure proliferation in a 3D in vitro model involves calculating 
the areas of cell aggregates. Images of tumoroids were taken using an Olympus 
CKX31 microscope (x200 magnification) with a Panasonic camera (x0.5 
magnification). Aggregate areas were measured using the Image J software (version 
1.47v, released 08/07/2013) (Figure 2.1). 
 
 
Figure 2.1 Demonstration of the use of Image J software to measure cell aggregate areas. Cell 
aggregates in 3D in vitro cultures were delineated by using the “Freehand selection” tool manually 




2.3 Approaches to cell molecular analysis 
 
Specific protocols involving cell culture and drug treatments prior to molecular 
studies will be described in subsequent chapters. The techniques explained here 
describe the experiments after the end point of the specific small molecule and 
siRNA treatment protocols. 
 
2.3.1 Protein extraction and quantification 
 
After washing remaining medium with PBS, plates were placed on ice and cells were 
lysed by adding 250µL of RIPA (Radio-Immunoprecipitation Assay) buffer (Sigma-
Aldrich R0278) supplemented with a mixture of protease inhibitors. Lysates were 
centrifuged at 12,000g for 5 mins at 4oC to precipitate large fragments of cells, and 
the supernatant containing the protein was stored at -20oC. 
Protein extracts were diluted in protease-free molecular grade water at a 1:5 dilution, 
and quantified using the Lowry assay (Thermoscientific, 23240). Absorbance was 
read at 750nm using a Jenway Genova Plus Spectrophotometer and protein 
concentrations were extrapolated from a the Lowry standard curve. 
 
2.3.2 Polyacrylamide gel electrophoresis (PAGE) and Western blot 
 
Total protein concentration was standardized for all samples through dilutions in 
RIPA buffer. After mixing the protein with a loading dye (NuPAGE® LDS Sample 
Buffer, Life technologies, NP0007) containing 12.5% β-Mercaptoethanol (Sigma 
Aldrich, M3148) to make a total of 40µL, samples were heated at 95oC for five 
minutes to denature the protein (heating block QBT1, Grant). 34µL of the samples 
were loaded in the corresponding lane of a NuPAGE 4-12% Bis-Tris polyacrylamide 
gel (Invitrogen, NP0322BOX) next to a pre-stained protein ladder (SeeBlue ® 
Prestained, Invitrogen LC5625) for molecular weight identification, covered in buffer 
(MES SDS running buffer, Life Technologies, NP0002) and run at 150V of voltage 
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(as limiting parameter), 150mA of current and 20W of power for 60-90 min in a XCell 
SureLock™ Electrophoresis Cell connected to a Consort EV231 powerpack. 
Once proteins are separated by weight, gels are set up against PVDF membranes 
(Immun-Blot® PVDF membrane, Biorad, 162-0177) as indicated in Figure 2.2 to be 
transferred, covered in transfer buffer (NuPAGE® transfer buffer, Life technologies, 
NP0006-1) and run at 30V of voltage, 250mA of current, and 20W of power for 90 
min in a (XCell II Blot Module, Invitrogen). Transfer was confirmed by the pre-stained 
protein ladder. 
 
Figure 2.2 Representation of the Blot Module set up. Blotting pads and filter papers were pre-
soaked in transfer buffer and layered as shown above. Bubbles were removed from every layer  by 
rolling with a plastic cylinder. 
 
Membranes were rinsed with PBS-tween20, blocked with a 5% milk solution (2.5% 
BSA for pERK detection) for 30 mins, and incubated with a specific primary antibody 
(diluted in 1% BSA solution) overnight at 4oC, or two hours at room temperature 
(details on the antibodies are shown in Table 2.1). After rinsing with PBS-tween, 
membranes were incubated with a secondary antibody linked to horseradish 
peroxidase (HRP) for 40 min, rinsed again, treated with the Bio-Rad Immuno-Star 
Western C developer (BioRad, 170-5070) and visualized using a BioRad Molecular 
Imager ®, ChemiDoc™ XRS+ with ImageLab™ Software.  
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After visualization, bound antibodies were removed using Restore Plus Western 
Stripping Buffer (Thermo Scientific, 46430), re-incubated with a GAPDH antibody for 
30 min, rinsed, incubated with a secondary antibody for 40 min, developed and 
visualized.  
This two-step approach is intended to prevent the strong signal from the 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from 
eclipsing the target protein. GAPDH was used to ensure equal loading among 
samples and to standardize the densitometry of Western Blot images, obtained with 
the Image J software (version 1.47v, released 08/07/2013). 
 
 
Table 2.1 Source and details of the antibodies used in this research. All antibodies were used at 
dilutions that range from 1:500, in the case of anti-ETAR, and 1:2000, in the case of anti-GAPDH. All 
antibodies are primary except for the HRP-linked antibodies raised in goat, which are secondary. 
 
 
2.3.3 RNA extraction and quantification 
 
After washing remaining medium with PBS, plates were placed on ice and cells were 
lysed using 350µL of RNeasy lysis buffer (RLT) buffer and passed through a 30G 
needle to homogenize the sample. RNA was extracted using the RNeasy mini kit 
(Qiagen, 74104) and quantified using a spectrophotometer (at wavelength 260 nm 




2.3.4 Conventional RT-PCR 
 
RT-PCR was performed using the OneStep RT-PCR Kit (Qiagen, 210210). Three 
master mixes were created separately to facilitate manipulation, and to increase 
accuracy by manipulating larger amounts of liquid. The first master mix contains 
0.6µL of enzyme mix, 3µL of (5x) buffer and 1.4µL of molecular grade water per 
reaction. The second master mix contains 0.9µL of each sense and antisense 
primers, 0.6µL of deoxinucleotides-tri-phosphate (dNTP) and 2.6µL of molecular 
grade water per reaction. The last master mix contains 20ng/mL of sample RNA in 
molecular grade water. For all this mixtures, an extra 10% volume of every reactant 
was added to allow for pipetting errors. 
5µL of each master mix were combined to make a total of 15µL (100ng of template 
RNA) and target sequences were amplified in a thermal cycler (Techne Flexigene) 
following a cyclic programme as indicated in Figure 2.3. PCR products were mixed 
with 2µL of 6x loading dye solution (Thermo Scientific, R0611) to facilitate handling, 
loaded in a 1% agarose gel containing ethidium bromide (EtBr) next to a 50bp DNA 
Step Ladder (Promega, G452A) and run for 20 min at 100V in a electrophoresis gel 
system (Midcell® Primo™ EC330, Thermo Electron), before visualizing them under 
UV light (100nm) using a BioRad Molecular Imager®, ChemiDoc™ XRS+ with 





Figure 2.3 Schematic representation of RT-PCR amplification cycles. Changes in temperature 
allow for the DNA strands to denature, anneal and amplify the sequence for 35 cycles. The process 
starts with the reverse transcriptase copying the target RNA sequence into complementary DNA. The 
enzyme is deactivated after the first denaturation. 35 cycles of amplification by a DNA polymerase 
follow. A final longer extension period is allowed before samples are visualized. 
 
2.3.5 Quantitative RT-PCR 
 
For accurate comparative measures of mRNA copy numbers a quantitative 
technique is needed. Quantitative RT-PCR was performed using the QuantiTect 
SYBR Green RT-PCR kit (Qiagen, 204243) and the LightCycler® 1.5, with 
LightCycler® Software 3.5.3 (Roche). mRNA copy numbers were determined using a 
housekeeping gene (G6PDH), both as an internal control to standardize the samples 
of the same template and to extrapolate the copy number from fluorescent signals 
and a standard curve. 
The method is similar to the conventional RT-PCR represented in Figure 2.3 with a 
few differences in the preparation and programme.  As before, three master mixes 
were prepared. The first one contained 0.2µL and 9.8µL of 2x buffer per reaction, the 
second one contained 2µL of each primer and 1µL of molecular grade water per 
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reaction, and the template mix was identical to the previous section (20ng/mL) (all 
mixtures were prepared adding an extra 10% of every reactant to account for 
pipetting errors). 5µL of the primer mix and 5µL of the template dilution (100ng of 
sample RNA) were mixed in a reaction tube, and 10µL of the enzyme mix were 
added last, protecting the glass capillaries from the light. Each template had an 
internal control of G6PDH, which was also used to create a standard curve for 
absolute quantification. 40 cycles of amplification of 3x30 sec each were run, 
accumulating fluorescent signals for the quantification and recording a melting curve 
to assess the quality of the reaction (n=3). Details on the primers used both for 
conventional and quantitative RT-PCR are shown in Figure 2.4. 
 
 
Figure 2.4 Details and sequence of the primers used in this research. All primers were designed 
to have melting temperatures and GC contents as similar to their counterparts as possible. All primers 
were obtained from Sigma-Aldrich. 
 
 
2.4 Statistical Analysis 
 
Results are shown grouping means and standard deviations from different 
experiments for representation, and treatment groups were normalised in reference 
to their control groups for convenience. This normalisation was done by considering 
the control group of that experiment as a 100% value (represented as 1 from a 0 to 1 
scale) and the different treatments as percentage fractions of that control (also 
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represented in a 0 to 1 scale). However, statistical analysis (indicated by asterisks 
and figure descriptions) was performed on the original data. 
Comparisons between two individual data sets such as the treatment with ET-1 
versus the control were analysed using the Student’s t-test. Drug concentration 
ranges and analyses involving more than two treatment groups were analysed using 
one-way ANOVA followed by post hoc analysis using Dunnett’s test or Bonferroni’s 
test. Differences were considered significant with p values equal or less than 0.05.  
Parametric tests were used since data can be considered to follow a normal 
distribution. Individual samples were considered independent (random sampling from 
defined populations) and standard deviations between treatment groups were 
similar, with n=12 for drug treatments. Parametric tests intrinsically have more 
statistical power and are designed to calculate differences between means as 
opposed to medians. 
All data analysis and graphical representations were done using the GraphPad 


































This chapter reports on the response of two colorectal cancer (CRC) cell lines to 
different therapeutic molecules currently in clinical trials. Three of them were 
chemotherapeutic molecules directed against the MAP kinase pathway, but a 
competitive antagonist of the ETAR receptor was also explored as a possible 
treatment combination.  
The therapeutic targets of interest have been widely reported to contribute to tumour 
growth and progression.  These are the mitogen activated protein kinase kinases 1 
and 2 (MEK1 and MEK2), and the endothelin A receptor (ETAR), whose activation 
triggers a phosphorylation cascade that also cross talks with the MAP kinase 
pathway. The expression levels of these molecules, as well as, ETAR natural ligand 
endothelin-1 (ET-1) and a membrane receptor associated to the MAPK pathway, the 
epidermal growth factor receptor (EGFR) were also studied, as they influence MAPK 
and ETAR signalling. 
The colorectal cancer cell lines used in this study, HCT116 and HT29, have known 
mutational status, both in terms of expression of these targets and natural ligands, 
but also in terms of other molecules within the pathways of interest, such as KRAS 
or BRAF, which are mutated in HCT116 and HT29, respectively (Little et al. 2011). 
The aim of these experiments is to define the most efficacious therapeutics to take 
forward into combination treatments, targeting both pathways simultaneously in 
cancer cells with known, relevant mutations; hypothesising that a treatment 
combination would be more effective than monotherapies. In the process of 
determining the most suitable therapeutic molecules or combinations for 
nanoformulations (described in this and the next chapter), a variety of unexpected 




3.2 Materials and methods 
 
3.2.1 Cell characterization 
 
The morphologies of HCT116 and HT29 colorectal cancer cell lines (ECACC, Sigma-
Aldrich, UK) are easily distinguishable. While HCT116 cells have visible, strongly 
defined pseudopodia giving them a barbed aspect, HT29 cells tend to form 
aggregates with round edges, mimicking the glandular epithelial tissue they arise 
from, therefore, these cells are more differentiated than HCT116. Both HCT116 and 
HT29 are small, fast-proliferating cells (HCT116 more than HT29) with abundant 




A number of small therapeutic molecules were tested in vitro, both alone and in 
combination with appropriate growth factors. This is in line with widely accepted 
experimental protocols where the efficacy of therapeutic drug against a 
receptor/target is tested in the presence of the natural ligand, such as the growth 
factors EGF and ET-1, that binds directly or upstream of the receptor/target, to 
promote activation.  Chemical representations of the key small molecules are shown 
in Figure 3.1. PD98059 was obtained from Enzo Life Sciences (EI-360-0005, UK), 
U0126-EtOH and AZD6244 (Selumetinib) were obtained from Selleckchem (S1102 
and S1008, Germany). ZD4054 (Zibotentan, ETAR antagonist) was purchased from 
Selleckchem (S1456), and BQ123 (ETAR antagonist; not shown in figure 1; used for 
comparison) was acquired from Sigma-Aldrich (B150).  For the growth factors, all 
three batches of Endothelin-1 (ET-1) were acquired from Bachem (H6995) and 
Epidermal Growth Factor (EGF) from Sigma-Aldrich (E9644).  
All inhibitor treatments were performed over a range of concentrations, while the 
growth factors EGF and ET-1 were used at 10 ng/mL and 10 nM, respectively, 
according to previous work in this department and the literature (Davenport 2002; 




Figure 3.1 Schematics of therapeutic small molecules. MEK inhibitors PD98059, U0126 and 
AZD6244, and ETAR-specific antagonist ZD4054. 
 
3.2.3 Cell culture and experimental protocols for therapeutic treatments 
 
Colorectal cancer cell lines HCT116 and HT29 were specifically selected for their 
different mutation profile regarding the MAPK pathway. All cell culture relative to this 
chapter was carried out without antibiotics.  
For drug testing, experiments cells were seeded in 24-well plates (3.2 x 104 cells/well 
for HT29s and 3 x 104 cells/well for HCT116) in 500µL of McCoy’s 5A medium 
supplemented with 10% fetal bovine serum (FBS). Serum was removed after 24 h to 
prevent possible drug-serum interactions and to semi-synchronize cell cycles (at G0). 
24 h later, small molecules were diluted into serum-free medium at a range of 
concentrations and used to treat cells for 48 h. At this end point, proliferation and 
metabolic activity assays were performed to measure inhibition (see chapter 2 (pg. 
30)). Ligands were added 1 hour after the start of inhibitor treatment for studies 
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investigating pathway activation with EGF (10ng/mL) or ligand competitive binding 
with ET-1 (10nM). 
Specifically for AZD6244, a set of experiments were carried out to attempt to 
duplicate published outcomes (Troiani et al. 2012); therefore,  the protocol followed 
mirrored that of Troiani and colleagues. Here cells were seeded in 24 well plates and 
left to grow in serum containing media for 48 h, prior to treatment. Inhibitor 
concentrations and time of exposure were exactly the same, but medium was 
substituted by DMEM. 
The following molecular investigations were carried out. For mRNA reference level 
analysis of target genes, 1 million cells were seeded in a Petri dish, and lysed using 
RLT buffer at 60% confluence.  
For protein studies, to determine the effect on MEK inhibition, cells were seeded in 
6-well plates (2.5 x 105 cells/well for HT29 and 2 x 105 cells/well for HCT116), 
following the same serum removal and treatments as for the proliferation assays 
described above. After one hour of treatment, 10ng/mL of EGF was added to the 
treated cells for 10 min to activate the MAPK pathway. Cells were then lysed using 
RIPA buffer supplemented with protease inhibitors. RNA and protein extraction, 





3.3.1 Reference mRNA expression profiles 
 
Before any treatment with growth factors or therapeutic molecules was carried out, 
quantitative RT-PCR of the target molecules was performed to determine if they 
were expressed by the two cell lines at significant levels 
Molecules investigated include the direct targets for the drugs used; MEK-1 (one of 
the targets of PD98059, U0126 and AZD6244), and ETAR being (the target of 
ZD4054 and BQ123). Also, EGFR was included as a common initiator of the MAPK 
pathway and as a known subject of transactivation through ETAR signalling and ET-
1 was included as the natural ligand for ETAR. Results show detectable levels of all 
target molecules (Figure 3.2), with average MEK-1 (~100-fold) and EGFR (~40-fold) 
levels much higher than the endothelin axis molecules. 
 
 
Figure 3.2 mRNA expression levels of target genes in HT29 and HCT116 colorectal cancer 
cells. 1,000,000 cells were seeded in Petri dishes, lysed at 60% confluence and processed for 
quantitative PCR. The relative expression levels in 100 ng of total RNA were determined using known 
standards of the housekeeping gene h-G6PDH (3261883001, Roche) and normalized accordingly. 




3.3.2 Treatment with MEK inhibitors 
 
All three inhibitors of MEK-1/2 (AZD6244, PD98059 and U0126) showed significant 
effects on both cell lines, HCT116 and HT29, although there were clear differences 
among molecules and cells as delineated below.  
The principle indicator of proliferation was the total DNA assay, and was supported 
by the MTT assay, which measures metabolic activity and is validated later in this 
chapter (see Response to ET-1). 
The approximate range of concentrations for each drug was obtained from the 
literature and previous studies from the group (Troiani et al. 2012; Davies et al. 2007; 
Dokladda et al. 2005; Yamaguchi et al. 2002; Tentler et al. 2010; Little et al. 2011; 
Favata et al. 1998; Haque et al. 2013); according to these PD98059 should be used 




When treated with PD98059, HT29s appeared to respond more readily than 
HCT116s, showing more proliferation inhibition especially at high concentrations of 
the drug. Cell proliferation was determined by measuring the total amount of DNA 
present in the sample culture and supported by a measurement of metabolic activity 
determined via MTT. The two assays showed similar trends to each other. 
HCT116 cells showed a drop in proliferation of less than 30% which appeared 
constant over 10-50 µM, followed by a further response to treatment at 100 µM 
resulting in a final proliferation inhibition of 45% and metabolic activity inhibition of 
29%, which reached significance of p<0.05 and p<0.01, respectively (Figure 3.3). 
HT29 cells showed a constant reduction in proliferation and metabolic activity with 
increasing concentrations of this inhibitor (Figure 3.4), reaching a 50% proliferation 





Figure 3.3 Effect of the MEK inhibitor PD98059 on HCT116 cells. Cells were treated with different 
concentrations of the drug for 48 h before total DNA assay (left) and MTT assay (right) were 
performed. Significance (compared to control): *p<0.05, **p<0.01. 
 
 
Figure 3.4 Effect of the MEK inhibitor PD98059 on HT29 cells. Cells were treated with different 
concentrations of the drug for 48 h before total DNA assay (left) and MTT assay (right) were 
performed. Significance (compared to control): *p<0.05, **p<0.01, ***p<0,001. 
 
In order to further explore the apparent plateau of response (from 10-50 µM) in 
HCT116 cells and the more significant and stepwise inhibition in HT29 cells, these 
experiments were repeated including an extra step: 10ng/mL of EGF was added 10 
min after the inhibitor, in order to activate the MAPK pathway and see differences 
which may be driven by the different mutation profiles of these cell lines.  
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Results were exciting. PD98059 changed the response profile of HCT116 cells, 
resulting in a more step-wise response and an overall greater response, with 50% 
proliferation inhibition (total DNA) and 27% metabolic activity inhibition (MTT) at the 
greatest concentration tested, 100 µM (p<0.01 and p<0.001, respectively, Figure 
3.5). For HT29 cells, the inhibition of proliferation that resulted from treatment with 
PD98059 (Figure 3.4) was abolished in the presence of EGF. Furthermore, the 
overall effect of PD98059 and EGF on these cells was one of significant proliferation 
increase (2-fold, p<0.05). Surprisingly, only a small reduction in metabolic activity of 
7% was observed at the highest PD98059 concentration (p<0.05, Figure 3.6) 
 
 
Figure 3.5 Effect of the MEK inhibitor PD98059 in the presence of EGF on HCT116 cells. Cells 
were treated with different concentrations of the drug for 1 hour. Following this, 10ng/mL of EGF was 
added to all treatment groups including the control in order to activate the MAPK pathway. 48 h after 
the treatment total DNA assay (left) and MTT assay (right) were performed. Significance (compared to 






Figure 3.6 Effect of the MEK inhibitor PD98059 in the presence of EGF on HT29 cells. Cells were 
treated with different concentrations of the drug for 1 hour. Following this, 10ng/mL of EGF were 
added to all treatment groups including the control in order to activate the MAPK pathway. 48 h after 





Similar to PD98059, U0126 treatment resulted in generally inhibitory responses 
when tested in HCT116 and HT29 colorectal cancer cells, with a major exception. 
In the case of HCT116 cells, proliferation inhibition (total DNA) appeared dose 
dependent  with a maximum response of 29% at the highest concentration of 1 µM 
(p<0.001), while the effect on metabolic activity (MTT) was slightly uneven 
(specifically for 100nM) reaching its maximum inhibition of 35% also at the highest 
concentration (p<0.001, Figure 3.7). However, the response of HT29 cells to this 
drug was totally different: the effect on proliferation was  a typical case of paradoxical 
activation, often reported with anti-cancer drugs (Wang et al. 2008). Over all 
concentrations tested, proliferation as measured by total DNA, increased almost 
reaching a two-fold enhancement at the highest point (100nM, p<0.001), while 
metabolic activity remained unchanged apart from a significant drop at the highest 




Figure 3.7 Effect of the MEK inhibitor U0126 on HCT116 cells. Cells were treated with different 
concentrations of the drug for 48 h before total DNA assay (left) and MTT assay (right) were 
performed. Significance (compared to control): *p<0.05, **p<0.01, ***p<0.001. 
 
 
Figure 3.8 Effect of the MEK inhibitor U0126 on HT29 cells. Cells were treated with different 
concentrations of the drug for 48 h before total DNA assay (left) and MTT assay (right) were 
performed. Significance (compared to control): ***p<0.001. 
 
As for PD98059, experiments were repeated in the presence of exogenous EGF. 
HCT116 responded to this treatment in a similar way to the treatment with U0126 
alone, with a 33% proliferation inhibition (total DNA, p<0.001) and 14% metabolic 
activity inhibition (MTT, p<0.05) at the maximum concentration of U0126 (1 µM). The 
reduction in proliferation was slightly less pronounce at 100 nM, although still 
significant (p<0.01) (Figure 3.9). The addition of EGF to the treatment significantly 
changed cell response for HT29 cells: the proliferation enhancement observed with 
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the drug alone was abolished. Furthermore, the combination of U0126 and EGF had 
no overall effect on the cells with no statistically significant changes observed either 
in proliferation (total DNA) or metabolic activity (MTT) (Figure 3.10). This could be 
due to a positive feedback on alterative pathways caused by the inhibitor that is 
counteracted by the external activation of the pathway.  
 
Figure 3.9 Effect of the MEK inhibitor U0126 in the presence of EGF on HCT116 cells. Cells 
were treated with different concentrations of the drug for 1 hour. Following this, 10ng/mL of EGF were 
added to all treatment groups including control in order to activate the MAPK pathway. 48 h after the 
treatment total DNA assay (left) and MTT assay (right) were performed. Significance (compared to 
control): *p<0.05, **p<0.01, ***p<0.001. 
 
 
Figure 3.10 Effect of the MEK inhibitor U0126 in the presence of EGF on HT29 cells. Cells were 
treated with different concentrations of the drug for 1 hour. Following this, 10ng/mL of EGF were 
added to all treatment groups including control in order to activate the MAPK pathway. 48 h after the 





Western blot assay was performed in order to confirm that the paradoxical increase 
in HT29 proliferation cause by U0126 in the absence of EGF corresponded with 
activation of the MAPK pathway (Figure 3.11). Since the function of MEK is adding a 
phosphate group to the ERK protein, its downstream target in the MAP kinase 
pathway, by detecting the amount of phosphorylated ERK (pERK, its activated form) 
we would get a direct indication of the activity (or inhibition of activity) of MEK. The 




Figure 3.11 Effect of the MEK inhibitor U0126 on expression of phosphorylated ERK, in HT29 
cells. Cells were treated with increasing concentrations of U0126 for 60 min and then the pathway 
was activated with EGF at 10ng/mL for 10 min. Western blot shows that protein levels of  pERK, the 
protein activated downstream of MEK,  are reduced with increasing concentrations of U0126, 
suggesting that the activity of MEK has been impaired. Control: no U0126 treatment. Top row: 




This inhibitor was specifically designed for cancers bearing mutations in RAS and 
RAF, present in cell lines HCT116 and HT29, respectively. For experiments with 
AZD6244, a wider range of concentrations is shown here, since it was chosen 
among the MEK inhibitors as the most suitable therapeutic molecule.  
Treatment with AZD6244 resulted generally in inhibition of proliferation in both cell 
lines used. Results were quite similar for HT29 and HCT116, with an inhibitory effect 
becoming evident at 100nM and higher doses, and responses appeared stepwise. In 
HCT116 cells, AZD6244 inhibited proliferation (total DNA) 22% at 1 µM and 43% at 
10 µM (p<0.001), and metabolic activity (MTT) 18% at 1 µM and 32% at 10 µM 
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(p<0.001, Figure 3.12). In HT29 cells, AZD6244 inhibited proliferation 26% at 1 µM 
and 48% at 10 µM (p<0.001), and metabolic activity 14% at 1 µM (p<0.01) and 24% 
at 10 µM (p<0.001) (Figure 3.13).Overall, results from AZD6244 treatments are more 
similar to PD98059 than U0126. 
 
 
Figure 3.12 Effect of the MEK inhibitor AZD6244 on HCT116 cells. Cells were treated with 
different concentrations of the drug for 48 h before total DNA assay (left) and MTT assay (right) were 
performed. Significance: **p<0.01, ***p<0.001. 
 
 
Figure 3.13 Effect of the MEK inhibitor AZD6244 on HT29 cells. Cells were treated with different 
concentrations of the drug for 48 h before total DNA assay (left) and MTT assay (right) were 




The reduction in pERK protein levels presented below following treatment with 
AZD6244 mimics the inhibition of proliferation and metabolic activity observed in 
both cell lines, resulting in apparent total abolition of protein at the highest AZD6244 
concentration (10 µm). This suggests that proliferation inhibition happens through the 
impairment of MEK kinase activity on ERK, caused by the inhibitor (Figure 3.14).  
 
 
Figure 3.14 Western blot of phosphorylated ERK, activated downstream protein of MEK, after 
treatment with AZD6244. The levels of pERK are reduced with increasing concentrations of 
AZD6244, suggesting that the activity of MEK has been impaired. HCT116 cells were seeded at 
200000cells/well and HT29 cells at 250000cells/well, after 24 h serum was withdrawn for another 24 
h, cells were treated with increasing concentrations of AZD6244 for 60 min and then the pathway was 
activated with EGF at 10ng/mL for 10 min. Cells were lysed, protein was extracted, quantified and 
analysed by PAGE and Western Blotting. 
 
Considering the above results for all three MEK inhibitors, AZD6244 was considered 
the best option for further work. In spite of AZD6244 showing the best results in 
metabolic activity and proliferation inhibition, the active concentrations of the drug 
shown here were much higher than those reported in the literature. For that reason, 
another experiment was designed to mimic the exact conditions and follow the same 
methods of one of the publications (Troiani et al. 2012) measuring AZD6244 efficacy 
by MTT. The most fundamental change in the protocol was not to starve the cells 
(not removing serum prior to the treatment). Under these conditions, HCT116 
showed paradoxical activation of metabolic activity at the highest AZD6244 
concentrations, 1 µM (14% inhibition, p<0.05) and 10 µM (18% inhibition, p<0.01), 
while HT29 only showed significant metabolic activity inhibition at 10µM (20%, 
p<0.001) (Figure 3.15). These paradoxical results are consistent with the presence 




Figure 3.15 Effect of AZD6244 on metabolic activity mimicking a protocol in the literature. Cells 
were cultured in DMEM supplemented with 10% FBS and 1% P/S for 48h before treatment, instead of 
removing growth factors (present in the serum). Significance (compared to control): *p<0.05, 
**p<0.01, ***p<0.001. 
 
Based on the results on the efficacy of the three MEK inhibitors, AZD6244 was 
deemed the most suitable and selected for combination treatments and 
nanoformulations. Also, due to the clear dose-dependent inhibitory response elicited 
by AZD6244 and its correlation with a reduction in target MEK1/2 activity, a 
comparative experiment involving EGF stimulation was not necessary in this case. 
 
3.3.3 Treatment with ETAR competitive antagonists 
3.3.3.1 Response to ET-1 
 
The pathways of interest naturally respond to growth factors such as EGF and ET-1. 
While EGF is a well-known activator of the MAPK pathway (Mebratu & Tesfaigzi 
2009; Gao et al. 2005) there is much less work carried out involving ET-1 (Grant et 
al. 2007; Haque et al. 2013). Cells responded to EGF as expected, with a maximum 
increase in proliferation at 10mg/mL and no differences in ERK phosphorylation 
between 1, 2 and 3 h of exposure to EGF (data not shown). 
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In the initial experiments exploring the effect of ET-1 (10nM) on HT29 and HCT116 
cells, the ligand increased metabolic activity between 1.5- and 2-fold (p<0.01 and 
p<0.001 after 48- and 80-hour treatments. This experiment was carried out in 24-well 
plates at two different seeding cell densities (25000 and 50000 cells/well). While the 
lower seeding density was affected by the treatment, the higher seeding density 
showed no response, probably due to a plateau in cell metabolism as a result of over 
confluence (Figure 3.16).  
 
 
Figure 3.16 Effect of endothelin-1 (ET-1) on colorectal cancer cells (metabolic activity). 48 h 
after seeding 25000 cells (left) and 50000 cells (right), 10nM ET-1 was added to the medium and left 
for 48 h before MTT assay was performed. Control: horizontal line. Significance (compared to 
control): **p<0.01, ***p<0.001. 
 
Cell counting was used as an alternative proliferation measurement for ET-1 
activation. Significant differences were observed between the two techniques, since 
for cell counting the 48-hour treatment showed no increase compared to the control 
in the lower seeding density, and a significant increase  was observed in the highest 
seeding density for both time points (Figure 3.17). Generally, HCT116 cells seemed 





Figure 3.17 Effect of endothelin-1 (ET-1) on colorectal cancer cells (cell counting). 48 h after 
seeding 25000 cells (left) and 50000 cells (right), 10nM ET-1 was added to the medium and left for 48 
h before cells were counted using a haemocytometer assay was performed. Control: horizontal line. 
Significance (compared to control): *p<0.05, **p<0.01, ***p<0,001. 
 
Unfortunately shortly after demonstrating the activity of ET-1 the two new batches 
purchased resulted in no increase in proliferation on these cell lines. This has 
important consequences on the course of this research. Due to the unpredictable 
efficacy of ET-1 in these experiments, it was impossible to know in which treatment 
groups ET-1 would enhance, inhibit or not effect proliferation at all (preliminary data 
not shown). For that reason, experiments with ETAR antagonists were treated as a 
blinded study (ET-1 treated controls were not compared to untreated controls, but 





The ETAR-specific antagonist BQ123 is commonly used to study the endothelin 
pathway as the gold standard for receptor inhibition studies (Ali et al. 2000; Haque et 
al. 2013). Figure 3.18 shows the results of MTT assay after 48 h of BQ123 treatment 
with or without the addition of ET-1. The inhibitor on its own elicited no change in 
proliferation in either HCT116 or HT29, while the addition of ET-1 promoted 




Figure 3.18 Effect of the ETAR-specific antagonist BQ123 on colorectal cancer cells. Cells were 
treated with different concentrations of the drug (followed by ET-1) for 48 h before MTT assay was 
performed. On the left, cells were only treated with the drug, on the right, all treatment groups 




Similar to BQ123, previous work (Haque et al. 2013) demonstrated the anti-
proliferative and pro-apoptotic effect of ZD4054 in the presence of ET-1. For  
experiments performed during the present research, as explained above ET-1 did 
not cause a consistent proliferative effect, and therefore the inhibition caused by the 
competitive binding of the antagonist could not be measured optimally. To compound 
the problem, different batches of ZD4054 also produced inconsistent effects on cells 
However, overall patterns of inhibition were observed for both cell lines used, as 
described below.  
Treatment with ZD4054 on its own led to significant inhibition of HCT116 cell 
proliferation (total DNA) with increasing drug concentrations (37% inhibition at the 
highest concentration (1 µM), p<0.001) (Figure 3.19), while HT29 cells remained 
unresponsive (Figure 3.20). Metabolic activity responses were more modest (less 
sensitive) with only the highest concentration of the antagonist (1 µM) eliciting an 





Figure 3.19 Effect of the ETAR-specific antagonist ZD4054 on HCT116 cells. Cells were treated 
with different concentrations of the drug for 48 h before DNA assay (left) and MTT assay (right) were 
performed. Significance (compared to control): ***p<0.001. 
 
 
Figure 3.20 Effect of the ETAR-specific antagonist ZD4054 on HT29 cells. Cells were treated with 
different concentrations of the drug for 48 h before DNA assay (left) and MTT assay (right) were 
performed. Significance (compared to control): ***p<0.001. 
 
The addition of ET-1 to the treatment resulted in confusing results, with total DNA 
and MTT responses often disconnected. For example proliferation inhibition (total 
DNA) in HCT116 cells caused by ZD4054 is attenuated in the presence of ET-1 
(Figure 3.21). A similar effect was observed for metabolic activity on HT29 cells, 
where ET-1 seems to enhance proliferation in the presence of 10nM (16%, p<0.001) 
and 100nM (21%, p<0.001) of ZD4054. Contrarily, on HT29 cells, ZD4054 is much 
more effective in the presence of ET-1 at the proliferation level (26% at 1 µM, 
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p<0.001) (Figure 3.22). In HCT116, metabolic activity remains unchanged in the 
presence or absence of ET-1, compared to ZD4054 alone. 
 
 
Figure 3.21 Effect of the ETAR-specific antagonist ZD4054 in the presence of ET-1 on HCT116 
cells. Cells were treated with different concentrations of the drug. All treatment groups including the 
control are in presence of ET-1 at 10nM. 48 h after the treatment total DNA assay (left) and MTT 
assay (right) were performed. Significance (compared to control): ***p<0.001. 
 
 
Figure 3.22 Effect of the ETAR-specific antagonist ZD4054 in the presence of ET-1 on HT29 
cells. Cells were treated with different concentrations of the drug. All treatment groups including the 
control are in presence of ET-1 at 10nM. 48 h after the treatment total DNA assay (left) and MTT 





In spite of partial positive conclusions that were drawn from these results and are 
further developed in the discussion, the effect of ET-1, BQ123 and ZD4054 is far 
from optimal (Figure 3.23). Figure 3.23 shows some results with a defective batch of 
ET-1 and two potentially defective batches of ZD4054 as proof of the many 
inexplicable effects these molecules caused on cells. Due to these inconsistencies, 
alternative treatments were explored and are described in the next chapter. 
 
Figure 3.23 Example of the inconsistent effect on proliferation elicited by potentially defective 
ET-1 and ZD4054 batches. HCT116 where treated with an ineffective batch of ET-1 and two different 
batches of ZD4054. Total DNA assay was performed after 48 h treatment. The control group is 








3.4.1 Inhibitors of the MAPK pathway 
 
There is considerable evidence that MEK inhibition is a promising approach as a 
cancer treatment, particularly directed against KRAS and BRAF mutant cells, at in 
vitro, in vivo, and clinical levels (Yeh et al. 2009; Chapman & Miner 2011). BRAF 
mutants however, tend to respond better to this type of therapy (Solit et al. 2006; 
Engelman et al. 2008). 
A number of studies have recently suggested that different mutations in the 
upstream molecules of the MAPK pathway lead to different mechanisms of activation 
of MEK1/2 (Blasco et al. 2011; Davies et al. 2002; Hatzivassiliou et al. 2013). The 
two most common mutations in CRC relevant to this pathway are K-RAS and B-RAF. 
Their different effects on MEK1/2 over-activation should be considered, since they 
greatly influence the efficacy of MEK inhibitors (Gilmartin et al. 2011; Hoeflich et al. 
2012; Friday et al. 2008). 
Here, the different mutational status regarding RAS and RAF is the core reference 
point for the discussion that follows. 
 
3.4.2 PD98059 and U0126 
 
Both the MEK inhibitors U0126 and PD98059 have been used experimentally for 
many years to investigate the MAPK pathway, not only in cancer but within normal 
physiological systems and other pathological conditions (Cuenda & Alessi 2000; 
Alessi et al. 1995; Davies et al. 2000). 
It is worth noting that some of the MEK inhibitors are often considered MEK-1-
specific as opposed to MEK-1/2-specific, with controversial reports on this matter 
(Davies et al. 2000). Although the three inhibitors used for the current body of work 
have slightly different reported affinities for these two molecules (MEKs), for this 
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discussion, all three MEK inhibitors are considered as MEK-1/2-specific, in line with 
most reported evidence (Favata et al. 1998; Dudley et al. 1995). 
 
3.4.2.1 PD98059 and U0126 in a K-RAS mutated cell line (HCT116) 
 
K-ras mutations are activating mutations that result in a potentiated signal with a 
number of growth and motility promoting cellular events. Importantly a substantial 
percentage of patients with colorectal cancer have such mutations (reports range 
from 25% to 50%, depending on studies and reported disease progression).  
Hatzivassiliou and colleagues suggested that MEK inhibitors that achieved higher 
efficacy on K-RAS mutated colorectal cancer cell lines (such as GDC-0623 and G-
573) did so by creating a strong hydrogen-bond with a Serine residue (S212) in the 
MEK molecule (Hatzivassiliou et al. 2013).This resulted in blocking this region of the 
protein which in turn prevented wild type BRAF from phosphorylating MEK as a 
feedback response to MAPK pathway inhibition, a well-known phenomenon in KRAS 
mutant cells (Friday et al. 2008; Pratilas et al. 2009). Being KRAS activation majorly 
mediated by wild type BRAF-CRAF heterodimers (Downward 2003), both GDC-0623 
and G-573 inhibited this signalling by forming stable BRAF-MEK complexes and 
therefore, preventing BRAF-CRAF interaction.  
Conversely, the phase III clinical trial MEK inhibitor cobimetinib, which acts by 
impairing the kinase activity of the already phosphorylated MEK, showed a much 
lower efficacy in KRAS than in BRAF mutated cell lines. These findings were 
transferred to in vivo studies in three xenografts of mutant K-RAS, in which inhibition 
by cobimetinib resulted in accumulation of phosphorylated MEK and a superior 
activation of ERK compared to the other two inhibitors. Following these results, other 
MEK inhibitors that prevent BRAF feedback phosphorylation of MEK (Gilmartin et al. 
2011; Alessi et al. 1995) could also show more efficacy in KRAS mutant cell lines. 
The MEK-1/2 specific non-ATP-competitive inhibitor PD98059 has been shown to 
inhibit growth and proliferation in colorectal cancer cells very effectively (Lu et al. 
2007; Fang & Richardson 2005).  
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HCT116 cells, used in this study,  bear the p.G13D mutation in KRAS and the 
p.H1047R mutation in PI3K (Troiani et al. 2012). Opposite to what was previously 
thought, the specific type of KRAS mutation present in HCT116 (codon 13) has 
recently been identified as a biomarker for poor outcome both in metastatic and non-
metastatic colorectal cancer (Salerno et al. 2002; Yoon et al. 2014). 
After EGF addition, in terms of proliferation measurements (total DNA) HCT116 cells 
showed a dose-dependent inhibitory curve similar to that of HT29 cells when treated 
only with PD98059, reaching 50% at the highest concentration used (100 µM). This 
was different to the response of HCT116 cells to PD98059 alone, where the 
response appeared to plateau at the middle range of drug concentrations (10-50 µM) 
and then reached 45% maximum inhibition at 100 µM. This suggests the slowing 
down of response was partially due to pathways alternative to MAPK, activated by 
the mutated KRAS. This possibility has been previously suggested (Church et al. 
2012). With EGF further fostering proliferation through the MAPK pathway, the 
inhibitory effect of PD98059 might have been more noticeable. However, this 
hypothesis is speculative. 
U0126 is also a very specific non-ATP-competitive MEK inhibitor. Its progression to 
the clinic has been hampered by pharmacological limitations, but it is widely used in 
vitro to study the MAPK pathway (Sebolt-Leopold et al. 1999). 
Although HCT116 cells responded to U0126 in a dose dependent manner the 
measurements of inhibition and the reduction resulting from each dose, in terms of 
total DNA and metabolic activity did not correspond step by step. For example, 
responses were step-wise reduction as measured by total DNA, but appeared to 
plateau by MTT. The converse was true when EGF was added to the system, where 
both proliferation and metabolic activity plateaued. This is indicative of the inherent 
limitations of assays (e.g. what do they measure exactly, what are the sensitivity 
limits, are the measurements subject to a lag effect), which is often not taken into 
account when reporting effects of drugs. A large number of studies depend only on 
metabolic assays, such as MTT to report drug efficacy, which is insufficient. 
Furthermore, for these cells, the addition of EGF resulted in less metabolic activity 
inhibition. Maximum inhibition values at the highest concentration were 35% 
66 
 
(p<0.001) for U0126 alone and 14% (p<0.05) in the presence of EGF (Figure 3.7 and 
Figure 3.9). 
The results are consistent with reports that KRAS signalling occurs through alterative 
pathways as well as the MAPK pathway, and this signalling could have been 
activated through EGFR via ligand binding. One example of these alternative 
pathways is the activation of the PI3K/AKT pathway by KRAS (Downward 2003), 
which is also mutated in this cell line. This abundance of alternative paths, which can 
be controlled or activated by proteins in the MAPK pathway seems logical, since the 
MAPK pathway is one of the pillar signalling systems that mediate proliferation and 
growth.  Such redundancy in the system makes complete inhibition almost 
impossible and could be related to the common problems that EGFR inhibition 
platforms face with KRAS mutant tumours (Magdeldin et al. 2014); or perhaps off-
target effects such as ERK-5 inhibition could play a role (Shields et al. 2000). In fact, 
the MAPK pathway is generally regarded as a non-linear pathway, with numerous 
regulatory proteins involved (Chang & Karin 2001; Dhanasekaran et al. 2007). 
U0126 and PD98059 inhibit MEK activity in a similar manner, through impairment of 
its kinase activity and not by preventing its activation (Dudley et al. 1995; Favata et 
al. 1998). According to Hatzivassiliou et al., these inhibitors should be ineffective 
against KRAS mutant cells, or at least less effective than against BRAF mutant cells 
(Hatzivassiliou et al. 2013). With the exception of U0126-induced paradoxical 
activation in HT29 cells, discussed below, the present data is consistent with this 
hypothesis. Firstly, BRAF mutant HT29 cells are more sensitive to PD98059 than 
KRAS mutant HCT116 cells (dose dependent strong response vs. plateau at 100nM, 
Figure 3.3 and Figure 3.4). Secondly, HCT116 were much less sensitive to U0126 
(~30% inhibition at 1µM) than to PD98059 (~50% inhibition at 1µM), despite U0126 
having a much higher specificity and affinity for both MEK-1 and MEK-2 (IC50 of 
72nM and 58nM respectively for U0126, compared to IC50 values of 10µM for both 
in the case of PD98059) (Favata et al. 1998; Dudley et al. 1995). Furthermore, the 
protein levels of MEK-2 protein were much higher than MEK-1 protein in both cell 
lines (data not shown), suggesting that the higher affinity of U0126 to MEK-2 would 
contribute to superior efficacy. However, this was not demonstrated for HCT116 
cells, which are less sensitive to U0126 instead. This tendency to equalize the 
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efficacy of PD98059 and U0126 suggests a lower efficacy of these inhibitors in 
KRAS mutants and supports Hatzivassiliou’s hypothesis. 
There are several possible explanations for this KRAS-mutant-mediated resistance 
to MEK inhibition. For example, MEK-independent BRAF signalling, BRAF-
independent MEK signalling and RAF-independent RAS signalling have all been 
suggested (Bromberg-white et al. 2012; Lim et al. 2005; Yip-Schneider et al. 1999), 
and the idea that alternative KRAS-activated effector pathways contribute to this 
resistance has been indicated in a variety of studies, including in HT29 and HCT116 
cell lines (Little et al. 2011) 
Signalling through the PI3K/Akt/mTOR system is commonly upregulated in cancer. 
In a natural state, mTOR is activated in response to nutrient availability and is 
positively regulated by the core survival pathway PI3K/Akt (Hay & Sonenberg 2004; 
Bjornsti & Houghton 2004). There is evidence of this pathway being activated as a 
result of MEK inhibition, by inhibiting the feedback loop that attenuates 
phosphorylation of Akt, and hence conferring resistance to MEK inhibition (Faber et 
al. 2009; Turke et al. 2012; Hoeflich et al. 2009; Mirzoeva et al. 2009; Yoon et al. 
2009), there is also evidence of opposite regulation, i.e. inhibition of the 
PI3K/Akt/Mtor pathway activates the MAPK pathway, or even Akt survival signalling 
(Wang et al. 2008; Ebi et al. 2013; Carracedo et al. 2008; Serra et al. 2011). 
Combinations of inhibitors targeted at these two pathways are currently being 
explored (Tentori et al. 2013; Shimizu et al. 2012; Wang et al. 2008),  including in 
HT29 and HCT116 cell models (Zhang et al. 2009). 
Another pathway that might be involved in the resistance to MEK inhibitors is the 
Wnt pathway. In the case of CRC, mutations in the APC protein are especially 
abundant and can constitute the first tumorigenic step. A recent study analysed 224 
CRC samples and found over 90% of them had a mutation in the Wnt pathway 
(Cancer & Atlas 2012). Generally though, alternative resistance suggested include 
over-activation, up-regulation or over-expression of surface receptors, and other 
RAS or RAF subtypes (Villanueva et al. 2011; Nazarian et al. 2010; Montagut et al. 
2008).  
Other proteins involved in MEK inhibitor resistance are less studied, or exhibit 
contradictory results. A recent study by Mazur et al. discovered that the kinase 
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MAP3K2 is methylated by the methyltransferase SMYD3, causing the former to 
dissociate from its negative regulator and activate the MAPK pathway in KRAS-
mutant cancers (Mazur et al. 2014). DUSP4, a phosphatase known to de-
phosphorylate ERK, has been shown to both inhibit the MAPK pathway in BRAF 
V600E and KRAS G12V-mutated cells (Cagnol & Rivard 2012) and increase 
proliferation in HCT116 (Gröschl et al. 2013). 
 
3.4.2.2 PD98059 and U0126 in a B-RAF mutated cell line (HT29) 
 
It has been demonstrated that the activation of MEK by RAF is significantly different 
between the non-tumorigenic BRAF/CRAF wild type system and an aberrant BRAF 
V600E (Garnett et al. 2005; Röring et al. 2012). Contrarily to KRAS mutant cells, 
which are more effectively inhibited by drugs that bind to the S212 residue in MEK, 
BRAF mutated cell lines respond better to the strong blockage of phosphorylated 
MEK (i.e. by cobimetinib). This is due to the very high basal levels of MEK 
phosphorylation in BRAF mutant tumours (Pratilas et al. 2009), as proven by higher 
phosphorylated ERK levels in HT29 cell lines compared to HCT116 (data not 
shown). In fact, it has been demonstrated that the phenomenon of “oncogenic 
dependency” is more pronounced in BRAF mutant cells than KRAS mutant or 
KRAS/BRAF wild type cells (Solit et al. 2006), therefore sensitizing BRAF-mutants to 
MEK inhibition (Sebolt-Leopold et al. 1999). Feedback phosphorylation by wild type 
BRAF does not occur significantly in this case, since wild type BRAF levels are low 
in BRAF mutated cells (Pratilas et al. 2009). Conversely, evidence on a correlation 
between KRAS status and ERK activation is controversial and still being explored 
(Lim et al. 2005; Yip-Schneider et al. 1999; Schmitz et al. 2007; Yip-Schneider et al. 
2001). 
The present results are partly, but not wholly consistent with the above reports. 
PD98059 activity is through inhibiting the kinase activity of MEK on ERK. That 
confers it higher efficacy on BRAF-mutated cell lines. HT29 cells showed a 
significant reduction in both metabolic activity and proliferation levels from 10µM 
PD98059 and reach ~50% and ~80% inhibition in proliferation and metabolic activity 
respectively at 100µM. On the other hand the KRAS mutant cell line HCT116 
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reaches a plateau between 10 and 50µM at the proliferation level and only 50% 
inhibition at 100µM at the metabolic activity level. 
Despite the ability of PD98059 to inhibit mutant BRAF activation of the pathway, the 
addition of EGF to activate the pathway triggers an almost two-fold increase in 
proliferation. This could be easily explained through natural wild type KRAS 
activation through EGFR signalling. In spite of the low levels of wild type BRAF to 
transmit KRAS signalling (Pratilas et al. 2009), a number of studies suggest that 
KRAS signalling also occurs through alternative pathways (Lim et al. 2005; Yip-
Schneider et al. 1999). 
Conversely, in the BRAF-mutant cell line U0126 triggers a typical response of 
paradoxical activation at the proliferation level, fostering proliferation almost two-fold 
at 100µM. Interestingly, metabolic activity remains impaired except at the highest 
concentration, in which it confers significant inhibition. The molecular mechanisms 
behind this paradoxical activation are not fully understood, but in this case feedback 
activation of BRAF is unlikely due to the low levels of wild type BRAF in BRAF-
mutated cell lines (Pratilas et al. 2009). There is a significant difference in the basal 
pERK levels of these two cell lines, probably in part due to their differential 
expression of the DUSP4 phosphatase. HCT116 shows a much higher expression of 
DUSP4 than HT29 (Gröschl et al. 2013), in accordance to its KRAS mutant status. 
Higher basal levels of pERK in HT29 cells could have contributed to the paradoxical 
activation by U0126. 
Activation of the MAPK pathway in CRC cell lines after drug treatment has also been 
observed with other families of drugs such as paclitaxel (Xu et al. 2009) or 
rapamycin (Wang et al. 2008), and it is a very common phenomenon. This surprising 
effect has also been observed as a side effect in a systemic manner upon treatment 
with BRAF inhibitors, which might lead to the development of secondary 
malignancies by activating the MAPK pathway in other tissues (Heidorn et al. 2010; 
Poulikakos et al. 2010; Arnault et al. 2012). 
When EGF was added to HT29 cells after treatment with U0126, paradoxical 
activation was reversed. As hypothesized in the results section, the reason could be 
that the exogenous activation of wild type KRAS, and hence its alternative signalling 
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pathways, increased proliferation in the untreated cells and brought them to the 
same level than cells treated with U0126.  
Despite it has been recently suggested that levels of phosphorylated ERK might not 
always be a good indicator of successful MEK inhibition (Yeh et al. 2009), this 
approach has been generally used for that purpose. Levels of pERK in HT29s after 
treatment with U0126 correlated very tightly to the increase in proliferation. However, 
protein was extracted after 10 min of exposure to EGF to activate the MAPK 
pathway. The fact that levels of pERK follows the same pattern as non-EGF-treated 
HT29 proliferation, as opposed to EGF-treated proliferation, suggests that the 
reversal of U0126-mediated proliferation increase caused by EGF addition might be 
mediated by a complex interaction of regulatory proteins in alternative pathways. 
Opposite to the reversal of paradoxical activation, is the evidence that exposure to 
RTK ligands can revert drug sensitivity to MAPK pathway inhibitors (Wilson et al. 
2012). These results support the significant effect of surface receptor activation on 
MAPK-targeted drug treatments. As indicated before, there are numerous regulatory 
mechanisms related to the MAPK pathway, and that not only affects KRAS-mutated 
but also BRAF-mutated cells. For example, the inhibition of BRAF has been 
associated with MEK and ERK activation (Johannessen et al. 2010; Nazarian et al. 
2010), suggesting alternative pathways involved. In the light of these findings, BRAF 
and MEK inhibitors are being studied as a possible treatment combination, with very 
promising results (Flaherty et al. 2012). 
It is worth noting that a number of controversial results have been reported with 
these two inhibitors. For example, a study by Dang et al. suggests that these two 
inhibitors have different effects on adipogenesis and osteogenesis in osteoprogenitor 
cells, and that those effects are not just through inhibition of the MAPK pathway 
(Dang & Lowik 2004). Furthermore, Dokladda et al reported that U0126 and 
PD98059 cause an elevation of ADP and AMP and activate the AMPK in a non-
MAPK-mediated manner (Dokladda et al. 2005); while Harmon et al. suggested that 
both inhibitors reduce 2-deoxyglucose uptake in adipocytes upon insulin stimulation 
(Harmon et al. 2004), presumably also through AMPK activation. Both studies 
suggest that PD98059 and U0126 cross-react with other pathways, and experiments 
using these inhibitors should be interpreted with care  
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Furthermore, both PD98059 and U0126 at concentrations normally used for MEK1/2 
inhibition in vitro, attenuate the apoptotic mechanism triggered by p45-JNK activation 
as a response to oxidative stress and, in the case of PD98059, interleukin-1. In fact, 
PD98059 has been shown to fade apoptosis in several occasions (Jiménez et al. 
1997; Bhat & Zhang 1999), and it is known to inhibit MEK5 apart from MEK1 and 
MEK2, contributing to the hypothesis of cross-reactions (Kamakura et al. 1999) . 
In the light of these and previously published controversial results with these two 
MEK inhibitors, neither of them was taken to the next phase of study, and the novel 
effective inhibitor AZD6244, currently in clinical trials, was explored for potential 
combination treatments and nanoformulations. 
 
3.4.3 AZD6244 on HCT116 and HT29 cells 
 
AZD6244 is a strong orally bioavailable specific inhibitor of MEK-1 and MEK-2, and it 
is specially designed for BRAF and KRAS mutant cell lines (Adjei et al. 2008; Yeh et 
al. 2007; Board et al. 2009). Its mechanism of action is also non-ATP competitive. It 
has reached phase I and II clinical trials with a variety of positive (Farley et al. 2013; 
Ho et al. 2013) and negative (Hayes et al. 2012; O’Neil et al. 2011; Kirkwood et al. 
2012) results, being NCT01278615 and NCT01752569 for Diffuse large B-cell 
lymphoma and Kaposi’s sarcoma, respectively, currently ongoing (reviewed in 
(Martin-Liberal et al. 2014)). Most of the failed clinical trials for AZD6244 were not 
successful because there was no RAS/RAF mutant selection. However, some 
studies without this selection showed promising results (Farley et al. 2013; Ho et al. 
2013). 
Contrary to the previous MEK inhibitors, there is very little difference between the 
effect of AZD6244 in HCT116 and HT29 cells. Both cell lines showed a smooth dose 
dependent response both at the metabolic activity and proliferation levels, 
suggesting that this small molecule is the best option for further combination 
treatments and nanoformulations. Davies et al. classify both HT29 and HCT116 cell 
lines are sensitive to AZD6244 (Davies et al. 2007). 
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This observation is consistent with the general hypothesis that there is not a 
statistically significant difference between the inhibitory effect of AZD6244 in KRAS 
and BRAF mutant cells, among other gene mutations (Tentler et al. 2010; Troiani et 
al. 2012). Said work was conducted both in vitro and in vivo showing similar results, 
and also classifies cell lines as resistant or sensitive to AZD6244 and states that all 
sensitive cell lines were mutant in either BRAF or KRAS. 
The kinase inhibitory effect of AZD6244 was not dependent on the reference levels 
of phosphorylated ERK (found to be very different among CRC cell lines). In fact, it 
inhibits basal levels, as well as, newly induced phosphorylation in CRC, among other 
cancers. In this work, HCT116 shows moderate resistance to AZD6244, reaching its 
IC50 at ~1µM after a 72-h treatment. This result is quite similar to what was found in 
this work, with an IC50 of ~10µM after a 48-h treatment. On the other hand, HT29 is 
found as an extremely sensitive cell line, with an IC50 of less than 0.1µM after a 72-h 
treatment, which is non-consistent with our data. 
It is worth noting that there is some controversy about the validity of pERK levels as 
an indicator of AZD6244 efficacy in CRC cell lines. Contrary to the hypothesis that it 
is not a suitable predictor (Tentler et al. 2010; Balmanno et al. 2009), Davies et al. 
performed experiments in human tumour xenografts and suggested that it is a robust 
indicator (Davies et al. 2007). 
One of the possible explanations for HCT116 cells partial resistance is a feedback 
activation of an alternative pathway that corrects the proliferation inhibition through 
the MAPK pathway. When the expression of Frizzled homolog 2 (FDZ2) was 
knockdown, HCT116 became more sensitive to AZD6244 treatment, suggesting that 
a feedback activation of the WNT5/FDZ pathway was involved in the partial 
resistance of HCT116 (Tentler et al. 2010). This of course offers new possibilities for 
combination treatments that aim to inhibit both pathways in pursuit of a synergistic 
inhibitory effect.  
Oppositely, Troiani et al. also classifies a number of CRC cell lines as resistant or 
sensitive to AZD6244, but shows a much superior inhibitory effect on HCT116, with 
an IC50 of approximately 0.25µM after 48 h treatment (compared to the ~10µM 
obtained in this work), but shows no results on HT29 cells (Troiani et al. 2012). 
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These differences could be explained through some acquired resistance or change 
in the proliferation profile caused by differences in the culture conditions. 
For that reason, a drug treatment mimicking the experimental conditions in that 
publication was conducted for both HT29 and HCT116. Figure 3.15 shows that not 
only this protocol promotes less inhibitory effect on both cell lines, but the drug 
exhibits paradoxical activation in HCT116 at the highest concentrations. This is 
probably due to the fact that in this culture conditions cell cycle is not synchronized 
prior to drug treatment, making the effect of the drug less accurate and conclusions 
confusing. For example, MEK-1, but not MEK-2, can be strongly activated by serum 
(Xu et al. 1997), one of the main differences between the two cell culture protocols. 
The differential levels of MEK-1 and MEK-2 in these cell lines, as well as, the 
different affinities of this small molecule to each of them, can significantly affect the 
outcome of the experiments. These differences are more noticeable at the metabolic 
activity level, since its correlation to proliferation is much more unpredictable. 
In regard to KRAS/BRAF status and the fact that different inhibitors are needed for 
different activation mechanisms, the BRAF-mutated HT29 cells could be expected to 
respond more effectively to AZD6244 inhibition, as reported in Tentler et al. 2010. 
The mechanism of action of AZD6244 is proposed to disrupt signalling at the 
catalytic stage of its kinase activity, after allowing MEK-1/2 phosphorylation, and not 
at the activation of MEK1/2 itself (Yeh et al. 2007). As mentioned earlier, these types 
of inhibitors tend to be more effective in counteracting the strong MAPK pathway 
activation characteristic of BRAF mutants, and not the additional alternative pathway 
activation characteristic of KRAS mutants. 
A number of cases of AZD6244 resistance have been reported, and alternative 
pathway activations have been suggested (Tentler et al. 2010; Troiani et al. 2012). 
One possible mechanism of resistance to AZD6244 is the activation of protein kinase 
A. KRAS activation as also been proposed as a resistance mechanism against MEK 
inhibition in murine CRC. The up-regulation of MAPK pathway genes such as BRAF- 
or KRAS-mutants by intrachromosomal amplification in HCT116 and HT29 cells has 
also been suggested as a mechanism of resistance against AZD6244 upon 
treatment with the inhibitor (Troiani et al. 2012; Wang et al. 2005). It can be 
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hypothesised that this resistance could have been conferred along a 48 hour 
treatment, affecting the final proliferation count. 
Despite the efficacy of AZD6244 on HT29 and HCT116 cells being lower than 
previously reported, and a moderate degree of resistance being present, this MEK 
inhibitor is the most suitable option for combination treatments and nanoformulations 
studies. For that reason, AZD6244 was explored in combination with the ETAR-
specific antagonist ZD4054 (see chapter 4 (pg. 82)). 
 
3.4.4 Treatment with ETAR competitive antagonists 
 
The discussion in this section interprets a set of results regarding ET-1, ZD4054 and 
BQ123, and has a much stronger component of speculation than those regarding 
inhibitor of the MAPK pathway. The reason for this is unexpected inefficacy in the 
treatment with these compounds. Several batches of these molecules often elicited 
paradoxical or inconsistent effects on cell proliferation and metabolic activity, so the 
discussion and partial conclusions drawn in this section are interpreted with care.  
Fundamentally, batch production is controlled by testing on endothelial models. 
These produce and respond at fold differences higher than cancer cells. Therefore, 
any loss of sensitivity or subtle changes would not be easily detected by gross 
testing in endothelial models. Also, to exclude operator error, independent use of all 
the endothelin axis molecules and determination of their effect on colorectal cancer 
cell lines were carried out by another researcher in the group. The same inconsistent 
outcomes were reported.   
However, Due to the large body of work carried out with these molecules (great part 
of it not included in the thesis) and previous reported success within this research 
group, abstract patterns in cellular response, however misleading, are worth 






3.4.4.1 Response to ET-1 
 
Experiments performed to evaluate the efficacy of ET-1 are included in this section, 
together with ETAR receptor antagonists. 
The initial response of HCT116 and HT29 cells to ET-1 was very encouraging. MTT 
assay showed no significant differences in metabolic activity after 48- or 80-hour 
treatments in the high seeding density group (50000cells/well) (Figure 3.16), cells 
having reached a visible state of confluence. The fact that all treatment groups 
equalized to the control indicates a reduction in metabolic activity due to nutrient 
competition. Conversely, the superior increase in cell number after 80 h of ET-1 
treatment on the same seeding density (Figure 3.17) is consistent with a commonly 
known characteristic of cancer, lack of cell contact inhibition (Hanahan 2000). 
Results are much clearer in the low seeding density group (25000cells/well). ET-1 
elicits a proliferation increase in both cell lines, following a very similar pattern for 
both cell counting and MTT assay, and validating the later as an indirect measure of 
proliferation. This correlation however, is subject to ambiguity since molecules or 
other factors affecting cell behaviour might trigger significant changes in the 
metabolic state of the cell, without necessarily affecting cell division. For that reason 
results of the MTT assay were interpreted as a secondary supporting technique 
rather than conclusive data (particularly in the event of no correlation). 
All experiments that showed significant differences in the effect of ET-1 (i.e. cell 
counting and MTT assay at the low seeding density, as well as, cell counting at the 
high seeding density) indicate that HCT116 has a prevalent response to ET-1. This 
is surprising, since the expression levels of ETAR in HCT116 cells are slightly lower 
than in HT29 cells. Furthermore, the expression levels of endogenous ET-1 are 
slightly higher, suggesting that we could expect a lower increase in proliferation by 
the addition of exogenous ET-1. On the other hand, as discussed earlier, Zhang et 
al. suggested that mRNA expression levels are not necessarily a good indicator of 
protein levels (Zhang et al. 2014), and this is probably more significant with such 
small differences in expression. 
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The activation of ETAR by its natural ligand ET-1 triggers a phosphorylation cascade 
that converges with the MAPK pathway at the RAF level. While HT29 cells bare the 
V600E mutation in BRAF, and that confers low levels of wild type BRAF (Pratilas et 
al. 2009), the levels of wild type BRAF in HCT116 cells remain normal, making this 
cell line more susceptible to ETAR-mediated MAPK pathway activation and justifying 
a higher proliferation increase. 
While promising, these results following ET-1 treatment were limited to the initial 
studies. Further experiments involving ETAR antagonists in the presence of ET-1 
were performed utilizing new batches of the ligand. A number of these experiments 
(mostly omitted here) failed, partly due to the inability of the new ET-1 batches to 
increase proliferation in these cell lines. In some cases, treatment with the molecule 
inhibited proliferation instead. The only explanation for such unexpected 
phenomenon would be the induction of cell cycle arrest by accumulation of cycline 
products. It has been suggested that excessive acute phosphorylation of ERK could 
trigger this response (Meloche & Pouysségur 2007), and this might have been 
caused by the further activation of the already overactive MAPK pathway by ET-1. 
However, this has never been reported with ET-1 treatment before and is highly 
unlikely. Similarly, ETAR-specific antagonists showed very different results than 
expected, either increasing proliferation in the presence of ET-1 or significantly 
inhibiting proliferation in the absence of ET-1. One of the possible explanations for 
ZD4054 eliciting unexpected responses is the fact that this small molecule was 
purchased from a different company than previously done in this department. 
Unfortunately, the company that kindly donated ZD4054 to our department in the 
past, did not support nanoformulations. Some of the contradictory results are 
collected in Figure 3.23. 
Due to the unpredictable efficacy of newly acquired ET-1 even within the same batch 
and the contradiction between current results and data previously reported in this 
department, the discussion of results regarding ETAR antagonists in the presence of 
ET-1 will be significantly brief and under the assumption that ET-1 elicits a 
proliferative response. However, caution is advised when interpreting these 






Due to the antagonistic mechanism of action of BQ123, a treatment with this 
molecule in absence of ETAR natural ligand ET-1 should not elicit an inhibitory 
response. This is consistent with our data. However, in the presence of the ligand, 
previous reports show antagonistic efficacy, while our data concludes the opposite. 
Furthermore, at the highest concentrations of BQ123 and in the presence of the 
ligand, the antagonist significantly increases proliferation in HCT116 cells (Figure 
3.18). 
Despite BQ123 being a ETAR-specific antagonist, previous reports from our group 
have demonstrated that high concentrations of this receptor antagonist could show a 
degree of ETBR binding. The effect of ET-1 binding to ETBR in colorectal cancer has 
been shown to trigger an opposite effect to ETAR binding (unpublished data). 
Hence, the possible unspecific binding of BQ123 to ETBR could explain the 





There is a strong body of evidence that ET-1 mediated ETAR signalling elicits a 
proliferative response in several types of cancers. This is done by modulating 
apoptosis, angiogenesis, mitogenesis and invasion (Ali et al. 2000). ZD4054 is a 
highly specific ETAR antagonist, with IC50 of 21nM for ETAR, and is able to prevent 
ET-1 binding to ETAR by competitive antagonism of the receptor (Bradbury et al. 
1997; Morris et al. 2005; Rosanò et al. 2007a; Grant et al. 2007). This therapeutic 
molecule has been deeply studied at the clinical trial level, with some promising 
results. 
Considering ZD4054 in absence of the ligand as a competitive antagonist of 
endogenously produced ET-1, HCT116 cells showed a more prominent response to 
ZD4054 inhibition than HT29, probably due to their already seen superior response 
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to the ligand. A number of CRC cell lines and cancers have been shown to produce 
significant endogenous ET-1 (Ali et al. 2000; Kusuhara et al. 1990). 
As hypothesized earlier, one of the possible reasons for this is the constitutive 
activation of the MAPK pathway by V600E mutant BRAF in HT29 in contraposition to 
the higher levels of a wild type BRAF susceptible to ETAR-1mediated activation in 
HCT116. Surprisingly, the addition of ET-1 to the ZD4054 treatment reduced the 
efficacy of the antagonist. This data is very controversial, since ZD4054 should only 
elicit significant proliferation inhibition in the presence of ET-1. However, work 
described in those publications doesn’t involve HCT116 cells, and therefore the 
reasons for this behaviour in this cell line remain unknown. 
Contrarily to the hypothesis that higher endogenous production of ET-1 by HCT116 
cells could explain the more significant response to ZD4054 in the absence of 
exogenous ET-1, the expression levels of ETAR are lower in this cell lines. However, 
the expression levels of MEK are higher. This demonstrates that expression levels of 
effector proteins do not necessarily correlate to the efficacy of a drug treatment, 
particularly when mRNA is what is being measured. Or perhaps the addition of 
endogenous and exogenous ET-1 balances the rate of binding towards ET-1 instead 
of ZD4054. At the metabolic activity level however, the effects of ZD4054 are similar 
with or without the presence of ET-1. 
Results obtained from HT29 treatment are more consistent with previous work. On 
the one hand, the constitutive high activity of V600E mutant BRAF in this cell line 
could be expected to soften the proliferation increase through ETAR activation. 
However, a significant difference between treatments with or without ET-1 can be 
observed, being cells activated by ET-1 more susceptible to ZD4054 inhibition, as 
expected from a competitive mechanism of action. 
This efficacy could be explained because HT29 have less endogenous production of 
ET-1 compared to HCT116 so the influence of exogenous ET-1 would be clearer in 
HT29 cells. However, compared to HCT116 there is little wild type BRAF that could 
be phosphorylated by ET-1 activation. In this case, the transmission of the signalling 
cascade could be explained by transactivation of surface receptors such as EGFR 
(Vacca et al. 2000; Grant et al. 2007). In the EGFR transactivation scenario, the 
direct phosphorylation of scarce wild-type BRAF by ETAR-mediated signalling is 
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substituted by the KRAS-mediated activation of alternative pathways. This effect 
would sum up to the proliferation increase caused by V600E BRAF. Furthermore, 
ETAR activation triggers a network of complex alternative protein interactions that 
could also be responsible of mitogenic effects. Some of these directly or indirectly 
activated proteins are PI3K, PKC, PLC, PLD, PLA2, adenylate cyclase, guanylate 
cyclase, Raf-1, IP3, diacylglycerol (DAG), akt, mTOR, COX-1, COX-2, and 
prostaglandin E2 (Grant et al. 2007; Blaukat et al. 2000; Shome et al. 2000). 
Considering numerous alternative pathways and surface receptor transactivation as 
a mechanism of increased proliferation by ETAR-mediated signalling, the superior 
inhibitory effect of ZD4054 on HT29 in the presence of the ligand is logical. 
Results obtained from ZD4054 with or without ET-1 activation are contradictory and 
cannot be fully explained. In addition to the unpredictable effect of these molecules, 
it is worth noting that HCT116 cells occasionally secreted exosomes when treated 
with ZD4054, an indicator of stress (Figure 3.24). 
 
 





3.4.5 Selected molecules for combination treatments 
 
While PD98059 and U0126 elicited significant proliferation inhibition consistently, 
there are too many controversial reports regarding these two molecules. 
Furthermore, efforts towards their clinical usage have been practically abandoned. 
Besides, U0126 exhibits paradoxical activation in one of the cell lines, and the 
concentrations needed to elicit any effect are far beyond previously reported doses.  
Among the MEK inhibitors, AZD6244 seems the most suitable option, and 
combination experiments in the next chapters are carried out with this molecule. 
AZD6244 elicits a clear dose dependent inhibitory response, consistent with a 
reduction in ERK activation at the protein level. Moreover, numerous studies praise 
its efficacy and clinical testing has been performed and is currently ongoing. 
Despite the controversial results obtained from ET-1 and the ETAR antagonists, 
previous work in this department has demonstrated their efficacy. It seems that the 
major problem regarding ZD4054 efficacy is actually due to defective ET-1. 
Optimally, the addition of ETAR natural ligand to receptor antagonist testing is 
necessary to assess their efficacy, but ZD4054 shows moderate efficacy inhibiting 
proliferation, presumably due to the blockage of endogenously produced ET-1 
binding to the receptor, especially in HCT116 cells. 
For that reason, AZD6244 and ZD4054 will be explored in combination, however in 
the absence of ET-1, to explore the possibility of a synergistic inhibitory effect of 
these two compounds. This is a very likely possibility due to the evidence on ETAR-
mediated cross-activation of the MAPK pathway (Grant et al. 2007; Vacca et al. 
2000). Furthermore, a similar MAPK/ETAR inhibitory combination has been 
attempted with very promising results. Rosanò et al. achieved significant tumour 
regression and reduction in biomarkers of angiogenesis in ovarian carcinoma 






























In the previous chapter, AZD6244 was selected as the most suitable MEK inhibitor 
for combination treatments. However, since the efficacy of ETAR-specific 
antagonists was potentially compromised by deficient ligand-binding activation, an 
additional combination treatment was considered. 
This chapter briefly describes the therapeutic potential of ETAR- and MEK- targeted 
therapies in combination. Firstly, the co-administration of ZD4054 and AZD6244 was 
explored, with a very interesting but paradoxical outcome. For that reason, the 
possibility of combining AZD6244 with interfering RNA targeted against MEK-1, 





4.2 Materials and Methods 
 
In this chapter, most experiments were performed on HCT116 cells only, with the 
exception of the initial siRNA/OFA ratio optimization and the AZD6244/ZD4054 




Details on the small molecules AZD6244 and ZD4054 are compiled in chapter 3 (pg. 
42). SiRNAs targeted against specific genes (ETAR, MEK1 and MEK2) and a control 
(scrambled) siRNA were all part of the ON-TARGET plus SMART pool series and 
were purchased from (Darmacon, Lafayette, USA). SiRNA transfections were 
performed using the reagent Oligofectamine (OFA) (Invitrogen). 
4.2.2 Cell culture and siRNA evaluation 
 
For the optimization experiments, cells were seeded on 6-well plates 
(250000cells/well for both HT29 and HCT116 cells) and left for 24 h to allow 
attachment and starting proliferation, before serum was removed.  After 24 h of 
serum starvation, cells were treated with different volumes of oligofectamine (OFA) 
(3 or 4 µL) and different concentrations of target-specific (ETAR, MEK1 and MEK2) 
siRNAs (10, 50 or 100 nM). OFA and siRNA were mixed and added to the cells as 
instructed (Invitrogen): OFA was allowed to interact with serum-free medium for 8 
min, then siRNA was mixed with serum-free medium and both solutions were added 
together and left for 18 min to interact. 800 µL of serum-free medium were added in 
advance to each well and the 200 µL of the concentrated OFA/siRNA mixture were 
added to make a total of 1 mL. After 4 hours of transfection, 500 µL of serum-free 
medium were added to give a final volume of 1.5 mL; cells were left for 24 h before 
RNA extraction and analysis were performed, following the protocols described in 
chapter 2 (pg. 30). Quantitative PCR was performed to determine which combination 
achieved the most efficient gene silencing.  
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Once the optimal ratios were chosen, a whole characterization of siRNA efficacy at 
the mRNA and protein levels was done on HCT116 cells (seeding at 250000 
cells/well).  Similar to the optimization experiments, 48 h after seeding (including a 
24-hour starvation step) cells were treated with specific and scrambled siRNAs using 
OFA and following the same protocol. The selected OFA/siRNA ratios were: 3 µL 
OFA and 50 nM siRNA (for ETAR and MEK2 siRNAs) and 3 µL OFA and 100 nM 
siRNA (for MEK1 and control siRNAs). Proteins and RNAs were extracted 24, 48 
and 72 h after transfection. For protein experiments involving siRNAs targeted 
against MEK1 and MEK2, cells were treated with EGF for 10 min before protein 
extraction to activate the pathway. Quantitative PCR of ETAR, MEK1, MEK2 and 
G6PDH and Western Blot of ETAR, MEK1, MEK2, pERK1/2 and GAPDH were 
performed following protocols described in section 2.3 (pg. 34 and pg. 38). 
Densitometry of protein bands in Western blot was achieved by isolating each band 
and quantifying its intensity using the Image J software. The intensity of the bands 
was standardized in reference to GAPDH. 
 
4.2.3 Cell culture and proliferation assays 
 
For proliferation experiments involving drug and siRNA treatments, protocols 
described in section 2.2 (pg. 30) and section 3.2.3 (pg. 44) were followed. Cells were 
seeded on 24-well plates (32000cells/well for HT29 and 30000cells/well for HCT116) 
and cultivated with 500µL of McCoy’s 5A supplemented with 10% FBS. Serum was 
removed after 24 h to prevent possible drug-serum interactions and to semi-
synchronize cell cycles. After a 24-hour starvation step cells were treated with either 
a combination of AZD6244 and ZD4054, or target-specific siRNAs (ETAR, MEK1, 
MEK2, control) alone or in combination with AZD6244. The use of siRNAs in these 
experiments was performed following the same silencing protocol described earlier, 
although adapted to the volumes in 24-well plates (200 µL of medium were added to 
the well with an additional 50 µL of the siRNA/OFA mixture). After 4 h, 125 µL of 
either medium or AZD6244 in medium were added and cells were left for 48 h. After 
48 h, proliferation and metabolic activity assays were performed to measure the 
effect of the treatments on proliferation. For ZD4054 and AZD6244 combination 
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experiments AZD6244 concentration remained at 1 µM for all treatment groups and 
ZD4054 concentration ranged between 0.01-1 µM. For AZD6244 and siRNA 
combination experiments AZD6244 concentration remained at 100 nM in all 
treatment groups and siRNA concentrations were those derived from the 
optimization experiments (50 or 100 nM) while the volume of OFA was reduced to 2 







4.3.1 Optimization of OFA/siRNA ratio 
 
Oligofectamine (OFA) is a transfection agent, widely used to introduce nucleic acids 
into cells. When mixed with the target nucleic acid in an aqueous solution OFA forms 
particles that allow its transport through the cell membrane; it has been successful in 
mediating siRNA transfections (Resnier et al. 2014). However, the exact molar ratio 
between the transfection agent and the transfected molecule can only be found 
through experimentation. 
For this reason, different volumes of OFA and different concentrations of siRNA were 
tested to approximately determine which combination elicited the best silencing 
response.  Since the efficacy of this molecule is being tested, it is crucial to find the 
right combination before performing more complex experiments involving time points 
or treatment combinations. 
Table 4.1 shows the standardized quantitative RT-PCR copy numbers of the target 
mRNAs (ETAR, MEK-1 and MEK-2) after being treated with different combinations of 
















(µL) HCT116 HT29 HCT116 HT29 HCT116 HT29 
10 
3 4957.301452 9391.054699 187790.3119 21600.96541 387979.9125 568774.7861 
4 4963.777837 6894.87543 106556.3087 145315.1618 423643.4109 1257360.96 
50 
3 2188.36886 7607.655502 73217.02875 143488.024 346868.7207 616604.4776 
4 40898.20359 7960.245758 112797.8694 232781.9957 171343.2836 949828.3098 
100 
3 2461.402735 9069.487294 138945.5782 201483.0508 272914.8376 293658.754 
4 32734.72593 6721.432527 96060.27094 182231.6384 306727.8287 1209831.739 
 
Table 4.1: Silencing efficacy of different OFA/siRNA ratios. HT29 and HCT116 cells were seeded 
on 6-well plates and treated with target-specific siRNAs at different OFA/siRNA ratios. Results are 
expressed as copy number present in 100ng of RNA template and normalized to 50000 copies of 
G6PDH. The highlighted values show the lowest copy number for each target mRNA after treatment. 
 
 
The highlighted values are the lowest copy number for each target mRNA after 
treatment and therefore indicate the optimal OFA/siRNA ratio for each individual 
target (Table 4.1). These ratios, however, are selected considering the lowest copy 
number of both HCT116 and HT29, to standardize the protocol between cell lines for 
simplification. This simplification was due to the initial plan of performing silencing 
experiments on both cell lines. However, due to some confusing results derived from 
HT29 cell experiments (such as a drop of ETAR expresion after a number of 
passages), silencing experiments and experiments in the following chapters are 
limited to HCT116 from this point onwards. The selected OFA/siRNA ratios were 3 
µL and 50 nM for ETAR and MEK2 siRNAs, and 3 µL and 100 nM for MEK1 and 
control siRNAs (100 nM were chosen for scrambled siRNA as it represents the non-
target-specific damage that the transfection process may elicit on the cells and 




In order to further confirm the efficacy of the primers selected for qPCR experiments, 
conventional PCR of the genes of interest (ETAR, EGFR, MEK1, MEK2 and GAPDH 
(housekeeping gene)) was performed on HCT116 cells (Figure 4.1). While both 
techniques are performed in one step and based in the reverse transcriptase (RT), 
the main difference between them is that quantitative PCR detects and quantifies the 
amplified genes in real time, while conventional PCR is semi quantitative. 
 
 
Figure 4.1: Conventional PCR of key proteins in HCT116 cells. 1000000 HCT116 cells were 
seeded on a Petri dish and left to proliferate until 60% confluence. RNA was extracted and purified 
and conventional PCR was performed following the protocol described in chapter 2 (pg. 30). 
 
 
4.3.2 Effect of target-specific siRNAs on mRNA expression over time 
 
In order to select the timepoint in which maximum silencing is achieved for each 
target, quantitative RT-PCR was performed 24, 48 and 72 h after silencing 
treatment, including a control (scrambled) siRNA. There was a maximum silencing 
effect at 24 h for ETAR-specific siRNA, and 48 h for MEK-1 and MEK-2-specific 
siRNAs, all of which started to recover to reference levels 24 h after that point 




Figure 4.2 Effect of target-specific siRNA on mRNA levels. 200000 HCT116 cells were seeded in 
6-well plates, starved for 24 h and treated with specific siRNAs assisted by OFA. RNA was extracted 
after 24, 48 and 72 hour treatments and quantitative PCR was performed for the siRNA targets. 
Results from quantitative PCR were standardized against a housekeeping gene (G6PDH), used both 




Cells treated with scrambled siRNA as the non-specific siRNA control also showed a 
certain reduction in the levels of the target mRNAs, probably by causing some cell 
damage that inhibited the expression of certain proteins in response. Results shown 
here compensated for that effect, as the results are normalised to the basal levels 
obtained from the siRNA control treatment. At the macroscale, the damage elicited 
by siRNA transfection in cells is also visible even for the control group (Figure 4.3), 




Figure 4.3 Effect of control (scrambled) siRNA on cells. A certain degree of cell damage is 
observed in some regions within the treated plates, including those treated with scrambled siRNA. 
Left: healthy HCT116 cells, right: apoptotic HCT116 cells, both images taken from different regions of 
the same well. Scale bars = 100 µm. 
 
 
Wells treated with siRNAs, both specific and control, present a mixture of both 
morphologies, which explains why differences in expression are still visible, even in 
the presence of abundant cell death. This is partly due to the fact that siRNA 
transfection is a very heterogeneous process, in which not all cells receive the same 
amount of the treatment or contribute equally to the visible changes in expression. 
Even so, this needs to be taken into account. If the mere phenomenon of non-
specific transfection is causing apoptosis, this could present non-specific side effects 
in a combination treatment involving siRNA. 
 
4.3.3 Effect of specific siRNAs on target proteins 
 
Once the mRNA silencing efficacy was proven, Western Blot was performed to 
determine whether knocking out target genes effectively reduced the levels of target 





In the case of ETAR, this task was particularly difficult. Two different anti-ETAR 
monoclonal antibodies were used and neither of them seemed to recognize the 
target protein specifically. Figure 4.4 show the whole membranes after immunoblot, 
with very unspecific recognition of proteins of a variety of sizes. The highlighted 
bands (Figure 4.4c) are potentially subunits of ETAR (isolated and magnified) with 
their corresponding housekeeping gene bands), based on protein size extrapolated 






Figure 4.4 Non-specific protein recognition by two different ETAR antibodies. Following 
treatment with ETAR-specific siRNA, HCT116 protein extracts were ran in a polyacrylamide gel, 
transferred to a PVDF membrane and recognized by ETAR-specific antibodies. However, results 
consistently showed non-specific recognition. a) whole membrane treated with Abcam ETAR antibody, 
b) whole membrane treated with Alomone labs ETAR antibody, c) bands presumed to represent 
ETAR or ETAR subunits according to their size and response to ETAR-specific siRNA next to 
housekeeping protein GAPDH (top: Abcam ETAR antibody, band at 49kDa, bottom: Alomone labs 
ETAR antibody, band at 25 kDa). 
 
Densitometry of the selected bands (Figure 4.5) was calculated to have a graphical 
representation of increases or decreases of protein levels, standardized using the 
housekeeping gene. While the levels of one of the potential subunits recognized by 
the Abcam antibody are relatively stable over treatment times, the potential subunit 
recognized by the Alomone labs antibody shows significant increases over time, 
suggesting two possible explanations. On the one hand, it could be either a subunit 
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of ETAR that gets paradoxically overexpressed when the mRNA that codifies for it is 
silenced, or it could be a peptide functionally related to ETAR that gets expressed in 
response to a reduction in ETAR mRNA. It could also be a peptide completely 
unrelated to ETAR that happens to get overexpressed after a traumatic event such 
as transfection occurs. In any of those cases, in spite of the clear reduction in mRNA 
levels following its silencing, the treatment could not be proved to reduce the levels 
of the target protein. Nevertheless, due to the extremely unspecific binding of the 
antibody to proteins of many sizes, there is no evidence that the peptides or subunits 
analysed here are part of ETAR at all.  
 
 
Figure 4.5: Densitometry analysis of selected ETAR bands. The bands that could potentially 
represent ETAR were isolated and their intensity was quantified using the Image J software and 
standardized to the intensity of the housekeeping protein GAPDH for each lane. 
 
 
4.3.3.2 MEK-1 and MEK-2 
 
In contrast to the difficulty demonstrating ETAR protein inhibition, silencing MEK1 
and MEK2 at the mRNA level showed a clear correlation with decreases in target 
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protein levels. A clear reduction in the levels of both proteins is shown in (Figure 4.6 
and Figure 4.7) for MEK1-specific siRNA and MEK2-specific siRNA, respectively. In 
these images, MEK1 and MEK 2 are represented together in the same band since 
they are close in size, and they are also effectively recognized by the same antibody. 
 
 
Figure 4.6: Effect of MEK1-specific siRNA on MEK-1/2 levels. Following treatment with MEK1-
specific siRNA, HCT116 protein extracts were separated by PAGE, transferred to a PVDF membrane 




Figure 4.7: Effect of MEK2-specific siRNA on MEK1/2 levels. Following treatment with MEK2-
specific siRNA, HCT116 protein extracts were separated by PAGE, transferred to a PVDF membrane 
and recognized by a MEK1/2-specific antibody. MEK-1/2 is shown next to GAPDH control.   
 
Densitometry supports these findings and reveals that while both MEK1- and MEK2-
specific siRNAs steadily decrease the levels of MEK1/2 with increasing treatment 
times, the effect of MEK-1 is more pronounced (Figure 4.8), and this is clearly visible 




Figure 4.8: Densitometry analysis of MEK1/2 bands after treatment with MEK1- and MEK2-
specific siRNAs. Bands were isolated and their intensity was quantified using the Image J software 
and standardized to the intensity of the housekeeping protein GAPDH for each lane. 
 
4.3.3.3 Downstream marker pERK 
 
The ultimate aim of reducing the levels of MEK1/2, whether it is by blocking it with a 
drug or by silencing its expression is reducing the activation of ERK1/2 and therefore 
reversing the aberrant proliferation resulting from hyper-activation of MAPK pathway 
signalling. An additional experiment was designed to determine the effect of MEK1- 
and MEK2- specific silencing as well as a combination of both on the levels of 
phosphorylated ERK1/2 (Figure 4.9). Densitometry results were very promising, 
showing that not only each of this individual siRNAs reduce both pERK1 and pERK2, 
but a combination of both could be even more effective, although the differences 




Figure 4.9: Effect of MEK1- and MEK2-specific siRNAs on the levels of phosphorylated ERK1/2. 
Following treatment with MEK1- and MEK2-specific siRNA, individually or in combination, HCT116 
protein extracts were separated by PAGE, transferred to a PVDF membrane and recognized by a 
pERK1/2-specific antibody. pERK-1/2 is shown next to GAPDH control.    
 
 
Figure 4.10: Densitometry analysis of pERK1/2 bands after treatment with MEK1 and MEK2-
specific siRNAs. Bands were isolated and their intensity was quantified using the Image J software 






4.3.4 Combination treatments 
 
4.3.4.1 Combination of small molecules: AZD6244 and ZD4054 
 
It is believed that the downstream signalling cascade derived from the activation of 
ETAR is cross-linked to the MAPK pathway. For that reason, one of the main 
objectives of this research was to find a treatment combination that interrupts 
proliferative signalling cascades at two different points: the ETAR at the cell surface 
and the intracellular MEK1/2. Due to the availability of small molecules targeted at 
both proteins and the previous work with the endothelin receptors that took place in 
this department (Asham et al. 2001; Ali et al. 2000; Haque et al. 2013), one of the 
combinations explored here is that of AZD6244 (MEK inhibitor) and ZD4054 (ETAR 
antagonist). Due to the interaction or cross-talk between pathways, it has 
hypothesized that these two small molecules could achieve a synergistic inhibitory 
effect if administered together. 
To prove that hypothesis, HT29 and HCT116 cells were treated with different 
concentrations of AZD6244 and ZD4054 in combination. AZD6244 was chosen as 
the most appropriate MEK inhibitor for further experiments because of its superior 
status in research and clinical trials, its consistent dose-dependent effect among cell 
lines and its specific efficacy in RAS and RAF mutated tumours (Davies et al. 2007; 
Troiani et al. 2012; Tentler et al. 2010). 
A number of concentrations of both AZD6244 and ZD4054 were tested in 
combination, however, the major conclusion can be drawn from keeping AZD6244 at 
its highest concentration (1 µM) and testing it in combination with a range of ZD4054 





Figure 4.11: Effect of the combination of AZD6244 and ZD4054 on HCT116 cells. HCT116 cells 
were treated with 1 µM AZD6244 alone or with a range of ZD4054 concentrations (0.01 - 1 µM) for 48 
h before total DNA assay (left) and MTT assay (right) were performed. Significance: *p<0.05, 
**p<0.01, ***p<0,001, compared to the AZD6244 treatment alone. 
 
 
Results from this combination are not consistent with the hypothesis of synergism. 
The superior proliferation inhibition observed in the group treated with AZD6244 
alone suggested that this drug was the only one producing the desired effect. 
Moreover, cells treated with both ZD4054 and AZD6244 presented less proliferation 
inhibition than cells treated with the same concentration of AZD6244 in absence of 
ZD5054, suggesting that ZD5054 has an antagonistic effect towards the inhibitory 
effect of the MEK inhibitor. 
 
4.3.4.2 Combination of small molecule and silencing: AZD6244 and siRNAs 
 
In view of the antagonistic effect elicited by the combination of AZD6244 and 
ZD4054, a new approach was designed involving the combination of AZD6244 with 
various target-specific siRNAs. While the effect of ETAR-specific siRNA on its 
protein levels could not be demonstrated, its effect at the mRNA level was very 
positive (Figure 4.2). On the other hand, MEK1- and MEK2-specific siRNAs showed 
promising results both at the RNA, protein, and kinase activity levels (Figure 4.2, 
Figure 4.8 and Figure 4.10). The ability of all three siRNAs to inhibit proliferation was 
assessed independently and in combination with AZD6244. A 48-hour treatment was 
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chosen since the kinase activity of MEK1/2 was significantly reduced at this point 
and the silencing of ETAR mRNA reaches its maximum at 24 h (and the subsequent 
effect on the ETAR protein if there were any would happen at the earliest after that). 
Surprisingly MEK1-, MEK2- and MEK1/2-specific silencing treatments did not inhibit 
metabolic activity in HCT116 cells, but promoted it instead, as indicated by MTT 
assay (Figure 4.12). This could be an overall increase in metabolism through other 
pathways to compensate a reduction in MAPK pathway signalling. On the other 
hand, ETAR silencing did cause a slight reduction in metabolic activity, perhaps due 
to a milder and indirect effect on the key MAPK pathway.  
The addition of 100 nM AZD6244 to the silencing treatments reversed these results 
completely. In the presence of AZD6244, cells treated with MEK1- and MEK2-
specific siRNA and the combination of both exhibited an exact correlation between 
the inhibition of metabolic activity (Figure 4.12) and the previously observed 
inhibition of MEK1/2 activity (Figure 4.10), with the combination of both siRNAs 
eliciting the highest inhibitory response. The addition of AZD6244 also reversed the 





Figure 4.12: Effect of target-specific siRNAs alone and in combination with AZD6244 on 
HCT116 cells. Cells were treated with target-specific siRNAs, with or without AZD6244 for 48 h, 
before MTT assay was performed. Significance: *p<0.05, **p<0.01, ***p<0,001, compared to control 







An initial objective in this research was finding an effective combination of two small 
molecules that could achieve a synergistic inhibitory effect. Interfering RNA was then 
used as an alternative to the second small molecule component in this combination 
therapy approach. Besides, even though AZD6244 doesn’t show a particularly high 
chemical toxicity (non-target specific) compared to other inhibitors, it is a concern to 
take into account when using small molecules, and this makes silencing as an 
alternative therapy a potential candidate. Here, first the efficacy of the target-specific 
siRNAs and then combination treatments are discussed. 
Different ratios of OFA and target-specific siRNA were tested to find the optimal ratio 
for each molecule. The scrambled siRNA control was not included in this step since 
it does not target a specific molecule and no reduction in target mRNAs should be 
observed after treatment with it. Even though most combinations proved effective, 
the maximum efficacy was achieved with 100nM siRNA + 3uL OFA in the case of 
MEK-1, and 50nM siRNA + 3uL OFA in the case of MEK-2 and ETAR. Initially, the 
combination experiments were planned for both HT29 and HCT116 cell lines, so the 
maximum efficacy ratio was chosen to achieve maximum response in both cell lines 
using the same ratio. However, due to changes in gene expression of HT29 cells 
over time, the efficacy of siRNA and combination experiments following the 
OFA/siRNA ratio optimization were assessed only on HCT116 cells. 
Despite the absolute quantification of gene expression performed in this research, 
the levels of target mRNAs are higher than the reference expresion showed in 
chapter 3 (pg. 42). This is due to the different conditions of the experiment; while 
silencing experiments were done in 6-well and 24-well plates and subject to 
treatments, to determine the reference levels of expression cells were grown in Petri 
dishes and they were not subject to any treatment or serum removal steps . For 
example, if a population of cells is treated with a therapeutic or silencing agent, cells 
might respond by overexpressing certain proteins to counteract an inhibitory effect, 
and that response would be very different from the reference levels even if that gene 




4.4.1 ETAR silencing efficacy 
 
As shown in (Figure 4.2), the silencing efficacy of the ETAR-specific siRNA peaks 
after 24 h. Based on this, if protein levels of ETAR were indeed reduced after ETAR-
specific siRNA treatment, this would have happened at least 24 h after the treatment. 
Two different ETAR-specific antibodies were used to explore the reduction in protein 
expression, but unfortunately that hypothesis could not be demonstrated (Figure 
4.5). The antibody purchased from Abcam recognized a large number of bands with 
different intensities and only one of the weak bands corresponded to the size that the 
company suggested for ETAR. Even though said band showed a slight reduction in 
protein levels 24 and 48 h after the ETAR-specific siRNA treatment, the lack of 
specificity of this antibody suggests that the band could represent another protein, or 
a number of different proteins other than ETAR.  
The other antibody used was purchased from Alomone labs, and in this case only 
two bands were clearly intense. One of them did correspond to the size suggested 
by the company but the protein level increased considerably as the ETAR-specific 
siRNA treatment time increased. Considering this ETAR-specific siRNA has 
previously been used by this group with positive results (unpublished data), the 
increase in ETAR protein levels might not be a coincidence, however discouraging 
this result may be. On the other hand, the effect of ETAR-specific siRNA on the 
levels of ETAR was not examined in those previous experiments, as they were 
performed to study changes in the expression of other proteins, not ETAR. 
Assuming the silencing of the ETAR gene was in fact related to an increase in the 
protein levels, this could be explained as a compensatory decrease in its turnover. 
After the interaction with its ligand, at least part of the ETAR is known to be recycled 
and returned to the cell membrane, as opposed to constantly destroyed and new 
receptor synthesized. A reduction in the level of ETAR mRNA could result in 
compensatory translation of the remaining transcripts and increased expression of 
the protein or reduced receptor turnover, which combined with the recycling of the 




4.4.2 MEK-1 and MEK-2 silencing efficacy 
 
The efficacy of MEK-specific siRNAs was much clearer than in the case of ETAR. 
Both subtype-specific siRNAs elicited a significant reduction of their targets at the 
mRNA (Figure 4.2) and protein (Figure 4.8) levels, and they successfully reduced 
their activity, as shown by decreased levels of pERK (Figure 4.10). 
According to these experiments, in HCT116 cells the expression levels of MEK-1 
were significantly higher than those of MEK-2, and so were the levels of ERK-2 
compared to ERK-1. This is consistent with previous reports in the literature (Lefloch 
et al. 2009). At the same time, MEK-1 silencing was more efficient lowering the 
mRNA levels of MEK-1/2 than MEK-2 silencing, although this could be due to the 
higher initial levels of MEK-1 or the higher concentration of siRNA used to silence 
MEK-1 compared to MEK-2. On the other hand, silencing MEK-2 was more efficient 
reducing the levels of both pERK-1 and pERK-2 even though the basal levels of 
MEK-2 and the amount of siRNA to silence it were lower than MEK-1; and the levels 
of activated ERK-1/2 (pERKs) are the principal targets of interest. Similar findings in 
this area have been reported, such as the fact that MEK-1 expression alone is not 
enough for melanoma proliferation but MEK-2 is (Lee et al. 2011), or the fact that 
knocking out MEK-2 expression has a more prominent effect as a proliferation 
inhibitor than knocking out MEK-1 in colorectal cancer (Voisin et al. 2008). This idea 
is also supported by T. W. Sturgill, who suggested that MEK-2 might have a role 
compensating the silencing of MEK-1 (Sturgill 2008). Specifically in HCT116 cells, it 
has been demonstrated that silencing MEK-1 induces p21Cip1 and promotes G1 
arrest, which appears to be compensated by MEK2 activity (Ussar & Voss 2004). 
These findings suggest a more important role of MEK-2 in cancer proliferation than 
MEK-1, but interestingly also point towards a differential function of MEK-1 and 
MEK-2. 
A large body of work suggests that some of the roles of MEK-1 and MEK-2 are 
differential (Giroux et al. 1999; Bélanger et al. 2003; Scholl et al. 2009), but not all of 
them are in favour of MEK-2 as the most important protein. For example, it is 
believed that MEK-1 and MEK-2 have a different role in G1 progression, since MEK-
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1 function is activated in human glioblastoma, mouse embryonic fibroblasts and 
Chinese hamster ovary cells by the addition of serum to culture media, and this does 
not happen to MEK-2 (Xu et al. 1997).  
This is different in the case of ERK-1 and ERK-2, both of them believed to have a 
similar function in G1 progression (Lefloch et al. 2009), which then suggests that 
MEK-1 at least has the ability to phosphorylate both ERKs in that phase. Contrary to 
this theory, it has been hypothesised, although as pure speculation, that MEK-1 may 
preferentially act on ERK-2 (Sturgill 2008). This is because while mice knockouts of 
MEK-2 (Bélanger et al. 2003) and ERK-1 (Pagès et al. 1999) are viable, the 
equivalent for MEK-1 (Giroux et al. 1999) and ERK-2 (Hatano et al. 2003; Saba-El-
Leil et al. 2003) are embryonic lethal. However, if this hypothesis were true, it might 
only be significant in stages of embryonic development and not have an effect on 
cancer. 
The efficient reduction in MEK1/2 activity elicited by MEK-specific siRNAs was 
surprising. HCT116 is a KRAS-mutant cell line and therefore a number of alternative 
signalling pathways originating upstream of MEK are expected. Furthermore, there is 
increasing evidence of RAF-independent MEK signalling. These results are 
consistent with the theory that the MAPK pathway elicits oncogenic dependency 
(Weinstein & Joe 2008; Weinstein 2002), since many alternative pathways lead into 
the MAPK pathway via MEK and other upstream kinases. 
 
4.4.3 Combination treatments 
 
The general aim of this chapter was finding a combination of therapeutic agents 
more effective than monotherapy to take forward for nanoformulations and 3D 
testing. In many cancers, the MAPK pathway harbours constitutively active 
mutations in key proteins, eliciting the phenomenon of “oncogenic dependency” or 
“oncogenic addiction”, in which the cancerous behaviour of the cell heavily relies on 
signalling through this pathway (Weinstein & Joe 2008; Weinstein 2002). Although it 
is highly interconnected to other pathways, the interactions between certain proteins 
are almost exclusive, such as MEK-1 and MEK-2 being the only known substrates of 
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RAF, or the ERKs being the only known substrate of the MEKs (Ahn et al. 2001). 
This fact, together with the oncogenic dependency, throws light on the possibility of 
combining therapies that are closely related to the same pathway to achieve a 
synergistic effect. 
Two different approaches have been explored in this chapter: one combining two 
small molecules (AZD6244 and ZD4054), and after their unexpected antagonistic 
effect, another one combining AZD6244 and target-specific siRNAs. 
 
4.4.3.1 Combination of AZD6244 with ZD4054 
 
The initial approach was combining two small molecules that could potentially show 
a synergistic inhibitory effect: AZD6244, an inhibitor of MEK-1/2 and ZD4054, a 
competitive antagonist of ETAR. Many therapeutic molecules have been combined 
with MEK inhibitors as a combination therapy, some with very positive outcome. 
Some of these combinations were with more toxic traditional chemotherapies such 
as irinotecan or docetaxel (Davies et al. 2007), and others aimed for specific cancer-
related pathways such as BRAF inhibitors (Flaherty et al. 2012), or inhibitors of the 
PI3K/Akt/mTOR axis (Shimizu et al. 2012; Tentori et al. 2013). Similarly, ZD4054 
showed promising efficacy in vivo combined with the cytotoxic drug paclitaxel, and 
the EGFR inhibitor gefitinib (Rosanò et al. 2007a; Rosanò et al. 2007b). 
These results combining AZD6244 and ZD4054 were not so promising. In spite of 
the clear dose-dependent inhibitory effect of AZD6244 and the potential of ZD4054 
in absence of ET-1 in these cell lines, the administration of both seemed to elicit an 
antagonistic response. Both metabolic activity and proliferation assays showed that 
concentrations of ZD4054 equal or superior to 100 nM in combination with 1 µM of 
AZD6244 reversed the inhibitory effect of the later.  
The reasons for this are uncertain, since no antagonistic effect of ETAR therapeutics 
has been reported before, but there could be a number of explanations for this 
unexpected cell behaviour. Some of the alternative pathways explained in the 
previous chapter that could have hindered the efficacy of MEK inhibitors might also 
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have a role in this antagonism. The binding of ETAR to its ligand ET-1 activates wild-
type BRAF, which is more abundant in HCT116 cells than HT29 cells. The blockage 
of this receptor could therefore affect HCT116 cells slightly more, which is what we 
observe in our data. 
Any pathway that cross-talks with the MAPK pathway could be affected by a positive 
or negative feedback, in the event of ETAR and MEK signalling being impaired or 
reduced simultaneously. ETAR signalling has a mitogenic effect through the 
activation of a number of proteins, such as PI3K, PKC, PLC, PLD, PLA2, adenylate 
cyclase, guanylate cyclase, Raf-1, IP3, diacylglycerol (DAG), akt, mTOR, COX-1, 
COX-2, and prostaglandin E2 (Grant et al. 2007; Blaukat et al. 2000; Shome et al. 
2000). 
As considered in chapter 3 (pg. 42), the activation of the Wnt/FDZ pathway is 
partially responsible of the suboptimal effect of AZD6244 on HCT116 (Tentler et al. 
2010). Also, the inhibition of MEK could activate the PI3K/mTOR/Akt pathway 
(Mirzoeva et al. 2009) and reactivation of MEK and ERK might lead to resistance to 
BRAF inhibitors (Johannessen et al. 2010; Nazarian et al. 2010), which at the same 
time could cause secondary malignancies in other tissues by fostering MAPK 
pathway signalling (Heidorn et al. 2010; Poulikakos et al. 2010; Arnault et al. 2012). 
Any of these paradoxical feedbacks could be of a similar nature to the ETAR and 
MEK dual blockade antagonistic effect. 
The fact that a portion of the ETAR pathway signalling is upstream of KRAS 
indicates that more alternative pathways would be involved in both HT29 and 
HCT116 cells than in the case of a direct phosphorylation of BRAF. Some of these 
alternative pathways involve PI3K or PKC, which have been proven to be part of the 
ETAR signalling network (Grant et al. 2007; Asham et al. 2001), among many others. 
One of the major ways by which ETAR induces proliferation is the transactivation of 
other surface receptors. For example, Vacca and colleagues demonstrated that ET-1 
induced phosphorylation of EGFR in ovarian carcinoma cells and this is in part what 
triggers ET-1-mediated mitogenesis (Vacca et al. 2000). Similar data was reported 
by Grant and colleagues in colorectal cancer cells (Grant et al. 2007). In human 
smooth muscle cells, ET-1 increases the effect of PDGF, which interacts with similar 
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surface receptors (Yang et al. 1999). This receptor transactivation has been 
exploited to find successful therapeutic combinations, such as the tumour regression 
achieved after co-administration of ZD4054 and gefitinib on ovarian carcinoma 
xenografts (Rosanò et al. 2007b). 
The success of ZD4054 in combination with paclitaxel and gefitinib suggests that the 
antagonistic effect we observed in combination with a MEK inhibitor could just be 
due to the lack of exogenous ET-1 or the suboptimal efficacy of ZD4054 itself. 
However, human cancer cell lines, including colorectal, produce large amounts of 
ET-1 in vitro (Kusuhara et al. 1990; Sone et al. 2000) and the autocrine effect of ET-
1 has been demonstrated in colorectal cancer cell lines (Ali et al. 2000), suggesting 
that ZD4054 should have some inhibitory effect and at least not induce proliferation. 
Also, the inhibitory effect of the dual surface receptor inhibition (ETAR and EGFR) 
observed in ovarian cancer (Rosanò et al. 2007b) could be due to the inhibition of 
alternative pathways that signal upstream of MEK, although most of these pathways 
eventually lead to MEK (Grant et al. 2007; Asham et al. 2001; Shome et al. 2000; 
Blaukat et al. 2000). In any case, the efficacy of this combination could change 
drastically if an active ET-1 that consistently triggers ETAR signalling could be 
included in the experiment, or if the efficacy of ZD4054 could be properly assessed 
as a monotherapy. 
 
4.4.3.2 Combination of AZD6244 and target-specific siRNAs 
 
Surprisingly, ETAR-specific siRNA did elicit an inhibitory response in the absence of 
AZD6244, while the addition of AZD6244 apparently reversed this inhibitory effect 
(Figure 4.12). Since, to my knowledge, the silencing of ETAR has never been used 
as a therapy, it is difficult to put these results into context. However, the fact that the 
inhibition of MEK cancels the inhibitory effect of ETAR silencing suggests that the 
effect of AZD6244 could simply be overtaking that of ETAR silencing. Note that the 
control for the combination of AZD6244 and ETAR silencing contains AZD6244 and 
scrambled siRNA (Figure 4.12). Since ETAR signalling indirectly acts through the 
MAPK pathway, the blocking of MEK1/2 by AZD6244 might be the limiting point 
regardless of a reduction in ETAR signalling. 
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Since MEK1/2 are widely used targets for small molecules, the use of siRNA 
directed against these molecules is seldom used as a therapeutic agent, while many 
studies have used siRNA to knock down MEK in order to study the effect of both 
upstream and downstream proteins of cancer pathways. To my knowledge, this is 
the first time a small molecule and siRNA have been targeted against the same 
protein as a therapeutic approach. Results were interesting, since it showed a 
statistically significant difference compared to the small molecule on its own. 
In order to explain the results obtained from the AZD6244 and MEK silencing 
combination it should be pointed out that we are observing changes in metabolic 
activity, not proliferation per se (Figure 4.12). 
Overall, the effect of AZD6244 as a small molecule inhibitor on metabolic activity 
appears to be more efficient than silencing MEK1/2. There are some pieces of 
evidence in favour of a stronger effect of AZD6244. First, AZD6244 inhibits both the 
already existing active and inactive forms of MEK1/2 in colorectal cancer while 
siRNA can only prevent the translation of new protein. Therefore the effects of siRNA 
are more likely to be compensated by the pre-existing protein. Besides, AZD6244 
has been reported to induce apoptosis, suggesting that it is not only cytostatic but in 
fact cytotoxic (Huynh et al. 2007; Troiani et al. 2012). 
As mentioned earlier, the increase in metabolic activity observed in the MEK1-, 
MEK2-, and MEK1/2-specific siRNA treatments could just be to compensate a 
reduction in MAPK signalling. In the absence of the apoptotic effect of AZD6244, this 
could translate in an overall increase in metabolic activity. However the silencing of 
MEK1/2 expression in combination with the blockage of active and inactive forms of 
the pre-existing protein do elicit an additive inhibitory effect, which is significant 
considering the difference between AZD6244 alone and the combination is 
statistically significant (p<0.001, Figure 4.12), and so is the difference between 
AZD6244 and the untreated control (p<0.001, Figure 3.12). 
The silencing of MEK1 in the absence of AZD6244 enhanced metabolic activity more 
effectively than the silencing of MEK2, and in the presence of AZD6244 its inhibitory 
effect was also lower. This could be explained under the hypothesis that MEK2 has 
the ability to compensate for the absence or reduction of MEK1, including specific 
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data on HCT116 cells (Ussar & Voss 2004; Sturgill 2008), which also makes the 
former a better target for cancer therapy. This is especially surprising considering 
that HCT116 cells express significantly more MEK1 than MEK2 mRNA (also 
probably the reason why double the amount of siRNA was needed to knock-down 
expression levels), so it could be expected that a greater reduction in the levels of a 
key protein would have a greater proliferation inhibitory effect. Additionally, the 
higher activity of MEK2 over MEK1 could be supported by the fact that MEK2, unlike 
MEK1, is not activated by serum (Xu et al. 1997) and all these treatments were in 
fact performed in the absence of serum, potentially increasing the importance of 
MEK2. 
 
4.4.4 Selected molecule for nanoformulations and 3D culture testing 
 
The work performed in this and the previous chapter yielded both positive and 
negative results. While both the inhibition and silencing of MEK1/2 showed inhibitory 
promise at the proliferation, metabolic activity and molecular levels, studies on the 
endothelin axis have been challenging and mostly unfruitful from the very beginning.  
The inability of ZD4054 to elicit a significant and reproducible inhibitory response, 
either alone or in the presence of ET-1, combined with its antagonism of AZD6244-
mediated inhibition was instrumental in the decision to abandon the endothelin axis 
completely and focus on MEK1/2 as the only target for nanoformulations and studies 
using a 3D model. Due to the oncogenic dependency that the MAPK pathway elicits 
on these cells (Weinstein 2002; Weinstein & Joe 2008) the inhibition of MEK1/2, 
although not optimal, should be sufficient for further investigations. 
While results from the use of MEK1- and MEK2-specific siRNAs alone and in 
combination with AZD6244 do suggest a potential combination therapy, there are 
some limitations regarding the use of siRNA as a therapeutic. First and foremost, the 
clear toxicity elicited by all siRNA treatments, including the non-target-specific 
control, supposes too much of a toxicity risk for the rest of this research. Whilst it is 
not clear whether it is the method of transfection or the effect of the siRNA itself, any 
inhibitory success derived from siRNA as a therapeutic agent would potentially be 
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related to this off-target toxicity. However, it must be noted that, in general terms 
gene silencing remains a promising anti-cancer therapeutic approach (Ryther et al. 
2005; Misale et al. 2014). Secondly, however significant, the additional inhibitory 
potential achieved by combining AZD6244 with MEK-specific siRNA was so subtle 
that the creation of a dual-cargo nanoformulation of this complexity with no 
guarantee of success would not be worth the time and resources.  
For these reasons, AZD6244 was once again selected as the only therapeutic 









































AZD6244 was chosen for nanoparticle-mediated drug delivery in 2D and 3D 
colorectal cancer models. This chapter contains everything related to the fabrication 
and characterization of nanoparticles, including micelles and liposomes loaded with 
AZD6244 as a therapeutic agent, Nile Red and quantum dots as fluorescent tracking 
agents and control nanoparticles containing only water. During fabrication, different 
approaches and techniques were evaluated to optimize the nanoparticles before 





5.2 Materials and Methods  
 
5.2.1 Fabrication of liposomes made from cholesterol and phospholipids 
 
DC-cholesterol, DOPE and DOPC (Figure 5.3) were obtained from Avanti polar lipids 
(Alabama, USA). Liposomes were fabricated using variations of some of the 
protocols described by Mozafari (Mozafari 2010). The process can be divided in two 
fundamental parts: 1) the formation of large vesicles by rehydrating a thin layer of 
lipid components attached to a glass surface, and 2) the formation of nanoliposomes 
derived from these vesicles. The second part of the protocol was initially achieved 
through ultrasonication, but it was later substituted by extrusion, during the 
methodological development phase. 
 
5.2.1.1 Thin layer rehydration method 
 
Equimolar concentrations (5mM) of DOPE (or DOPC) and DC-cholesterol (Avanti 
polar lipids) were dissolved in chloroform-methanol (2:1). This represents a relatively 
high amount of cholesterol, in order to provide good stability and low leakage of the 
content out of the nanocarrier, as well as increase the fraction of cationic moieties in 
the surface. If a hydrophobic molecule was to be encapsulated in the batch, 2mM of 
AZD6244 or Nile Red were included in the mixture at this stage. Organic solvents 
are essential for the dissolution of hydrophobic molecules, such as cholesterol, 
phospholipids, and small molecules like AZD6244 or Nile Red. The final 
concentration in the mixture for both the phospholipid and cholesterol components 
was 5mM, and the volume was 9mL. The mixture was placed in a rotaevaporator to 
remove the solvents and leave a thin film in the inner surface of the glass containing 
the lipids. To remove any trace of solvents left, the film was further dried with N2. 
Note: Nile Red is a dye that only fluoresces in a hydrophobic environment and is 
therefore suitable to selectively track nanoparticles with a hydrophobic regions such 
as liposomes and micelles. 
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The thin film containing the hydrophobic components was then rehydrated in 10mL 
of deionized water. If hydrophilic gold quantum dots were encapsulated within the 
aqueous core of the nanoparticle, 1 mg of these were included in the 10mL 
rehydration solution. A combination of 1 minute vortexing and 5 minute sonication in 
a water bath were used to fully detach all layers of lipids from the surface, which 
spontaneously formed large multilamellar vesicles (MLVs). 
 
5.2.1.2 Ultrasonication method 
 
For the ultrasonication method, MLVs were transferred to a beaker and left for 1 hour 
at room temperature to stabilise. The beaker was then placed in a water bath and 
calculated probe sonication steps were used to turn MLVs into nanoliposomes. 
Probe sonication cycles consisted of 20 sec ON/OFF at a pulsed rate at amplitude 
30% for a total time of 10 min (Cole-Palmer Instruments, Illinois, USA). The 
suspension was then centrifuged at 12000 x g for 30 min to remove large lipid 
clusters, and the remaining solution was left at room temperature for 1 hour to 
stabilise again. Nanoliposomes were dialysed against deionised water for six cycles 
of two h using a 10 mm diameter, 12000 kDa cut-off membrane (Sigma Aldrich) to 
remove unencapsulated drug or fluorescent marker, and then stored at 4oC. 
 
5.2.1.3 Extrusion method 
 
For the extrusion method, MLVs were transferred to a polystyrene tube and left for 1 
hour at room temperature to stabilise. The suspension was then extruded 14 times 
through a polycarbonate membrane (7 through 1000nm and 7 through 200nm) using 
a liposome extruder with 1 mL syringes (Figure 5.1) (Avanti polar lipids, Alabama, 
USA) and always keeping the first loading syringe separated from the last receiving 
syringe to minimize debris (Figure 5.2). Nanoliposomes were dialysed and stored as 
in the sonication protocol. This method, although more complex, was eventually 
chosen for liposome fabrication and cell in vitro testing for a number of reasons. 
Since the last part of the thin layer step involves detaching the lipids from the glass 
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using ultrasonication, the thin layer-extrusion combination does involve a small 
ultrasonication step and therefore some nanoliposomes do form before extrusion. 
 
 
Figure 5.1 Liposome extruder and support with 1 mL air tight glass syringes (Avanti Polar 
Lipids). A polycarbonate membrane flanked by filter supports is placed between two teflon 
membrane supports and the system is locked using an outer casing and a nut. The extruder 
containing the membrane is then placed on a support and the syringes are introduced into the 







Figure 5.2 Extrusion method. A solution of large vesicles is injected into the left side of the extruder. 
The particles are forced through two support filters, a polycarbonate membrane and another two 
support filters. Nanoliposomes are collected on the right side syringe and the process is repeated 
back and forth between both syringes 7 times through a 1000nm polycarbonate membrane and 
another 7 times through a 200nm polycarbonate membrane. The last extrusion is collected on the 
right side syringe to remove large debris. 
 
5.2.1.4 Liposome methodological development 
 
Before the fabrication of AZD6244- and Nile Red-loaded liposomes for drug 
treatments and penetration studies, a few experiments aimed at optimizing 
encapsulation and liposome formation were performed. To create fluorescent 
liposomes at this stage, 1 mg of gold Quantum Dots was added to the rehydration 
phase at the final stage of the thin layer method. Upon rehydration of the lipid layer, 
these hydrophilic QDs were encapsulated in the liposomes aqueous core. Confocal 
microscopy was used to image these fluorescent nanoparticles, mostly as 
precipitated aggregates due to the difficulty to image a single nanoparticle in 
suspension. An attempt was made, however, to image single liposomes by 







5.2.2 Fabrication of micelles made from GCPQ 
 
5.2.2.1 Polymer synthesis and characterization 
 
Unlike the liposome components, which were purchased commercially, quaternary 
ammonium palmitoyl glycol quitosan (GCPQ) was synthesized in the laboratory prior 
to its use to encapsulate a hydrophobic molecule. GCPQ was fabricated following 
the protocol described in (Uchegbu et al. 2001), with slight modifications. The 
polymer was provided by Professor Uchegbu’s research group (School of Pharmacy, 
UCL), and all experiments involving GCPQ micelles on cell monolayers and 
tumouroids derive from the same highly palmitoylated batch of the polymer. 
 
5.2.2.2 GCPQ micelle fabrication 
 
Using the previously synthetized polymer, micelles were fabricated following a 
modified version of the protocol described in (Qu et al. 2006). This protocol is similar 
to the liposome ultrasonication method, but the nature of the polymer induces the 
formation of micelles. 20mg of highly palmitoylated GCPQ polymer 
(palmitoylation=18.9%, quaternalization=11.2%, MW=17,120 g/mol), were dispersed 
in 2 mL of deionised water. For micellar formulations encapsulating a hydrophobic 
molecule, either 2 mg of AZD6244 or 1.3 mg of Nile Red were added to this solution. 
The mixture was vortexed until it became turbid and sonicated in a water bath for 
one minute to assist homogenisation. The homogenised solution contained in a 
glass vial was placed inside an ice bath to reduce sample heating and probe-
sonicated with amplitude 45% for six five-minute cycles alternated with three-minute 
breaks (Qsonica, Connecticut, USA). The sonicator tip was placed just below the 
surface of the fluid to minimize the formation of foam. The resulting GCPQ micelles 
were allowed to stabilize for 15 min at room temperature before filtration through a 
0.45 µm filter and centrifuged at 1000 x g to remove unencapsulated drug crystals. 
Due to the inclusion of this step, AZD6244-loaded micelles were not dialysed to 
remove unencapsulated drug like in the case of liposomes, while Nile Red-loaded 
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micelles underwent identical dialysis steps to the liposomes. After fabrication, GCPQ 
micelles were also stored at 4oC. 
 
Figure 5.3 Chemical structure of liposome components. Liposomes were fabricated using 
equimolar ratios of DOPE and DC-cholesterol or DOPC and DC-cholesterol. 
 
5.2.3 Fabrication of gold Quantum Dots 
 
Gold quantum dot fabrication was undertaken by Dr. Bala Ramesh (Division of 
Surgery, UCL). Before fabrication, glassware was washed with chromic acid and 
ammonium hydroxide to remove impurities. HAuCl4 (20mM) and MSA (20mM) were 
mixed in a 20mM Na2B4O7 and 20mM of trisodium citrate buffer solution adjusted to 
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pH 7.2, and underwent vigorous stirring for 10 min before being transferred to a 
single neck flask attached to a condenser and refluxed at 250oC with mixing. 500 µL 
of DMF were then added drop by drop to the mixture as a reductant until colour 
change to light brown was observed after one hour, indicating the presence of gQDs. 
The maximum emission of gQDs is located at 800 nm wavelength in the near 
infrared region. All chemical used in this synthesis were purchased from Sigma-
Aldrich. 
 
5.2.4 Nanoparticle characterization 
 
5.2.4.1 Dynamic light scattering (DLS) 
 
Dynamic light scattering (DLS) was used to determine the size of nanoparticle and 
nanoparticle aggregates in an aqueous solution. A diluted suspension of 
nanoparticles was placed in a disposable cuvette and measured 3 times for 15 
repeats each for size analysis in a Malvern Nanosizer ZS (Malvern, Worcestershire, 
UK). For the analysis, parameters were set to backscatter mode and a 1.33 
dispersant refractive index. Results are shown maintaining the format of the Malvern 
Zetasizer software. 
 
5.2.4.2 Transmission electron microscopy (TEM) 
 
Transmission electron microscopy (TEM) was used to visualize the particles in the 
nanoscale, and to determine their morphology and approximate size. An aqueous 
suspension of nanoparticles was placed on a Formvar © / Carbon Coated Grid 
(F196/100 3.05 mm, Mesh 300, Tab Labs Ltd, England) and stained with a 1% w/v 
aqueous solution of uranyl acetate. However, no negative staining was needed to 
image gold QDs, as they are electron dense. TEM images were taken at a minimum 
of 30000 X magnification using a Philips CM120 BioTwin transmission electron 
microscope, (Philips, Eindhoven, The Netherlands) with a AMT 5 megapixel digital 
camera (AMT, UK). 
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5.2.4.3 Encapsulation efficiency and compound measurement (HPLC) 
 
Drug content of both formulations was determined by HPLC against a standard 
curve of free AZD6244 (Figure 5.4). This standard curve was repeated before every 
set of measurements to minimize possible variations caused by the UV lamp losing 
power through usage. Samples were diluted in methanol (1:3 for micelles and 1:25 
for liposomes) to break the nanoparticles open and then filtered through a 0.2 µm 
membrane prior to chromatography analysis. 30 µL of the sample were 
chromatographed over a 5 µm bead, 4.6 mm diameter, 100 mm length Luna C18 
reverse phase column preceded by a Safeguard pre-column (Phenomenex, 
Cheshire, UK) at 25 C, using a Waters TM717 autosampler, a Waters TM515 HPLC 
pump and a TM486 absorbance detector set at 260nm wavelength (Waters, 
Hertfordshire, UK). The mobile phase was HPLC grade methanol with an isocratic 
flow rate of 0.8 mL/min, and AZD6244 showed a retention time of 21.5 min under 
these conditions. The concentration of AZD6244 contained in liposomes and 










Figure 5.4 Example of AZD6244 standard curve. Different concentrations of AZD6244 were used to 
create a standard curve on HPLC before each set of measurements. Standard curves such as this 
one were used to extrapolate the drug content within the nanoparticles, after releasing the drug using 
methanol. 
 
5.2.4.4 Confocal microscopy 
 
In this chapter, confocal microscopy was used to evaluate the potential of liposomes 
to internalize a hydrophilic molecule. These preliminary experiments were initially 
designed to inform further experiments involving the encapsulation of nucleic acids 
such as the siRNA treatments tested in chapter 4 (pg. 82). While AZD6244 was 
eventually selected as the only therapeutic molecule for nanoformulations, these 
experiments helped determine the nature and morphology of the liposomes. 
Furthermore, the penetration of quantum-dot loaded liposomes into the tumouroids 
and their individual aggregates established the basis for penetration studies included 
in section 6.3.7. (pg. 162). 
500 µl of liposome solution were placed in a 24-well plate, and confocal images were 
taken from the precipitated aggregates at the bottom of the well or from 
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nanoparticles suspended in the fluid. The excitation wavelength for gold quantum 






5.3.1 Liposome methodological development 
 
As mentioned earlier, the protocol used here for liposome fabrication involved two 
steps. The first step consisted on dissolving the lipid components in organic solvents 
and letting them form a thin lipid layer on a glass surface after evaporation. When 
this layer was rehydrated with deionised water, large vesicles formed. Several 
attempts were undertaken to image both the large vesicles and subsequent 
nanoliposomes in solution, by encapsulating hydrophilic gold quantum dots into their 
aqueous core. However, this presented many complications since the particles 
tended to aggregate and precipitate and they also quickly drifted when dispersed in 
aqueous media (Figure 5.5).  
 
 
Figure 5.5 TEM images of gold quantum dots (gQD). (Left) magnification 175000X, HV=80.0kV, 
scale bar = 100 nm. (Right) magnification 230000X, HV=80.0kV, scale bar  = 100nm. gQDs were 
encapsulated into liposomes for imaging purposes. 
 
As shown, these large vesicles successfully encapsulated gold quantum dots that 
were added to the aqueous phase during the rehydration step.  The fluorescent 
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signal emitted by the quantum dots co-localizes with the black and white image of 
the organic nanoparticles. Large vesicles formed large aggregates in the aqueous 




Figure 5.6 Gold quantum dot-loaded vesicles form large precipitates in aqueous solution. 
Large fluorescent vesicles were imaged as a precipitate at the bottom of a 24-well plate using 
confocal microscope. Scale bar = 20 µm. 
 
The imaging of the large vesicles in suspension was attempted; however, their fast 
movement did not allow obtaining a clear image. By suspending the vesicles in 
glycerol instead of water, a blurred image of individual moving nanoparticles in 
solution could be obtained due to the high viscosity of the dispersion medium (Figure 





Figure 5.7 Gold quantum dot-loaded and empty large vesicles suspended in glycerol. Scale bar 
= 20µm 
 
After the rehydration step and formation of large vesicles, two methods were 
explored to create nanoliposomes: ultrasonication and extrusion. (Figure 5.8) shows 
TEM images of after following both methods, which produced similar nanoparticle 
morphology and size. DLS analysis also showed similar sizes for the nanoliposomes 
in aqueous suspension, around 165-180 nm in diameter (Figure 5.9 and Figure 




Figure 5.8 TEM images of nanoliposomes fabricated using two different methods. 
Ultrasonicated nanoliposomes (left, HV=80.0kV, scale bar = 100nm, magnification 66000X) and 
nanoliposomes extruded through 1000nm and 200nm polycarbonate membranes (right, scale bar = 
500nm, HV=80.0kV, magnification 15000X) show similar morphology and size under TEM. 
 
 
Figure 5.9 DLS analysis of ultrasonicated liposomes. Vesicles were probe sonicated for 10 min 
following ON/OFF pulsed cycles at 30% amplitude, allowed to stabilize for an hour and dialysed 
against deionised water. Each colour represents a measurement repeat. The format for this graph is 
slightly different from those of extruded liposomes and GCPQ micelles because it was outsourced to 




The extrusion method was chosen over the ultrasonication method for further 
experiments due to its less aggressive nature and very positive reports in the 
literature. Thus, extrusion was used to create nanoliposomes derived from large 
vesicles encapsulating gold quantum dots, for similar imaging purposes. The 
resulting nanoliposomes were also imaged using confocal microscopy. The removal 
of large lipid debris and the overall reduction in particle size seemed to disperse the 
nanoliposomes slightly more compared to the large vesicles (Figure 5.10). Co-
localization of fluorescent quantum dots and the clearly defined nanoliposomes 
suggests that the interaction between both nanoparticles was kept after extrusion. 
Both quantum dot-loaded (fluorescent) and hollow (non-fluorescent) nanoliposomes 
were visible. A higher magnification of these nanoliposomes revealed that the 
quantum dots were in fact encapsulated within the aqueous core of the nanoparticle 
(Figure 5.11) as opposed to adsorbed to the outer surface as it is very common with 
nucleic acid-nanoparticle clusters. 
 
 
Figure 5.10 Quantum dot-loaded liposomes extruded through 1000 nm and 200 nm 
polycarbonate membranes. Nanoliposomes were imaged as a precipitate at the bottom of a 24-well 





Figure 5.11 Higher magnification of a single liposome loaded with fluorescent Quantum Dots. 
The image reveals that the gold QDs are encapsulated in the aqueous core of the nanoparticle and 
not adsorbed to the surface of the membrane. Scale bar = 1 µm. 
 
5.3.2 Micelle methodological development 
 
While most of the methodological development regarding the GCPQ polymer and its 
micellar formulations was done previously by our group, it is worth including here an 
additional step in the micelle formation protocol that was included to solve a problem 
with the presence of drug crystals (Figure 5.12). Due to their large size and 
hydrophobic nature these crystals could be removed through simple filtration and 
centrifugation steps. Freshly formed micelles were allowed to stabilize for 15 min 
before they were forced through a 450 nm filter and centrifuged at different speeds 
for 15 min. Crystals were not visible in the 1000 x g and higher speed centrifugation 
samples. DLS analysis showed a drop in the size of micelle aggregates (and drug 
crystals) as centrifugation speed increased, reaching a plateau between 3000 and 
4000 x g and a significant drop below 300 nm in average diameter at 2000 x g, which 
suggest a significant loss of usable micelles (Figure 5.13). For that reason a 
combination of filtration through a 450 nm filter and 15 minute centrifugation at 1000 
x g were chosen as the preferred protocol to remove drug crystals with minimal loss 




Figure 5.12: TEM image of AZD6244 crystal. Unencapsulated drug crystals were present in solution 
after the fabrication of AZD6244-loaded GCPQ micelles (scale bar = 2 µm, HV=120.0Kv, 
magnification 7400X). 
 
Figure 5.13: DLS analysis of size of AZD6244-loaded GCPQ micelles after different 
centrifugation speeds. Micelles were allowed to stabilize for 15 min before filtrated through a 450 






5.3.3 Characterization of optimized DOPE/DC-cholesterol and GCPQ 
nanoparticles  
 
After the fabrication parameters were established, these were used to create 
liposomes and micelles with three types of compounds (AZD6244, Nile Red and 
control nanoparticles) for all cell-related experiments described in chapter 6 (pgs. 
155, 153, 157, 159, 162).  
DOPE/DC-cholesterol liposomes were fabricated by dissolving the lipid components 
and hydrophobic molecules (AZD6244, Nile Red, or none) in a mixture of chloroform 
and methanol (2:1) and evaporating the solvents to rehydrate the remaining thin 
layer. The type of molecule did not influence the size or morphology of the 
liposomes, which remained spherical and in the same size range, as imaged by TEM 
(Figure 5.14a).  
 
Figure 5.14: TEM images of organic nanoparticles. a) AZD6244-loaded DOPE/DC-Cholesterol 
liposomes (scale bar = 500 nm, magnification 31000X, 80.0 kV), b) AZD6244-loaded GCPQ micelles 
(scale bar = 100 nm, magnification 135000X, HV120.0 kV). 
 
Sizes for AZD6244- or Nile Red-bearing liposomes ranged between 70 nm and 500 
nm with the majority at approximately 170 nm, as shown by DLS analysis (Figure 
5.15a/c). Occasionally, DLS analysis also revealed a very small peak at 3-6 µm, 
indicating the tendency of these nanoparticles to form aggregates in aqueous media. 
For control liposomes with no encapsulated molecules, the main peak at 180 nm 
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was very similar to that observed for the loaded nanoparticles, but with a broader 
size range (30 to 1100 nm) (Figure 5.17a). TEM revealed that the morphology of 
control liposomes was no different from those encapsulating a molecule (Figure 
5.16a). A second type of liposome made of DOPC/DC-cholesterol instead of 
DOPE/DC-cholesterol was fabricated only for control nanoparticle testing purposes. 
These control liposomes showed a narrower size range very similar to the AZD6244-
bearing DOPE/DC-cholesterol liposomes, in spite of not containing AZD6244 (Figure 
5.17c). TEM images also showed a very similar morphology and size range to their 
DOPE/DC-cholesterol counterpart, with the exception of a seemingly slight less 
tendency to flattening on the carbon grid surface (Figure 5.16c). 
 
 
Figure 5.15: DLS analysis of organic nanoparticles. a) AZD6244-loaded DOPE/DC-cholesterol 
liposomes, b) AZD6244-loaded GCPQ micelles, c) Nile-red loaded DOPE/DC-cholesterol liposomes, 





Figure 5.16 TEM images of control organic nanoparticles. a) DOPE/DC-Cholesterol liposomes 
with no encapsulated molecules (scale bar = 100 nm, magnification 66000X, HV=80.0kV), b) GCPQ 






Figure 5.17 DLS analysis of control organic nanoparticles.  a) DOPE/DC-Cholesterol liposomes 
with no encapsulated molecules, b) GCPQ micelles with no encapsulated molecules (note that b) is in 
a different size range from the other DLS graphs), c) DOPC/DC-cholesterol liposomes with no 
encapsulated molecules. Each colour represents a measurement repeat. 
 
GCPQ micelles were fabricated using tip sonication of an aqueous solution 
containing GCPQ and the hydrophobic compound (AZD6244 or Nile Red), or just 
GCPQ for the control nanoparticles. After an additional centrifugation and filtration 
step to remove non-encapsulated drug, TEM analysis revealed a spherical 
morphology for micelles (Figure 5.14b). Similar to the liposomes, GCPQ micelle size 
was not influenced by the type of compound (AZD6244 or Nile Red), as shown by 
DLS (Figure 5.15b/d). TEM revealed that micelle diameters were on average 
approximately 30 nm while DLS analysis showed a distinct peak at 350 nm, ranging 
from 260 to 550 nm for AZD6244-loaded micelles (Figure 5.15b) and from 300 to 
700 nm for Nile Red-loaded micelles (Figure 5.15d). These larger sizes were 
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probably due to the tendency of GCPQ micelles to form aggregates in aqueous 
media (Qu et al. 2006). In contrast, control micelles with no encapsulated molecules 
formed two different sized aggregates in solution, showing peaks at 9 and 50 nm in 
DLS with ranges of 5-12 nm and 40-80 nm respectively (Figure 5.17b). The smaller 
size of control micelles in contrast to those with encapsulated molecules was also 
clearly visible in TEM images (Figure 5.16b). 
As part of nanoparticle characterization, HPLC analysis of AZD6244 contained within 
the nanoparticles was performed for every batch, and AZD6244 concentration was 
extrapolated from a standard curve (Figure 5.4). Both drug-loaded nanoparticles 
yielded AZD6244 concentrations between 0.85 and 1.15 mM, representing 
encapsulation efficiencies between 45% and 55%. This information was used to 
standardize the concentration of AZD6244 in liposome, micelle and free drug 









5.4.1 Observations on DOPE/DC-cholesterol liposomes 
 
The combination of phospholipids and cholesterol is a common approach in 
liposome-based drug delivery. The liposomes used in this work were fabricated with 
a considerably higher content of cholesterol compared to most of the liposomes 
found in the literature. That decision had two main purposes: 1) to increase the 
stability of the liposomes as much as possible, and 2) to create a cationic surface to 
exploit the inherent benefits for cellular internalization derived from the interaction 
with the anionic cell membrane (Pelaz et al. 2013; Hino et al. 2012; Dokka et al. 
2000). 
 
5.4.1.1 The role of liposome composition on stability and encapsulation 
 
Liposomes have been used to successfully encapsulate both hydrophilic and 
hydrophobic molecules. Specifically, DOPE/DC-cholesterol liposomes have been 
extensively used for nucleic acid delivery (Zhang et al. 2010; Ciani et al. 2004; 
Rodríguez-Pulido et al. 2008). That was one of the main reasons to select this type 
of liposome initially, since a combination of a small molecule with interfering RNA 
was always in consideration (chapter 4 (pg. 82)). As previously mentioned, the 
positive charge in the polar head of the DC-cholesterol molecule not only allows the 
interaction with nucleic acids but also with the cell membrane, and this electrostatic 
interaction works similarly to encapsulate negatively charged gold quantum dots 
(Figure 5.11). 
Contrary to these quantum dots, which served only as a control for a possible 
hydrophilic molecule encapsulation and for imaging purposes, AZD6244 has a 
strong hydrophobic character. The encapsulation of AZD6244 in liposomes was 
proven by HPLC analysis after liposomes went through dialysis, consistently yielding 
encapsulation efficiencies of approximately 50% of the original drug concentration 
included during the fabrication. This is relatively high, considering previous reports 
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on reduced encapsulation efficiencies of hydrophobic molecules after following steps 
used here such as extrusion, compared to the non-extruded counterparts (Bhardwaj 
& Burgess 2010). Due to its nature, AZD6244 is expected to be encapsulated in a 
stable manner inside the membrane bilayer of the liposome, as it has been reported 
for other hydrophobic small molecules (Daneshpour et al. 2011; Mohammed et al. 
2004; Cagdas et al. 2011). The ratio of lipids-to-AZD6244 chosen for liposome 
fabrication (5mM of each lipid for 2mM of the drug) was loosely based on similar 
work done with the molecule α-tocopherol (Cagdas et al. 2011), which displays 
similarities in lipophilicity and molecular weight to AZD6244. 
There are different opinions regarding the best phospholipid/cholesterol ratio in 
liposomes in terms of stability and encapsulation, even among reports using the 
exact same lipid components: DOPE and DC-cholesterol (Yang et al. 2012; Farhood 
et al. 1995; Colosimo et al. 1999; Mukherjee et al. 2005). There is no ultimate 
formula, as the fabrication method and the encapsulated molecules make each case 
unique, and therefore, we must rely on our specific data. The high encapsulation 
efficiency achieved by the liposomes described in this chapter could be due to the 
high amount of cholesterol present in these liposomes, which is known to stabilize 
the liposomes by inserting itself in between the long chain phospholipids 
(Gregoriadis & Davis 1979). Moreover, a phospholipid/cholesterol ratio of 1:1 such 
as the one present in our DOPE/DC-cholesterol liposomes has been suggested as a 
particularly stable approach with little bilayer permeability (Kirby et al. 1980). While 
the work by Bhardwaj and Burgess suggests that the addition of cholesterol did in 
fact hinder the ability of their liposomes to encapsulate dexamethasone, they also 
suggested that this was caused by the close similarities between the two molecules 
(Bhardwaj & Burgess 2010). According to Cagdas and colleagues, the stabilization 
achieved by adding cholesterol to the liposome membrane is more important for 
hydrophilic compounds, such as the in-house manufactured gold quantum dots, 
while the interaction of hydrophobic compounds such as AZD6244 with the liposome 
bilayer remains stable even in a more fluid membrane (Cagdas et al. 2011). 
Regarding the phospholipid DOPE, the other compound in the present liposomes, it 
has a relatively long alkyl chain (18C) with one point of asymmetry (unsaturation) 
(Figure 5.3). The fact that the presence of asymmetric phospholipids in the liposomal 
bilayer creates spaces within the membrane has been hypothesized to improve the 
137 
 
encapsulation of hydrophobic molecules. However, Ali and colleagues recently 
demonstrated that unsaturated alkyl chains had no improvement on encapsulation 
(Ali et al. 2013). On the other hand, the same work suggests that long alkyl chains 
such as the 18C chains found in DOPE do indeed improve encapsulation. Combined 
with the increased stability provided by the high cholesterol content, the long alkyl 
chains found in DOPE could explain the high encapsulation efficiencies achieved by 
our DOPE-DC-cholesterol liposomes. 
 
5.4.1.2 The role of liposome fabrication method on size and encapsulation 
 
While the current results are very promising compared to other much lower 
encapsulation efficiencies found in the literature (Bhardwaj & Burgess 2010; Ali et al. 
2013), this parameter varies a lot depending on the molecule and the method of 
fabrication. More complex techniques, such as the microencapsulation vesicle 
(MCV) method used to encapsulate ibuprofen and fluribuprofen have achieved 
encapsulation efficiencies as high as 90% (Nii & Ishii 2005). 
The thin layer method (also called dry film method, thin film evaporation method or 
thin film hydration method) used here for the fabrication of nanoliposomes 
precursors (large vesicles) has been commonly used over the years and is 
considered one of the most effective methods (Yang et al. 2012; Cagdas et al. 2011; 
Bhardwaj & Burgess 2010). For the second phase of fabrication, there were very 
little differences between DOPE/DC-cholesterol liposomes fabricated through 
sonication and extrusion methods. Both methods yielded liposomes of approximately 
170 nm in diameter (Figure 5.9 and Figure 5.15a), with a similar spherical 
morphology visible using TEM (Figure 5.8). Once again, the presence of cholesterol 
could be the reason for these similarities. Cagdas and colleagues studied the 
differences between extrusion and sonication, as well as, the presence and absence 
of cholesterol in DMPC and DMPG liposome fabrication. They reported that, while in 
the absence of cholesterol extruded liposomes had larger sizes than sonicated 
liposomes, the addition of cholesterol resulted in liposomes closer in size, regardless 
of the fabrication method. They also suggested that while the encapsulation of a 
hydrophobic compound like vitamin E was not affected by the fabrication methods, 
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the encapsulation of a hydrophilic compound like cytochrome C was lower in the 
sonicated samples. This was due to the fact that sonication disrupts the membrane 
of the liposomes and this allows the hydrophilic compound to leach out into the outer 
aqueous environment, while the hydrophobic compound remains stably attached to 
the bilayer, as mentioned earlier for cholesterol-stabilized liposomes  (Cagdas et al. 
2011). In general terms, extrusion has shown great results in the past (Kang et al. 
2011; Bhardwaj & Burgess 2010; Cagdas et al. 2011). Due to the similar results 
obtained between these methods in terms of morphology and size and the limitations 
of sonication, extrusion was chosen for the AZD6244- and Nile Red-bearing 
nanoparticles and for the control nanoparticles that were used on cell treatments 
described later in chapter 6 (pg. 144). 
It is worth noting that the single liposome diameters observed in the TEM images are 
often larger than the average diameters shown by DLS analysis. While these 
liposomes are stable they are not rigid, and there is always a tendency for organic 
vesicles to be flattened by gravity in contact with a stiff surface. This flattening could 
have increased the apparent diameter of liposomes during TEM imaging on a carbon 
grid surface, particularly after the aqueous medium in which they were suspended 
dried out prior to imaging. DOPE has been suggested to assist the transition of the 
liposome into a more liquid phase that promotes membrane destabilization (Farhood 
et al. 1995; Pisani et al. 2011; Wasungu & Hoekstra 2006). The substitution of DOPE 
for DOPC in control liposomes seemed to have an effect on liposome toxicity, and it 
is further discussed in chapter 6 (pg.144 ). This phenomenon could also be related to 
the seeming less flattening of DOPC/DC-cholesterol liposomes on the carbon grid 
surface compared to DOPE/DC-cholesterol liposomes (Figure 5.14a/c). 
 
5.4.2 Observations on GCPQ micelles 
 
Contrary to liposomes, which have an aqueous core and a membrane bilayer, 
polymeric micelles contain a hydrophobic core designed to encapsulate hydrophobic 
molecules such as Nile Red or AZD6244. GCPQ in particular has shown special 
promise in the encapsulation of hydrophobic molecules, due to its tendency to create 
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larger supramicellar structures, while simultaneously being suitable for oral drug 
delivery (Qu et al. 2006; Siew et al. 2012; Lalatsa et al. 2012).  
There is a positive correlation between the degree of hydrophobicity of GCPQ and its 
ability to solubilize a hydrophobic molecule (Qu et al. 2006; Siew et al. 2012). This 
derives from the concept of critical micellar concentration (CMC). The lower the CMC 
is (i.e. the more hydrophobic the polymer is), the lower concentration of GCPQ is 
needed to form micelles, the larger the micelles (and the multimicellar aggregates) 
formed and the more hydrophobic drug can be encapsulated. From the different 
batches of GCPQ fabricated in the laboratory during methodological development, 
the one used here is highly palmitoylated (18.9% palmitoylation), which increases 
the polymers hydrophobicity and therefore, reduces its CMC. Similar to the 
liposomes, the AZD6244 encapsulation efficiency achieved with GCPQ micelles was 
approximately 50%, which is similar to the 45% reported before for other 
hydrophobic drugs (Qu et al. 2006). According to Qu and colleagues, this 
extraordinary encapsulation efficiency is due to the formation of multimicellar 
aggregates, which was also detected in solution through DLS analysis (Figure 
5.15b). 
The quaternary ammonium in the polar head of GCPQ gives the micelles a cationic 
surface. Similar to the liposomes, this positively charged surface facilitates the 
cellular uptake of GCPQ micelles and creates stable electrostatic interactions with 
the surrounding aqueous environment. Intuitively, the highly polar head of the 
amphiphilic molecule polymer GCPQ would create stable micelles that repel each 
other, but due to the low CMC of the highly palmitoylated polymer, these individual 
micelles tend to create larger multimicellar aggregates that then act as a stable 
larger particle and do indeed exhibit repulsive behaviour towards each other (Qu et 
al. 2006). 
5.4.2.1 Formation of AZD6244 crystals and their removal 
 
As a hydrophobic small molecule, the higher the concentration the higher the 
tendency AZD6244 exhibits to form crystals in aqueous solution. The fabrication of 
AZD6244-bearing GCPQ micelles involved mixing the polymer GCPQ and the drug 
AZD6244 in aqueous solution followed by vortexing and sonication. Since the 
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concentration of this therapeutic agent (2mM) was above its water solubility 
saturation point during fabrication, the formation of crystals was unavoidable (Figure 
5.12). Because the behaviour of these crystals during cell treatments would be 
extremely difficult to predict (especially in a three-dimensional environment where 
there is a physical barrier), the unencapsulated drug crystals needed to be removed 
through filtration and centrifugation steps before characterizing and using the 
micelles. 
 
5.4.3 The influence of encapsulated molecules on the formation of 
nanoparticles 
 
According to DLS analysis, DOPE/DC-cholesterol liposomes and GCPQ 
multimicellar aggregates showed virtually no difference in size whether they bore 
AZD6244 or Nile Red (Figure 5.15). Both compounds are small molecules of 
hydrophobic nature, and both of them contain benzene rings and no long aliphatic 
chains. Furthermore, the molar ratio between the lipid or polymer content and the 
encapsulated molecule was the same for both. The real difference was observed 
between the loaded nanoparticles and the control nanoparticles. 
The absence of encapsulated molecules seemed to affect liposome size dispersity, 
making the range of sizes broader in the control liposomes than in the AZD6244- 
and Nile Red-loaded liposomes. To our knowledge, there is no evidence of this 
phenomenon in the literature, and we can only speculate. Presumably, it could be 
that the fluid nature that DOPE confers to the liposome is reduced by the presence 
of a small hydrophobic molecule that intercalates with the unsaturated alkyl chains, 
acting in a similar way to cholesterol. This increase in stability could narrow the 
diameter range during the extrusion phase, although this requires further 
investigation. 
Micelles, on the other hand were extremely affected by the absence of encapsulated 
molecules. Not only the sizes detected by DLS analysis were much smaller than 
those for the molecule-bearing micelles, but two distinct peaks were visible, at sizes 
9 and 50 nm (Figure 5.17b). Siew and colleagues also reported a possible increase 
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in the size of GCPQ micelles in the presence of encapsulated hydrophobic drugs, 
compared with empty GCPQ micelles. In their work, self-assembled GCPQ created 
micellar aggregates between 40 and 200 nm in size, however, they could only 
speculate about the sizes of individual micelles within these aggregates, and these 
micelles were probably smaller than those numbers. On the other hand, the addition 
of the drug produced defined single micelles between 20 and 50 nm in size and 
aggregates between 100 and 500 nm in size. Like in our experiments with AZD6244, 
they also found crystals of unencapsulated drug after micelle formation (Siew et al. 
2012). The size of the drug-loaded micelles seems consistent with our data, which 
shows approximately 30 nm single micelles forming larger aggregates of around 350 
nm in size (Figure 5.14b, Figure 5.15b/d).  
There seems to be a close correlation between the hydrophobicity of the drug, the 
hydrophobicity of the polymer, the size of the micellar aggregates and drug 
encapsulation (Qu et al. 2006). While increasing the hydrophobic volume within the 
aggregates (i.e. forming supramicellar structures) improves the encapsulation of 
hydrophobic molecules like AZD6244, the high hydrophobicity of those encapsulated 
molecules increases the chances of micellar partition. This could be related to the 
double peak observed in our self-assembled GCPQ micelles. In the absence of 
AZD6244 to favour equilibrium between micellar partition and the assembly into 
larger particles, smaller clusters of GCPQ monomers with different characteristics 
(i.e. different degrees of palmitoylation) might have formed two different populations 
of self-assembled micelles and subsequent supramicellar aggregates in solution 
depending on their hydrophobicity, resulting in two different size peaks. 
 
5.4.4 Organic nanoparticles for 2D and 3D experiments 
 
The organic nanocarriers developed in this chapter seemed suitable for cancer cell 
treatment testing in vitro. AZD6244- and Nile Red-bearing liposomes and micelles, 
as well as their empty control counterparts were thus freshly fabricated and 
characterized before every treatment shown in chapter 6 (pg. 144). Surprisingly, 
steps naturally involved in their fabrication, such as filtration, extrusion, 
centrifugation, or the use of organic solvents and cold storage were enough to keep 
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these nanocarrier solutions aseptic. While no additional sterilization steps were 
included, no bacterial or fungal contaminations derived from nanoparticle treatment 
use were present in the subsequent cell in vitro work. 
In spite of their high stability, any organic nanocarrier encapsulating a therapeutic or 
fluorescent agent is susceptible to a small leakage after a certain period of time, 
particularly at higher temperatures such as at 37oC, (5%CO2 and 95% humidified 
air) at which cells were incubated or physiological conditions. For this reason, every 
fresh batch of nanocarriers fabricated with the purpose of therapeutic testing was 
immediately characterized and used within 24 h to prevent a loss in efficacy. The 
amount of drug that could leach out of the nanocarriers during this time was 
negligible and far within AZD6244s water solubility concentration range, thus 
preventing the formation of crystals. This, combined with the high reproducibility in 
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Following the formulation of AZD6244 in nanoparticles, this chapter comprises 
experiments to test therapeutic efficacy in colorectal cancer cells cultured both as 
monolayers and in tumouroids.  The chapter explains the fabrication of tumouroids, 
novel in vitro three-dimensional models, in detail and presents experimental data 
from preliminary studies to assess the penetration of nanoparticles, and their uptake 
by cancer cells to more specific toxicity, therapeutic efficacy and penetration 
experiments. 
6.2 Materials and methods 
 
6.2.1 Cell culture and treatment in monolayers and tumouroids 
 
For conventional in vitro experiments, cells were cultured in monolayers following the 
same methods previously described in chapter 3.2.3. (pg. 44). For the treatments 
with nanoformulations, the concentration of the therapeutic agent was determined by 
the overall AZD6244 content, and the same AZD6244 concentration range was used 
for free drug, micelle and liposome formulations.  
Briefly, cells  were seeded (30000 HCT116 cells/well or 32000 HT29 cells/well) in 
24-well plates (day 1), fed with 500 µL of McCoy’s 5A medium supplemented with 
FBS and P/S and allowed to grow for 24 h before substituting the culture medium 
with serum-free medium. Cells were treated 24 h later (day 3) with a range of 
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Table 6.1 Treatment timeline in monolayers and tumouroids. 
 
For toxicity and penetration experiments in 3D, tumouroids were fabricated using the 
plastic compression method (modified from Brown et al. 2005). At approximately 4oC 
of temperature, 400 µL of MEM medium (x 10 concentration) with Earle’s Salts, 
without L-glutamine and without sodium bicarbonate (First Link UK Ltd) were mixed 
with 3.2 mL of rat tail collagen type I (2.20 mg/mL in 0.6%v/v acetic acid). The 
mixture was neutralized with 5 M and 1 M sodium hydroxide until a colour change 
from yellow to pink was observed, and then 6,400,000 HCT116 cells suspended in 
400 µL medium were added to the mixture. The resulting solution was placed in a 
stainless steel mould resting on a sterile glass slide that was placed on a piece of 
30nm filter paper and left to gel for 30 min at room temperature. The mould 
containing the gel was then placed on a nylon mesh resting on a 165 µm stainless 
steel mesh placed on a piece of 30 nm filter paper. A 176g plunger was placed on 
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top of the gel allowing compression for 30 sec and the whole compression process 
was repeated on the other side of the gel (Figure 6.1). The resulting 2.6%w/v 
collagen dense mass (Nyga et al. 2013) was divided into 4 equal parts (artificial 
cancer masses, ACMs) with a surgical scalpel. Each of these 4 ACMs (measuring 
5.5 x 10 x 10 mm in size and shaped as a prism) was nested in 1 mL of 
uncompressed acellular collagen per well, in 12-well plates (Figure 6.2). The nested 
construct (tumouroid) was left for 20 min to gel at 37oC.  Fully supplemented medium 
(1mL) was added and cells were starved with serum-free media on day 6. After 24 h 
of starvation (day 7), cells were treated with a range of AZD6244 concentrations 
(0.01 to 1µM) as a free drug or in nanoparticle form (Table 6.1). 
The content of AZD6244 in the nanoformulations was determined by HPLC analysis, 
as described in section 5.2.4.3. (pg. 120). AZD6244 treatment was carried out for 48 
h in monolayers and for 24, 48 or 72 h in tumouroids. For control nanoparticle 
studies, cells were treated with the nanoparticle content equivalent to the AZD6244 
concentration of their drug-loaded counterparts. 
 
Figure 6.1 Plastic compression to create artificial cancer masses (ACMs). Collagen and MEM 
medium were mixed at 4
o
C and neutralized with NaOH until colour change from yellow to pink was 
observed. 6,400,000 HCT116 cells were added and mixed thoroughly and the mixture was placed in a 






Figure 6.2 Nesting ACMs into hydrogels to form tumouroids. Freshly prepared compressed gels 
were divided into four equal pieces (ACMs) with a surgical blade and nested into an acellular hydrogel 
prepared following the neutralization protocol to create tumouroids and placed into a 12-well plate. 
Plates containing tumouroids were then placed in the incubator for 20 min before 1 mL of fully 
supplemented medium was added to the tumouroid surface. 
 
For Western blot analysis, 200,000 HCT116 cells were seeded per well in 6-well 
plates and left to grow until 60% confluence. At that point, cells were treated with a 
range of AZD6244 concentrations (0.01 to 1µM) either free or in nanoparticle 
formulations for one hour and then 10ng/mL of EGF were added for 10 min to 
activate the MAPK pathway. Cells were lysed with 250µL of RIPA (Radio-
Immunoprecipitation Assay) buffer (Sigma-Aldrich) supplemented with protease 
inhibitors (Roche, Hertfordshire, UK) and samples were stored at -20oC until 
required.  
 
6.2.2 Protein analysis and proliferation assays 
 
For cells grown in monolayers, drug and nanoparticle efficacy was determined by 
MTT (metabolic activity) and total DNA (proliferation); while for tumouroids it was 
determined by Alamar Blue ® (metabolic activity) and area measurements of 
aggregates of cancer cells (proliferation). Protein analysis was performed by 




6.2.3 HCT116 metabolic standard curves in monolayers and tumouroid 
cultures 
 
The metabolic activity of HCT116 cells growing as monolayers and in tumouroids 
was correlated with cell density to compare drug efficacy results in both models. For 
monolayers, 50,000, 100,000, 250,000, 500,000 and 1,000,000 cells were seeded in 
24-well plates and allowed to attach and start normal metabolism for 24 h before the 
MTT assay (30 min, 12.5 µL at 20mg/mL) was performed. For tumouroids, 500,000, 
1,500,000, 3,000,000, 5,000,000 and 7,000,000 cells were seeded following the 
previously described plastic compression protocol, and also left for 24 h before 
Alamar Blue ® assay (4 h, 1mL, 1:10 dilution) was performed.  
6.2.4 Preliminary penetration and uptake studies 
 
Due to the scarce number of reports on nanocarrier drug delivery in natural 3D 
scaffolds, a number of preliminary experiments were performed to validate the 
approach. To determine whether cells take up large nanoparticles, HT29 cells were 
cultured as monolayers and treated with QD-loaded liposomes for 24 h. At this time, 
images were taken focusing on top of the cells and inside the cells using a confocal 
microscope. Free QDs were used for a similar experiment in tumouroids, to minimize 
size-dependent penetration issues that might be caused by the large size of 
liposomes or micelles. HCT116 cells were seeded in tumouroids and left to mature 
for 7 days before being exposed to QDs to test cellular uptake in 3D. Images of cell 
aggregates at the edge and core of the ACM were taken 24 h after exposure to the 
nanoparticles. 
 
6.2.5 Confocal microscopy imaging 
 
Confocal microscopy was used for some of the preliminary treatment tests, as well 
as for penetration studies (described later in this chapter). For preliminary 
experiments in monolayers (Figure 6.4) and for penetration studies (Figure 6.13), a 
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single averaged image at 1024x1024 pixel resolution was taken at the most 
convenient focus plane (i.e. just over the cell membrane and inside the cytoplasm for 
the monolayer experiments and 300 µm down from the top of the ACM for 
penetration experiments). For preliminary experiments in tumouroids (Figure 6.5) 
averaged stacks in the z-plane at the same resolution were taken to create a 
composite image that emphasizes the three-dimensional quality of cellular 
aggregates. The excitation wavelength was 488 nm for gold quantum dots and 543 
nm for Nile Red, while the emission was detected at a wavelength of 650 for both 
gold QDs and Nile Red. 
 
6.2.6 Penetration studies 
 
Nile Red liposomes and micelles were fabricated as indicated previously. The 
fluorescent signal of the solution was normalized for all formulations (liposomes, 
micelles, GCPQ-dye molecular solution and free dye dissolved in DMSO) before 
exposing the tumouroids to them. Confocal microscopy was used to focus on an 
optical plane 300 µm deep from the top of the ACM (approximately the core), using a 
green laser (543 nm) and a red detector (630 nm). Culture medium was removed 
and Nile Red formulations were added on top of the construct. Images of the central 
plane inside the ACM were taken over a period of 24 h to determine the rate of 







6.3.1 Standard curves 
 
In order to compare the efficacy of AZD6244 and its nanoformulations in monolayers 
and tumouroids, the proliferation of HCT116 cells (the cell line chosen for tumouroid 
culture) was characterized in both models. Known cell densities were seeded as 
monolayers and in tumouroids, and metabolic activity was measured 24 h later, to 
allow cells to settle and resume a normal metabolic pattern. Metabolic activity (an 
indirect method of measuring proliferation) was chosen since MTT (used for 
monolayer experiments) and Alamar Blue® (used for tumouroid experiments) are 
equivalent techniques - rather than total DNA and aggregate area measurements, 
which are the other two techniques used in this body of work to assess proliferation 
differences. Cells appeared to have a much steeper linear correlation between cell 
densities and metabolic activity in 2D, with absorbance measurements ranging from 
0.3 to 2.5 – roughly 2-fold differences, than in 3D. In the latter, there was a less 
steep increase in metabolic activity, which appeared to reach a plateau at the 
greatest concentration of 7,000,000 cells (Figure 6.3), consistent with other reports 
(Nyga et al. 2013). With cell density and metabolic activity correlated through a 
standard curve, differences in drug-to-cell ratios between both models can be 





Figure 6.3 HCT116 cells metabolic standard curves as monolayers and in tumouroids. Different 
concentrations of HCT116 cells were seeded as monolayers (left) and in tumouroids (right), left for 24 
h to settle and normalize their metabolism. MTT [a) monolayers] and Alamar Blue ® [b) tumouroids] 
assays were performed to correlate metabolic activity in both models.  
 
6.3.2 Preliminary penetration and uptake studies 
 
Due to the novel nature of these experiments involving a cancer 3D model and drug 
nanocarriers, preliminary tests were performed regarding encapsulation and 
internalization. Highlights of basic methodological development are summarised 
below. 
Once extrusion was established as the preferred method for liposome fabrication, 
manufacture by double extrusion through 1000 nm followed by a 200 nm 
polycarbonate membrane was compared to using the later alone. Results showed 
that there was no significant difference in size between these two methods, so the 
double extrusion was chosen for further experiments since it facilitates the process, 
presumably by pre-filtering large impurities. Similarly, QD-loaded liposomes were 
subject to freeze-thaw cycles to determine whether this technique would improve 
encapsulation (Xu et al. 2012), but results showed either equal or worse 
encapsulation efficiency when including this step, so it was not included in the final 
fabrication protocol. The conjugation of Doxorubicin-loaded DOPE/DC-cholesterol 
liposomes to a generic anti-EGFR antibody and to the clinically used Cetuximab also 
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showed no difference in treatment efficacy in vitro, so naked nanoparticles were 
used for these experiments. 
To determine the ability of colorectal cancer cell lines to uptake large nanoparticles, 
HT29 cells were treated with QD-loaded DOPE/DC-cholesterol liposomes for 24 h, 
and images of the cellular surface and the cytoplasm were taken. As shown in 
(Figure 6.4), 24 h after exposing the cells to the nanoparticles, most of the latter 
have been internalized by the cells.   
 
Figure 6.4 Nanoparticle uptake test. HT29 cells were cultured as monolayers and treated with QD-
loaded liposomes for 24 h to determine whether cells uptake large nanoparticles. Confocal 
microscope images were taken focusing at the top surface of the cells (left) and inside the cell (right). 
Scale bars = 20 µm 
 
A similar experiment was performed in HCT116 tumouroids with free QDs, to 
determine whether a small nanoparticle would penetrate the mass and be 
internalized by cells, forming aggregates in the construct. Figure 6.5 shows a very 
heterogeneous internalization of quantum dots by cell aggregates both at the edge of 
the ACM and at its core, suggesting irregular diffusion and cell behaviour throughout 
the cancer mass. Additionally, these images hint at the three-dimensional structure 




Figure 6.5 Nanoparticle penetration and uptake test in tumouroids. HCT116 tumouroids were 
exposed to QDs to test nanoparticle penetration and cellular uptake in the ACM. Quantum dots were 
chosen as the smallest nanoparticle possible (approximately 1 to 2 nm in diameter) to minimize size-
dependent penetration issues. Images at the a) edge and b) core of the ACM were taken 24 h after 
exposure. Scale bar = 100 µm. 
 
6.3.3 Toxicity assessment of control nanoparticles 
 
To establish the intrinsic toxicity of the nanoparticles and to be able to distinguish it 
from a more efficient delivery of AZD6244 into the cell and its internal processing, 
similar experiments with water-containing nanoparticles were performed. In these 
experiments, the concentration of nanoparticles was expressed as “equivalent to 
AZD6244 concentration”, in reference to the next experiments with drug-bearing 
nanoparticles. Despite these control nanoparticles being only loaded with water, the 
amount of polymer or lipid reaching the cells was approximately the same as that of 
the AZD6244-loaded nanoparticle solution. Also, a third type of nanoparticle 
(DOPC/DC-cholesterol liposomes) was included in these experiments to further 
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study the role of ethanolamine in nanoparticle toxicity.  For this experiment, one 
more order of magnitude was tested (10µM). 
For HCT116 cells, 1 µM AZD6244-equivalent concentration of nanoparticles elicited 
7% and 25% metabolic activity inhibition for liposomes and micelles respectively 
(Figure 6.6). For HT29 cells, toxicity was much greater, with 50% and 47% metabolic 
activity inhibition for liposomes and micelles respectively (Figure 6.7). When the 
concentration of nanoparticles was increased to 10 µM AZD6244-equivalent the 
inhibition resulted in 65% and 57% for HCT116 and 54% and 70% for HT29. This 
suggests a high degree of chemical toxicity caused by the nanoparticle components 
at sufficiently high concentrations, but a reasonably low toxicity in the case of 1 µM 
AZD6244-equivalent for HCT116 cells. 
Conversely, DOPC/DC-cholesterol liposomes showed a much lower toxicity even at 
the highest AZD6244-equivalent concentration (10 µM), with 32% metabolic activity 
inhibition for HCT116 cells and 10% for HT29 cells (Figure 6.6, Figure 6.7), 
suggesting that small changes in the nature of the nanoparticle components can 
have a huge effect on toxicity. 
 
Figure 6.6 Control nanoparticle toxicity on HCT116 cell monolayers. HCT116 cells were treated 
with control nanoparticles at nanoparticle concentrations equivalent to their AZD6244-loaded 
nanoparticle counterparts. Treatment was carried out for 48 h before MTT assay was performed. 





Figure 6.7 Control nanoparticle toxicity on HT29 cell monolayers. HT29 cells were treated with 
control nanoparticles at nanoparticle concentrations equivalent to their AZD6244-loaded nanoparticle 
counterparts. Treatment was carried out for 48 h before MTT assay was performed. Significance: 
**p<0.01 ***p<0.001. Control: horizontal line. 
 
6.3.4 Drug and nanoparticle efficacy in monolayers 
 
HT29 and HCT116 cells in 2D monolayers were treated with micelles and liposomes 
containing AZD6244, as well as, free AZD6244 for 48 h before total DNA and MTT 
assays were performed.  
For HCT116, AZD6244 treatment resulted in a 21% decrease in proliferation 
(determined by total DNA assay) at the highest concentration of the drug (1 µM), 
whilst liposomes and micelles with the same drug load resulted in 61% and 89% 
inhibition respectively (Figure 6.8). Results for HT29 cells were quite similar, with 
26%, 77% and 96% decreases in proliferation for free drug, liposomes and micelles 
respectively (Figure 6.9). 
Regarding metabolic activity measured by MTT, nanoformulations were clearly more 
efficient than the free drug, but the differences were slightly less pronounced (18%, 
60% and 40% for the free drug, liposomes and micelles, respectively for HCT116 
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(Figure 6.8), and 14%, 74% and 58% respectively for HT29 cells) (Figure 6.9). This 
may be due to an increase in metabolic activity by the surviving cells which have less 
competition for the nutrients in the medium.  
 
Figure 6.8 Effect of all three formulations of AZD6244 on HCT116 cell monolayers. Cells were 
treated with different concentrations of the drug in free, liposomal and micellar forms for 48 h before 
total DNA assay (left) and MTT assay (right) were performed. Significance: all p<0.001, except 
**p<0.01 and *no significance. Control: horizontal line. 
 
Figure 6.9 Effect of all three formulations of AZD6244 on HT29 cell monolayers. Cells were 
treated with different concentrations of the drug in free, liposomal and micellar forms for 48 h before 
total DNA assay (left) and MTT assay (right) were performed. Significance: all p<0.001. Control: 
horizontal line. 
 
For HCT116 cells, there was a statistically significant difference between micelle and 
liposomal formulations at every concentration tested, except at 0.01µM using the 
DNA proliferation assay and at 0.1µM when using the MTT assay. In the case of 
HT29 cells, all treatments at all concentrations resulted in statistically significant 
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inhibition of proliferation and metabolic activity (p<0.001). Interestingly, in both cell 
lines micelles appeared more toxic according to the total DNA assay, while MTT 
assay revealed a higher metabolic activity inhibition in the liposome-treated group, 
suggesting differences in the delivery and internal processing between these 
nanoformulations. 
6.3.5 Protein analysis of phosphorylated ERK 
 
To further confirm delivery of AZD6244 into the cytoplasm and specific 
pharmacological action on the target MAPK pathway, Western Blot analysis was 
performed (Figure 6.10). While it is clear that differences in protein expression 
between 2D and 3D models are expected, Western blot analysis was only performed 
in monolayer experiments. This is because it can be assumed that in monolayers the 
majority of the drug is delivered and the purpose of these experiments is determining 




Figure 6.10 Western blot analysis of phosphorylated ERK after treatment with AZD6244 
nanoformulations. HCT116 cells were grown in monolayers, serum starved and treated with 
increasing concentrations of AZD6244-loaded nanoparticles or free AZD6244 for 60 min; then the 
MAPK pathway was activated with EGF (10ng/mL) for 10 min. Cells were lysed, protein was extracted, 
quantified and analysed by PAGE and Western Blotting for the presence of the pERK, as an indicator 
of MAPK activation. Housekeeping protein: GAPDH. 
 
Cells were treated with the two nanoparticle forms carrying the same drug 
concentrations as well as with the free drug, and proteins were separated by size in 
a polyacrylamide gel. Phosphorylated ERK, a common indicator of MEK activity, was 
detected using a mouse monoclonal antibody (9106S, Cell signalling). Densitometry 
revealed that in all three forms, a dose-dependent reduction in the levels of 
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phosphorylated ERK occurred; these decreases were 86%, 80% and 53% for 
liposomes, micelles and free drug respectively (Figure 6.10). This suggests that 
AZD6244 reached its target and elicited a specific response at the protein level, and 
that the delivery was much more efficient when the drug was delivered via 
nanoformulations compared to the free drug. While control GCPQ micelles were 
significantly more toxic than control DOPE/DC-cholesterol liposomes (Figure 6.6, 
Figure 6.7), AZD6244-loaded liposomes elicited more inhibition of metabolic activity 
and MEK1/2 activity than AZD6244-loaded micelles (Figure 6.8, Figure 6.9, Figure ), 
suggesting a more efficient delivery of the drug. 
 
6.3.6 Drug and nanoparticle efficacy in tumouroids 
 
Tumouroids were initially fabricated with both HT29 and HCT116 cells, but some of 
the results with HT29 seemed to be inconsistent so they are omitted in the present 
work. All results in tumouroids presented here were performed on HCT116 cells and, 
consequently, any comparison in cell behaviour between tumouroids and 
monolayers is also done within HCT116 cultures in both models. 
The 3D in vitro cancer model used here (tumouroid) consisted of a dense collagen 
core containing the cancer cells (ACM) surrounded by an uncompressed collagen 
hydrogel (stromal surround) (Nyga et al. 2013). Tumouroids were left to mature for 
seven days before treatment, allowing cancer cells to form aggregates within the 
ACM, thereby mimicking in vivo avascular micrometastases. Treatment with free 
AZD6244 and the nanoformulations was performed for 24, 48 and 72 h. It is 
accepted routine in our laboratories to include extra 24 h incubation when moving 
from 2D to 3D cultures to optimise the effects of drugs, as more time is needed for 
the drug to reach the cells in 3D and the metabolism in 3D tumouroids is also slower 
(Figure 6.3). For that reason, when correlating the data between both models, the 48 
hour treatment in 2D was compared to the 72 hour treatment in 3D.  
Treatment with free AZD6244 and its nanoformulations showed increasing efficacy 
with increasing AZD6244 concentrations and treatment times. Inhibition of metabolic 
activity started to be significant at 0.1 µM. 
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Drug efficacy in tumouroids was different from monolayers. When comparing the 
results of metabolic activity assays, whilst the free drug was more effective in 3D 
than in 2D (38% vs 18% inhibition), the nanoparticle treatments were more effective 
in 2D (60% vs 26% inhibition for liposomes and 40% vs 34% inhibition for micelles) 
(Figure 6.11c). Overall, micelles were more toxic in tumouroids than the other 
formulations (Figure 6.11). Significant differences were observed at 0.1 µM AZD6244 
and at 24 h, where micelles were superior to liposomes (Figure 6.11a: p<0.01). 
Furthermore, at 1 µM and 48 h, micelles were superior to both liposomes (p<0.001) 
and free drug (p<0.01) (Figure 6.11b), while at 1 µM and 72 h only micelles were 
only superior to liposomes (p<0.05). In the latter treatment, the free drug also 
showed more toxicity than the liposomes (p<0.01), making the liposomes the least 
effective of the three formulations in tumouroids (Figure 6.11c). 
 
Figure 6.11 Inhibition of metabolic activity of tumouroids by AZD6244 and its 
nanoformulations. HCT116 tumouroids were manufactured and left to mature for 7 days. 
Tumouroids were treated with AZD6244 and AZD6244-loaded nanoparticles at a range of 
concentrations for 24(a), 48(b), and 72(c) h before Alamar blue ® assay was performed. Significance: 




Similar to the experiments in monolayers, a second technique was used to provide a 
more comprehensive characterization of drug efficacy in tumouroids. Aside from 
Alamar Blue ®, which measures metabolic activity, the areas of cancer cell 
aggregates at the edge of the ACM were measured as an indicator of cell 
proliferation within the tumouroid. Aggregates at the edge of solid cancer masses are 
believed to be metabolically active and migratory, representing actively growing and 
invasive boundary/potential micrometastases from colorectal tumours. Results from 
this assay followed a similar pattern to those of metabolic activity tests, except that 
statistical significance was more prominent in the former. All AZD6244 
concentrations showed statistically significant differences between formulations 
(from p<0.05), with the exception of outcomes using 0.1 µM at 48 h, where there was 
no statistical significance between liposomes and micelles (Figure 6.12). 
 
Figure 6.12 Reduction of cancer cell aggregate areas in tumouroids by AZD6244 and its 
nanoformulations. HCT116 tumouroids were manufactured and left to mature for 7 days. 
Tumouroids were treated with AZD6244 and AZD6244-loaded nanoparticles at a range of 
concentrations for 24(a), 48(b), and 72(c) h before fixation. The areas of cancer cell aggregates at 




6.3.7 Drug penetration studies 
 
In order to further explore the differences in the efficacy of nanoparticles for delivery 
of drug, tumoroids were cultured and matured for seven days and exposed to Nile 
Red-loaded fluorescent nanoparticles. The focal plane was set at 300 µm into the 
ACM core, and fluorescence was imaged and measured over time. As in the 
tumouroid drug efficacy studies, these experiments were performed in HCT116 
tumouroids. Two different controls were included: Nile Red dissolved in DMSO and a 
non-micellar mixture of Nile Red and GCPQ acting as an intermediate point between 
a molecular solution and nanoparticles of only 1 nm in diameter. 
These experiments revealed a clear size-dependent ability of the nanoparticles to 
penetrate the ACM. The penetration of the free dye control through the ACM core 
started reaching a plateau before two hours post-incubation (Figure 6.13a/c), with a 
fluorescent signal ten-fold higher than the one showed by liposomes and micelles 
after 24 h (Figure 6.13b/c). GPCQ micelles and DOPE /DC-cholesterol liposomes 
showed a very similar penetration profile, most likely due to the fact that they are 
both cationic and relatively large nanoparticles. 
The non-micellar GCPQ control, which shares the chemical properties with GCPQ 
micelles but with a much smaller size, exhibited a penetration profile much closer to 
the nanoparticles than the free dye, but clearly superior to the larger particles, 




Figure 6.13 Nanoparticle penetration into the tumoroids. HCT116 tumouroids were manufactured 
and left to mature for 7 days. Tumoroids were treated with a) Free Nile Red dissolved in DMSO and b) 
GCPQ-Nile Red molecular solution, liposomes and micelles containing Nile Red. Confocal Images of 
free and encapsulated dye present at the ACM core (300 µm from the surface) were taken over time 






This work explores the effect of cationic organic nanocarriers loaded with AZD6244 
on HCT116 colorectal cancer cells cultured both as monolayers and in tumouroids. 
The use of 3D cancer models aims to mimic the cell microenvironment found in vivo 
while still allowing the control of parameters in vitro. AZD6244 was chosen since it 
has been extensively studied in Phase I, II clinical trials in several cancers, including 
colorectal, with promising results, alone and in combination with other therapies 
(Ciombor & Bekaii-Saab 2015). 
 
6.4.1 Previous reports on nanoparticle testing in 3D models and in 
nanoformulations of MEK inhibitors 
 
MEK inhibitors other than AZD6244 have been encapsulated in nanoformulations. 
Basu and colleagues demonstrated that PLGA nanoparticles carrying the MEK 
inhibitor PD98059 successfully induced apoptosis and inhibited proliferation of lung 
cancer and melanoma in vitro, and improved the effect of cisplatin in melanoma cells 
in vivo (Basu et al. 2009). Similarly, a DGL cationic liposome containing a 
combination of the MEK inhibitor PD0325901 and Mcl I-specific siRNA reduced KB 
cells survival in vitro and induced 79% apoptosis in vivo (Kang et al. 2011). 
MEK inhibitors have also been tested in 3D cancer models. These include  PD98059 
for breast cancer cells grown in Matrigel (Polo et al. 2010) and GSK1120212 in 
combination with BRAF and AurkA inhibitors for melanoma using a skin 
reconstruction model (Caputo et al. 2014).  
As a free drug, the efficacy of AZD6244, the agent evaluated in this thesis, has been 
previously tested in a 3D model of melanoma grown within a collagen hydrogel, in 
combination with the SCR inhibitor saracatinib, showing promising results (Ferguson 
et al. 2012). This work differs significantly from the plastic compression approach 
adopted in the current studies: cells were cultured in an uncompressed collagen 
matrix with high water content, while the model I use undergoes plastic compression 
resulting in a cancer mass with a collagen density of 2.6%w/v. Therefore, to my 
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knowledge there are no publications that can offer a direct comparison to the present 
work. 
 
6.4.2 Standard curves and drug to cell ratios 
 
HCT116 cells were grown as monolayers and in tumouroids to correlate the results 
from MTT and Alamar Blue ® assays to cell density and allow for the hypothetical 
estimation of drug to cell ratio for each model (Figure 6.3). The factors that are 
needed to be taken into account for the estimation, in addition to the metabolic 
measurements specific to each cell density, include: the maximum AZD6244 
concentration (1 µM), the total volume of medium per well in 24-well and 12-well 
plates (500 µL and 1mL, respectively), and the fact that the untreated controls in the 
drug efficacy experiments gave a MTT colorimetric signal of approximately 0.5 and 
an Alamar Blue ® fluorescent signal of approximately 40 for monolayers and 
tumouroids, respectively. 
To calculate the drug to cell ratio in monolayers, the value of 0.5 obtained from the 
untreated controls was plotted into the standard curve and a cell number of 47766 at 
the day of treatment (day 5) was extrapolated. Considering a volume of medium of 
500 µL containing 1 µM AZD6244 (0.5 nmol of AZD6244 in 500 µL), the approximate 
drug to cell ratio in monolayers was 10.47 fmol/cell at the day of the assay (day 5). 
For tumouroids, the untreated controls gave a fluorescence value of 40. This value 
was plotted into the standard curve and a cell number of 7,250,000 at the day of 
treatment (day 10) was extrapolated. Considering a volume of medium of 1 mL 
containing 1 µM AZD6244 (1 nmol of AZD6244 in 1 mL), the approximate drug to cell 
ratio in tumouroids was 1.38 amol at the day of the assay (day 10). These 
calculations suggest a drug to cell ratio over 7500 times higher in monolayers than in 
tumouroids. 
The results from this are only approximated and the conclusions hypothetical, since 
cells do behave differently between the two models and that includes considerable 
differences in their metabolic rate. Furthermore, cell density at the day of the assay 
is not necessarily the same as at the day of treatment, especially for the controls, but 
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this day was chosen as an approximation for being the endpoint of the experiments. 
Even considering a large deviation from the real values, the drug-to-cell ratio would 
still be several orders of magnitude superior for the monolayers, which has great 
implications when comparing the efficacy of AZD6244 between the two models. As 
shown in (Figure 6.8 and Figure 6.11), AZD6244 seemed to be more effective in 
tumouroids than in monolayers in spite of the cells receiving much more drug in the 
monolayers. 
 
6.4.3 Preliminary uptake and penetration studies 
 
The preliminary tests performed in monolayers and tumouroids demonstrate that 
cells in both models were capable of internalizing nanoparticles, ranging from 1-2 nm 
in the case of QDs (Figure 6.4) to over 200 µm in the case of liposomes and micelle 
aggregates (Figure 6.5). This data indicates only cellular uptake without considering 
the ability to penetrate the dense collagen mass in the tumouroids. An efficient 
uptake of large nanoparticles is consistent with the data obtained from drug efficacy 
experiments, which showed efficient inhibition in proliferation and metabolic activity, 
as well as, successful delivery of AZD6244 to its target in the MAPK pathway by 
micelles and liposomes. Specific results are discussed in depth later on in this 
chapter. 
The images in Figure 6.5 clearly showed cellular aggregates in the order of several 
tens of microns across, present in 7-day matured tumouroids. The irregular 
distribution of fluorescent nanoparticles within the ACM indicates that drug and 
nanoparticle diffusion was not homogeneous, and this could have significant 
implications in the delivery of the drug in the tumouroids, especially in the case of 
nanoparticles. This is also suggested by the results of the penetration studies (Figure 
6.13), which showed great differences in the diffusion of therapeutic agents in line 
with differences in size and physicochemical properties. Again, this is discussed in 




6.4.4 Nanoparticle efficacy on monolayers 
 
Results demonstrated that non AZD6244-loaded DOPE/DC-cholesterol cationic 
liposomes exert very little toxicity (7% inhibition at the highest concentration, Figure 
6.6c) which, when considering efficacy of the AZD6244-loaded liposomes (61% for 
total DNA and 60% for metabolic activity, Figure 6.8a/b), suggests a very successful 
AZD6244 delivery platform. On the other hand, reports regarding the effect of 
cationic surfaces on cells could explain the toxicity of non AZD6244-loaded GCPQ 
nanoparticles (25% inhibition at the highest concentration, Figure 6.6c), which were 
significantly more toxic than the non-AZD6244 loaded liposomes (p<0.001, Figure 
6.6c). However, the drug-loaded GCPQ micelles exerted an even higher toxicity than 
the control (non AZD6244-loaded) micelles (40% for metabolic activity and 89% for 
total DNA, Figure 6.8a/b). 
Both DOPE/DC-cholesterol liposomes and GCPQ micelles have a positively charged 
surface. The cationic nature of these nanoparticles not only facilitates nucleic acid 
loading (as mentioned earlier for the liposomes) but also facilitates the adhesion to 
the negatively charged cell membrane (through an electrostatic interaction) and 
internalization (Pelaz et al. 2013; Hino et al. 2012; Dokka et al. 2000), leading to 
improved delivery and therapeutic effects. The drawback, however, is that a 
nanoparticle with a surface too rich in positive charges can disrupt the membrane 
(Lin et al. 2010). Aside from their cationic nature, there have been reports of 
liposomal toxicities that may be important in the context of their efficacy. For 
example, hybrid liposomes with no encapsulated molecules have been reported to 
prolong survival in mice with CRC xenografts by inducing apoptosis (Ichihara et al. 
2012). The adhesion of liposomes also causes mechanical stress and local 
contraction of the cell membrane (Murrell et al. 2014). Compared to these studies, 
the liposomes used in our work in the absence of AZD6244 showed relatively little 
toxicity. The presence of DOPE in this cationic liposomes could have the dual 
function of reducing their toxicity (Ciani et al. 2004) and potentially eliciting an 
inverted hexagonal phase transition that facilitates the delivery to the cytoplasm 
(Pisani et al. 2011). However, substituting DOPE for DOPC in the liposomes reduces 
their toxicity at high concentrations indicating that the toxicity of these liposomes is 
somehow related to the ethanolamine group in DOPE. Additionally, both DOPE and 
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DOPC are zwitterionic in nature, suggesting that the mild toxicity elicited by 
DOPE/DC-cholesterol liposomes is not necessarily due to the positive charge of DC-
cholesterol, common in both liposomes.  
Regarding the influence of size and charge in toxicity, it is worth noting that in spite 
of serum being removed at the time of the treatment, any protein or peptide present 
in the medium could potentially bind to the charged surface of the nanoparticles. This 
binding could not only modify the surface charge and therefore modify their ability to 
bind to the cellular membrane and their uptake, but it could considerably increase 
the size of the nanoparticles. The adsorption of proteins on the nanoparticle surface 
could also be responsible for additional nanoparticle aggregation, which is a 
phenomenon already observed in this formulations. Additionally, cells sense patterns 
of adsorbed proteins on surfaces and respond accordingly. In order to fully 
understand the role of surface charge and surface charge to mass ratio in these 
experiments, a more thorough characterization of the nanoparticle surfaces is 
needed. This can be achieved by performing experiments such as Zeta potential, 
secondary ion mass spectrometry (SIMS), or X-ray photoelectron spectroscopy 
(XPS), which should be included in future work. 
On the other hand GCPQ, as a polycation, does have a stronger positive surface 
charge that might destabilize the cell membrane (Lin et al. 2010) to a certain extent 
and cause cytotoxicity even in the absence of the drug.  While AZD6244-loaded 
liposomes elicited more proliferation inhibition than AZD6244-loaded micelles in 
terms of metabolic activity, AZD6244-loaded micelles were more efficient according 
to the total DNA assay (89% vs 61%, Figure 6.8a). This suggests that genotoxicity, 
as opposed to direct cytotoxicity, could be an indirect cause of the inhibition of 
cellular proliferation in this system. In a study by Shah and colleagues, the effect of a 
number of nanoparticles with different characteristics on DNA was evaluated: neutral 
and anionic nanoparticles did not exhibit genotoxic properties whilst cationic 
nanoparticles did, as demonstrated by the formation of micronuclei. The degree of 
genotoxicity did not correlate to the size or molecular weight of the nanoparticles, 
rather to the extent of the positive charges on the surface of the nanoparticles (Shah 
et al. 2013). This results support the findings reported here of greater nanoparticle 
toxicity elicited by a polycation such as GCPQ. It is worth noting that in the same 
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work, the overall cytotoxicity of neutral 20 nm diameter micelles was higher than that 
of 180 nm diameter cationic liposomes, indicating that the toxicity of our 30 nm 
diameter GCPQ micelles compared with the 165 nm diameter DOPE/DC-cholesterol 
liposomes even in the absence of AZD6244 could relate to their size.  
Similar to this, a fraction of our control micelles (without AZD6244) were smaller 
compared to the AZD6244-loaded micelles (9 nm vs 30 nm) (chapter 5 (pg. 112). 
This could partly explain their toxicity in the absence of AZD6244 compared to the 
other formulations, since smaller nanoparticles are more easily internalized and can 
even reach the cell nucleus (Huang et al. 2012). This is supported by the size-
dependent cytotoxicity reported by Shah and colleagues mentioned earlier (Shah et 
al. 2013). However, it is uncertain at what exact nanoparticle size this extra toxicity 
occurs, since 30 nm diameter GCPQ micelles were small enough to undergo 
efficient internalization (Andar et al. 2014). For that reason the toxicity of GCPQ 
control micelles is likely to be due to their positively charged surface. 
Aside from the higher toxicity of GCPQ micelles compared to DOPE/DC-cholesterol 
liposomes, both AZD6244-loaded nanoparticles seemed to be excellent delivery 
platforms as determined by proliferation (total DNA assay), metabolic activity (MTT 
assay) and enzyme inhibition (pERK levels). The toxicity of both control 
nanoparticles was significantly lower than that of the AZD6244-loaded nanoparticles. 
As determined by Western blot analysis of phosphorylated ERK1/2, all three 
formulations successfully inhibited the activity of MEK1/2 (Figure 6.10). The most 
efficient inhibition was elicited by the liposomal formulation. These results, in 
combination with the much higher cytotoxicity of liposomes and micelles compared 
to the free drug (61%, 89% and 21% inhibition of proliferation, and 60% 40% and 
18% inhibition in metabolic activity, respectively (Figure 6.8 and Figure 6.9)) suggest 
an efficient internal processing and delivery to the cytoplasm. Specifically, liposomes 
seem to be the best route of delivery in monolayers, since they inhibit metabolic 
activity (Figure 6.8) and MEK activity (Figure 6.10) rather more efficiently than both 
micelles and free drug, even though GCPQ micelles showed higher genotoxicity and 





6.4.5 Nanoparticle efficacy on tumouroids 
 
In the present work, treatment with free AZD6244 was more effective in tumoroids 
than in monolayers (18% inhibition at 48 h, 1µM in monolayers (Figure 6.8); 38% 
inhibition at 72 h, 1µM in tumouroids (Figure 6.11)). This was especially surprising 
considering that the cell density in tumouroids is extremely high compared to 
monolayers, resulting in a drug-to-cell ratio over 7500 times higher in the monolayer 
experiments, and therefore suggesting very different cell behaviour between the two 
models. This interpretation must be considered as a hypothesis, since the 
differences in proliferation inhibition were subtle and the time of treatment differed 
between the models, but the great difference in drug-to-cell ratio clearly suggests 
differences in drug delivery or efficacy. 
Previous work with spheroids and other 3D models of cancer have shown significant 
differences in drug response compared to monolayer cultures. However in most 
cases, unlike AZD6244 being more efficient in tumouroids than monolayers in this 
work, 3D cultures tend to be more resistant to anti-mitotic drugs than monolayers 
(Chambers et al. 2014; Mikhail et al. 2013). These differences are not properly 
understood, but cells in both models are certainly subject to different conditions. 
Some examples are changes in gene expression and cell behaviour when cells are 
in contact with each other, drug concentration gradients and differential proliferation 
patterns in acidic, hypoxic or nutrient deprived regions of the constructs (Nyga et al. 
2013; Minchinton & Tannock 2006). 3D cancer models mimic these conditions to 
promote cell behaviour more similar to real tumour tissues (Trédan et al. 2007). 
However, the differences in drug efficacy between 2D and 3D are unpredictable and 
that highlights the importance of 3D testing during drug development. For example, 
although Magdeldin and colleagues reported a 2-fold increase of EGFR expression 
in HT29 cell tumouroids compared to monolayers, the anti-EGFR monoclonal 
antibody Cetuximab elicited a weaker inhibitory response in the former (Magdeldin et 
al. 2014). It is worth noting, however, that the differences in therapeutic efficacy 
between 2D and 3D could be cell line dependent (Mikhail et al. 2013) and therefore 
AZD6244 would not necessarily always be superior in tumoroids. 
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In the present work, the role of the extracellular environment in the tumouroid system 
was simplified to a compressed collagen matrix, with no additional stromal cells. 
Therefore, any changes in behaviour of HCT116 cells are exclusively due to the 
dense collagen microenvironment of the ACM and the cellular three-dimensional 
conformation encouraged by a protein matrix. There is evidence that these 
parameters are enough to cause radical changes in cell behaviour (Hickman et al. 
2014). 
 
6.4.6 Penetration studies 
 
6.4.6.1 Rationale behind the parameters of the penetration studies 
 
While the preliminary nanoparticle experiments were performed using gold QDs  to 
track uptake, penetration and encapsulation, these experiments were performed 
using Nile Red as a marker. One of the reasons for this is that QDs could potentially 
aggregate in solution and create larger structures that would not be removed through 
dialysis and could give a false positive in penetration experiments. Whilst Nile Red is 
a hydrophobic dye and tends to form aggregates in an aqueous environment, it only 
emits a fluorescence signal in the presence of another hydrophobic molecule (such 
as GCPQ, DC-cholesterol or DOPE), allowing only the nanoparticles to contribute to 
the fluorescent counts. Additionally, single molecules are small enough to be 
removed through dialysis, especially after several cycles under agitation, displacing 
the solute equilibrium to further solubilize Nile Red in every cycle. For penetration 
studies both the free molecule and the encapsulated molecule needed to be as close 
as possible to the ones used in the AZD6244 toxicity experiments, and QDs are 
inorganic hydrophilic nanoparticles. Like AZD6244, Nile Red is a small molecule of 
hydrophobic nature containing several benzene rings (Figure 6.14). Its molecular 




Figure 6.14: Molecular structure of Nile Red 
 
The free dye seemed to start reaching a signal plateau in the ACM core, most likely 
due to the dye flooding the centre of the ACM and reaching concentration equilibrium 
throughout the mass rather than saturating the detector, as the curve is gradual. On 
the other hand the presence of GCPQ micelles and DOPE liposomes in the ACM 
core was still significantly increasing after 24 h of exposure. While initially these 
nanoparticles could have been left for a longer time to determine if the majority of 
them would make it to the core eventually, there are a few reason why a 24 hour 
treatment was chosen. Firstly, these penetration experiments were performed 
outside of an incubator, increasing the probability of the samples drying out or the 
medium becoming too basic for the cells in the long term. Nanoparticles and dye 
could not be diluted in a larger volume to make the pH and hydration last longer 
since the fluorescence would be significantly reduced and a higher dye loading could 
destabilize or change the nanoparticle structure. Even in the event of cells being 
viable after a 48 hour period due to their entrapment in a gel that potentially acts as a 
suitable microenvironment, cells could start behaving differently and this would affect 
nanoparticle uptake. By day 7 of maturation, which is when these experiments were 
performed, cells have formed aggregates and start migrating towards the acellular 
stroma. A way of minimizing how this affects the results is limiting the period of 
study. To optimize this experiments in future work, a microscope with a built-in 
incubator would be needed. Similarly, cells are exposed to a high power laser at 




Additionally, these dye-loaded nanoparticles are representative of the drug-loaded 
nanoparticles used for treatment in the previous experiments. Once nanoparticles 
have been released at room temperature or at 37oC (if it were in an incubator), the 
drug should be delivered to the cytoplasm as soon as possible, and is likely to lose 
part of its efficacy after 24 h. That makes the first 24 h of penetration the vital period 
of time to study. In the long term nanoparticles could have degraded or leaked the 
drug, or the drug itself could have lost efficacy, and after the drug has reached its 
target a lapse of time is needed for it to inhibit proliferation, which starts being 
measured at 24 h. 
 
6.4.6.2 Penetration hinders nanoparticle efficacy 
 
The greater effect of free AZD6244 in tumouroids compared to monolayers, 
combined with the superior delivery of the drug observed with the nanoparticles in 
monolayers, suggest that the reduction in efficacy observed in the nanoparticle 
treatment of the tumoroids (60% for liposomes and 40% for micelles in monolayers 
(Figure 6.8b) vs 26% inhibition for liposomes and 34% for micelles in tumoroids 
(Figure 6.11c)) was not caused by the drug itself. The most likely scenario to explain 
the suboptimal efficacy of these liposomes and micelle aggregates in tumouroids is 
their localization within the ACM.  Their diffusion towards the core could be partly 
limited by their large size, possible interactions with the collagen matrix and the 
uptake by cancer cell aggregates at the outer boundary of the ACM. The core of the 
ACM is representative of cancer cells hundreds of micrometres distant from a blood 
vessel in vivo, to which the drugs have limited access (Minchinton & Tannock 2006). 
This hypothesis is supported by our penetration studies (Figure 6.13). It is worth 
noting that further functionalization of the surface such as the addition of antibodies 
or PEG, would make these nanoparticles even larger. These functionalizations are 
commonly added to the nanoparticle surface for experiments in vivo and for clinical 
applications, in order to promote active targeting and avoid recognition by the 
immune system. 
The efficacy of micelles (or micelle aggregates) in tumouroids compared to the 
liposomes is closer to, and in some cases more effective than, the free drug. While 
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the efficacy of the free drug could be due to a much better penetration, the higher 
efficacy of micelles could be due to their cationic toxicity, however limited to the 
periphery. It is also possible that cells in the periphery of the ACM are more 
metabolically active than those of the core, due to limited diffusion of nutrients across 
the dense cancer mass. This would favour the toxicity of the nanoparticles that, 
however remaining in the outer layers of the ACM, have a greater inhibitory effect on 
metabolic activity. 
Molecular weight, solubility, shape and other physicochemical characteristics of a 
drug influences its diffusion through tissue (Minchinton & Tannock 2006). It has been 
suggested for large molecules such as antibodies, that size could affect their ability 
to penetrate 3D models (Magdeldin et al. 2014; Xiang et al. 2011). This is a very 
common occurrence in spheroids, due to their high density. In the case of antibodies, 
not only their size but their ability to bind to surface receptors could hinder their 
penetration by sequestration in the outer layers of cells. Similarly, the very uptake of 
drugs or nanoparticles in the periphery of the structure could limit the penetration to 
deeper layers (Minchinton & Tannock 2006). Penetration becomes especially 
important in the case of nanoparticles, which size far exceeds that of drugs, 
particularly small molecules. Huang and colleagues demonstrated that different sizes 
of gold nanoparticles have the ability to penetrate into tumour spheroids in a size-
dependent manner. Additionally, the smallest particles (2-6 nm) were able to reach 
the nucleus while the largest (15 nm) were confined to the cytoplasm of cells (Huang 
et al. 2012). 
According to Andar and colleagues, nanoparticle size affects the way they are 
internalized. In their work, larger nanoparticles (162.1 nm diameter) tended to be 
internalized by clathrin-dependent mechanisms whilst the smallest (40.6 nm 
diameter) were internalized by dynamin-dependent mechanisms (Andar et al. 2014). 
Smallest particles were internalized 12-fold more efficiently than the largest, and the 
internalization of intermediate-sized nanoparticles corresponded with a size-
dependent pattern. Even though this study was carried out with liposomes 




A fraction of our control micelles (without AZD6244) were smaller compared to the 
AZD6244-loaded micelles (9 nm vs 30 nm). This could partly explain their toxicity in 
the absence of AZD6244, since smaller nanoparticles are more easily internalized 
and can even reach the cell nucleus (Huang et al. 2012). This is supported by the 
size-dependent cytotoxicity reported by Shah and colleagues mentioned earlier 
(Shah et al. 2013). However, since 30 nm diameter GCPQ micelles were small 
enough to undergo efficient internalization (Andar et al. 2014), the toxicity of GCPQ 
































7 Conclusions and Future Directions 
 
The field of cancer therapy is one of the most challenging in medicine, and forces the 
scientific community to find novel and creative ways to overcome the many new 
hurdles and limitations that constantly arise. Some of the most significant advances 
in the field merge in this body of work namely targeted therapeutic molecules, 
nanotechnology-mediated drug delivery and tissue engineering. 
Finding a suitable therapeutic candidate for combination treatments and 
nanoformulations was a difficult task, as a number of molecules widely used at the 
preclinical and clinical level did not elicit the response that could be expected from 
them. While PD98059 and U0126, two of the MEK inhibitors used here have been 
allocated to laboratory work for a number of years now, AZD6244 is still undergoing 
clinical trials. While all three inhibitors showed promising results in conventional in 
vitro models, their efficacy was not as good as it had been reported before. The 
reasons for that phenomenon are still unclear; suffice to say inconsistency is not 
uncommon in the field of pharmacology. The design of combination therapies that 
involve MEK inhibitors is increasingly popular, and it took a turn in recent years when 
a combination of dabrafenib and trametinib (Flaherty et al. 2012), a BRAF inhibitor 
and a MEK inhibitor respectively, got FDA approval for the treatment of melanoma. 
Regarding the ETAR axis, previously validated as a promising therapeutic target in 
this research group, results were inconsistent and very discouraging, driving me to 
search for a therapeutic alternative. The use of RNA interference as a therapeutic 
target showed promise, with great ability to reduce target mRNAs and subsequently 
the expression of target proteins, and a significant therapeutic improvement in 
combination with AZD6244. Technical difficulties regarding excessive cellular 
damage together with the complexity of nucleic acid/inhibitor combinations forced me 
to abandon this option as a combination therapy. However, with the increase of 
knowledge and technologies available in the field of genetics, the use of RNA 
interference as a therapeutic approach is exciting and will increase exponentially. 
While part of the research developed here has yielded suboptimal results, valuable 
lessons can be learned regarding the inconsistencies present in the literature. 
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Special care must be taken in the process of drug development, as great 
investments often lead to failure at its final stages. 
In many cases, it is not the therapeutic potential of a molecule what hinders its 
efficacy, but the way it is delivered to the target tissue. Improving delivery has been 
the solution to many limitations such as degradation, solubility and off-target toxicity, 
and could potentially solve the toxicity issues observed in the use of RNA 
interference in this work. Nanotechnology has led the efforts regarding novel 
therapeutic delivery systems. While liposomes have been in the vanguard and are 
almost exclusively the nanoparticle of choice for anticancer therapy, micelles and 
protein-based nanoparticles are breaking into the clinic. 
The results from micellar and liposomal drug delivery observed in this work support 
this reality. Both DOPE/DC-cholesterol liposomes and GCPQ micelles significantly 
improved the efficacy of AZD6244 at the protein, metabolic activity and proliferation 
levels, whilst exerting little intrinsic toxicity in comparison. While encouraging, 
conventional in vitro approaches such as cell monolayers are often hyper sensitive to 
treatments and their genetic and proteomic status are far from that of a real tumour. 
The presence of an ECM and the three-dimensional structure of the cells play major 
roles in cellular behaviour and gene expression, and have obvious implications in 
therapy. 
Liposomes and micelles containing AZD6244 were less effective in tumouroids than 
it would be expected from the results obtained in monolayer experiments. 
Experiments on the tumouroid model suggested that the efficacy of these 
nanoparticles was hindered by their large size or interactions with cells and dense 
ECM. These observations are consistent with previous data on spheroid models, 
where the high density caused by the high cellular concentration and the absence of 
extracellular matrix tends to limit the penetration of drugs and nutrients. Whether it is 
the differences in cellular behaviour and gene expression or the physicochemical 
properties of the matrix itself, the differences between 2D and 3D models are many, 
and not limited to drug efficacy. 
The main difference between the spheroids and the tumouroids is the presence of 
that ECM, which makes the tumouroids potentially suitable for studies on invasion, 
metastasis and interactions with stromal cells. Our research group includes a prolific 
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branch of research in that field, and has produced valuable data regarding the effect 
of matrix mechanical properties and composition on invasion (unpublished data). 
Mimicking the tumour environment also provides a suitable platform to culture 
sensitive cells that would otherwise perish in the harsh laboratory environment. The 
possibility of growing patient’s primary cancer cells in the lab under controlled 
conditions makes tumouroids a promising route to personalised medicine. 
The research described in this thesis sets the basis for further investigation involving 
nanocarriers for drug delivery and their evaluation in colorectal tumouroids. Specific 
experiments should be completed to further understand the mechanisms that led to 
this results. Examples of these are: 
 Perform experiments such as XPS, SIMS or Zeta potential on GCPQ micelles 
and DOPE/DC-cholesterol liposomes to better understand the influence of 
surface charge and size to surface charge ratio in toxicity. 
 Optimize the size of these nanocarriers to 40-80 nm in diameter by modifying 
parameters in the fabrication protocols (i.e. sonication time, extrusion pore 
size or cholesterol content), and study the effect of size on penetration, 
uptake and toxicity. 
 Determine the molecular differences between colorectal cancer cells grown as 
monolayers and in tumouroids by performing thorough analyses at the genetic 
and protein levels on both models. 
 Perform the experiments described in this work on a panel of colorectal 
cancer cell lines to find common patterns among them and determine the 
influence of specific mutations on therapeutic response. 
 Increase the complexity of the tumouroids by including a stromal component 
composed of at least two cell types (fibroblasts and endothelial cells) and 
study their influence on treatment response. 
 Combine the nanoformulation treatment on tumouroids with a 
permeabilisation techniques and study its influence on penetration. 
 Utilize caspase assays to determine the effect of nanoformulations on 




 Modify the surface of nanocarriers with PEG to perform in vivo studies and 
study their relation to the EPR effect. 
 
The work presented in this thesis demonstrates the potential of organic 
nanoformulations as platforms for anti-cancer therapeutic delivery, and highlights the 
importance of including 3D models of cancer in the process of drug development. It 
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